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Abstract
The recruitment of different leukocyte subpopulations during an inflammatory response is regulated 
by various molecules expressed by the endothelium. This study examines how chemokine 
production, the expression of chemokine receptors and the binding of chemokines to the 
proteoglycan layer vary between endothelia from different vascular beds.
Human dermal, lung and liver endothelia were compared with endothelia derived from saphenous 
and umbilical veins and with a transformed bone marrow cell line. All endothelia produced MCP-1 
(CCL2) and IL-8 (CXCL8) constitutively with both these chemokines and IP-10 (CXCL10) and 
RANTES (CCL5) being secreted after TNF-aor IFN-y stimulation, whereas MlP-1a (CCL3) was not 
produced under any conditions tested. A combination of TNF-a and IFN-y stimulation increased 
RANTES and IP-10 production, but reduced IL-8 production. The addition of TGF-p reduced 
secretion of all chemokines. Differences were found in production levels of each of these 
chemokines depending on the tissue that the endothelial cells were derived from. MIP-1a, and 
RANTES bound to the cell surface of each endothelium tested at differing levels, but IP-10 bound 
only to lung endothelium. RANTES binding was found to be dependent on the presence of 
Heparan Sulphate Proteoglycan (HSPG), but MIP-1a appeared to bind via a different method. 
Chemokine receptors CXCR1, CXCR3 and CCR3 were expressed highly at the endothelial cell 
surface, with lower levels of CXCR2, CXCR4, CXCR5, OCRS and CCR6. Expression of CCR4 
varied widely. Using lectins to identify specific oligosaccharides, differences in the composition of 
the proteoglycan layer were probed. Small variations were shown, but these cannot account for the 
differences in chemokine binding.
These results demonstrate that endothelial cells could be important in the selective recruitment of 
leukocytes to different tissues, in particular in their expression of chemokines in response to 
inflammatory stimuli and their presentation of chemokines to the leukocytes In the blood stream.
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1. Introduction
1.1 The Endothelium
1.1.1 The functions of endothelium
For many years endothelium was considered to be a quiescent lining layer on the inside of blood 
vessels. It is now evident that endothelial cells are important in haemostasis and during immune 
responses, particularly because of their strategic position as an interface between the circulating 
blood and the tissues of the body (Fishman 1982; Simionescu and Simionescu 1986). The 
endothelium is made up of a continuous monolayer of cells joined together by junctional adhesion 
molecules and acts as a physical barrier between the blood and the tissues. It is now known to 
control transport of molecules into tissues, vascular tone, cell migration, angiogenesis and 
coagulation. Leukocyte migration from the blood stream through the vessel wall and into the 
tissues occurs constitutively as part of the normal immune surveillance, but increases at sites of 
inflammation.
Endothelial cells are able to control the vascular tone and blood flow through the production of 
dilators and constrictors, which can act on the vessel wall. The constant production of nitric oxide 
and prostaglandins, which act on adjacent smooth muscle cells, ensures that the patency of the 
vessel is maintained. This production is also antithrombotic and as such prevents aggregation of 
platelets and leukocyte adhesion. When the endothelium becomes activated, it can produce 
endothelin-1 and thromboxane which act as vasoconstrictors. Histamine receptors are also present 
on the cell surface (Simionescu and Simionescu 1986).
Leukocytes are required to extravasate during both innate and adaptive immune responses. 
Endothelial cells contribute to the local accumulation of leukocytes during an immune response by 
upregulating the expression of adhesion molecules on their surface and by increasing the 
production of chemokines and other mediators in response to cytokines (Pober and Cotran 1990b; 
Springer 1994). They can also contract to regulate capillary permeability to various molecules and 
cells. Since only a limited subset of circulating cells will respond to each chemokine, regulation of 
chemokine production can contribute to the selectivity of leukocytes recruited.
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1.1.2 The immune response
Inflammation is a defence reaction caused by tissue damage or injury, characterised by redness, 
heat, swelling and pain. The objective of inflammation is to remove or neutralise the irritant and 
repair the damaged tissue. The body does this by increasing the blood supply to the affected area, 
increasing the capillary permeability in the area and finally by the migration of cells of the immune 
system out of the blood stream and into the tissue.
In the early stages of the immune response, the proteins and cells of the innate immune system 
are the most important, these are non-specific. They include viral and microbial protein receptors 
on cells as well as plasma proteins such as the complement system. The cells involved in this early 
response are natural killer (NK) cells and phagocytic cells. Phagocytes include the granulocytes 
(eosinophils, neutrophils and basophils) as well as macrophages. Signals are then generated at the 
inflammatory site that activate the local leukocytes and adjacent endothelium.
Many mediators are involved including the kinin system, which causes vasodilation and increased 
permeability and the complement system that has many functions including triggering mast cell 
degranulatlon. One component of the complement system, C5a, has chemotactic properties for 
neutrophils and macrophages. The plasmin and fibrinolytic systems also act in a cascade during 
acute inflammation to finally allow fibroblasts to begin the repair process and restore the area to 
normal function. What follows is a series of events that forms the body’s inflammatory response - 
one of its most important defence mechanisms. It is the physiological response to injury, whether 
the injury is microbial or if it results from physical, chemical, thermal, toxic or immunogenic 
damage. This response is a well co-ordinated series of vascular and cellular reactions (Levy 1996). 
The earliest events involve the production of chemical mediators such as prostaglandins, C5a, 
histamine, thrombin, leukotrienes and cytokines including interleukins (IL) -1 and -6 and tumour 
necrosis factor (TNF-a). These mediators produced by phagocytes or by complement activation, 
cause vasodilation, increase vascular permeability and also initiate the recruitment of more effector 
cells.
1.1.3 Effects of cytokines on endothelium
Cytokines include the interleukins (IL-1 - 26), interferons (IFN-a, IFN-p, IFN^), tumour necrosis 
factors (TNF-a, TNF-p), transforming growth factors (TGF-a, TGF-p) and colony stimulating factors
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(GM-CSF, G-CSF, M-CSF); they function by binding to specific protein receptors on the target cells 
and then act by altering the behaviour of the target cell. Individual cytokines often modulate the 
effects of other cytokines on the same target cell - they can act in synergy causing a greater effect 
or a new effect that neither can produce alone. One cytokine will often cause the release of a 
second cytokine by its target cell - known as a cytokine cascade (e.g. TNF-a stimulates IL-1 
production by endothelium). Cytokines are not always secreted, but may be expressed on the 
surface of the stimulated cell (e.g. the transmembrane form of TNF-a or the chemokine fractalkine).
TNF-a and IL-1 are pro-inflammatory cytokines and the intracellular pathways which mediate their 
effects have been extensively researched, however less is known about how signals are integrated 
within the cell for instance to show an antagonistic or synergistic effect, though some details are 
beginning to emerge. Since more than one cytokine is likely to be found at any one site of 
inflammation, this is an important and developing area of research.
The endothelial layer lining blood vessels has also been shown to be an important focus of 
cytokine interactions (see table 1.1 and review Pober and Cotran 1990a). TNF-a and IL-1 cause 
endothelial cells to upregulate the expression of several cell surface and secreted molecules, 
including the adhesion molecules (Mantovani et al. 1997; Meager 1999). This process is known as 
endothelial activation. These changes can take varying lengths of time and can be the result of de 
novo synthesis or of release of vesicular molecules. The molecular mechanisms involved in the 
cytokine regulation of genes expressed by endothelial cells are now better understood (Foletta et 
al. 1998; Mantovani et al. 1998; Denk et al. 2001). In particular, NFkB is a crucial element for the 
cytokine-mediated inducibility of adhesion molecules and cytokines in endothelial cells (Collins et 
al. 1995; May and Ghosh 1998; Richmond 2002). Inflammatory cytokines promote leukocyte 
extravasation by altering the dynamics of microcirculation via nitric oxide (NO) and prostaglandins 
and by inducing adhesion molecules and chemotactic cytokines.
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Table 1.1 Molecules induced by cytokines acting on endothelium
MOLECULE INDUCED BY REFERENCES
MHC-I IFN-y, TNF-a Wedgwood et al. 1988
MHC-II IFN-y Wedgwood et al. 1988
ICAM-1 TNF-a Pober 1987, Detmar et al. 1990
IFN-y, IL-1 Dustin et al. 1986
VCAM-1 TNF-a, IL-1 Osborn et al. 1989
E-selectin TNF-a, IL-1 Bevilacqua et al. 1987 & 1989
iNOS TNF-a, IL-1 Kanno et al. 1994, Pellegatta et al. 1994
IL-8 TNF-a, IL-1 Sica et al. 1990a
MCP-1 TNF-a, IL-1 Strieter et al. 1989b
RANTES TNF-a & IFN-y Marfaing Koka et al. 1995
IP-10 IFN-y Luster and Ravetch 1987a
Gro-a TNF-a, IL-1 Wen et al. 1989
1.1.3.1 Tumour necrosis factor (TNF)
TNF is the principal mediator of the response to gram negative bacteria and may also play a role in 
innate immune responses to other infectious organisms (reviewed in Vassalli 1992). It was initially 
described in serum of endotoxin-treated mice as the mediator of necrosis of some transplantable 
tumours (Old 1985).
Mononuclear phagocytes are the predominant cellular source of TNF-a, although many other cell 
types, such as T cells, B cells, activated NK cells, activated mast cells and some tumour cells, may 
make TNF-a. TNF-p is produced solely by cytotoxic T cells. The genes for TNF-a and 
TNF-p (previously known as lymphotoxin) are located in tandem within the major histocompatibility 
compiex (MHC) - on chromosome 6 (Aggarwal et al. 1985). TNF-a is synthesised by the 
conventional secretory pathway through the endoplasmic reticulum and golgi apparatus as a non­
glycosylated transmembrane 25 kDa precursor polypeptide, which is processed to yield a large 
extracellular carboxy terminus derived 17 kDa product with a transmembrane leader sequence. 
This precursor subunit can be proteolytically cleaved off the membrane to produce the secreted 
form - a stable 51 kDa homotrimer in the shape of a pyramid (Arakawa and Yphantls 1987; Jones 
e/a/. 1989).
TNF-a exerts its biological effects by binding of the soluble trimer to one of two cell surface 
receptors (Bazzoni and Beutler 1996). These are of 55 and 75 kDa respectively, each encoded by
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a separate gene, but both present on most cell types. The affinity of TNF-a for its receptors is low 
for a cytokine, however it is synthesised in very large quantities and can easily saturate the 
receptors. Most biological effects have been shown to be mediated through TNFRI (p55) 
(Wiegmann etal. 1992; Mackay ef a/. 1993; Pfeffer efa/. 1993; Rothe etal. 1993). Endothelial cells 
express both the p55 and p75 TNFR, with the p75 form being the most abundant on the cell 
surface. The p55R is more abundant overall, but is expressed at much lower levels on the 
membrane itself, and is found mainly in the golgi apparatus and in cytoplasmic vacuoles. The effect 
of p75 is best observed at low TNF-a concentrations, which is in accordance with the concept that 
this molecule can present TNF-a at low concentrations to p55 (known as ligand passing) 
(Leeuwenberg et al. 1995). p75 also binds to the transmembrane form of TNF-a and is thought to 
be important in juxtacrine interactions between endothelial cells and leukocytes (Lukacs et al. 
1995). Activated cells shed their TNF-a receptors and these soluble receptors may act as 
competitive inhibitors of the cell surface receptor (Higuchi and Aggarwal 1994; Black et al. 1997; 
Hooper efa/. 1997).
Many TNF-a responses involve increased rates of expression of particular target genes, often 
through activation of NFkB or AP-1 transcription factors (May and Ghosh 1998). However, the 
signalling pathways are very complex and differ depending on the cell type. TNF-a acts by 
phosphorylating kBa, allowing its rapid degradation (Beg et al. 1993). This releases NFkB which 
migrates to the nucleus and binds specific sites on promotor regions of target genes which are then 
transcribed and protein synthesis occurs -  producing cytokines, chemokines and adhesion 
molecules as required by the cell (Ebnet etal. 1997; Martin etal. 1997).
TNF-a has varying biological effects at different concentrations. At low concentrations TNF-a can 
act on leukocytes and endothelial cells as a paracrine and autocrine regulator, in this way, it is a 
potent mediator of the inflammatory response (Pober and Cotran 1990a; Mantovani ef a/. 1997). It 
increases adhesion molecule expression on endothelial cells and leukocytes, stimulates 
mononuclear phagocytes and endothelium to secrete chemokines while inflammatory leukocytes 
such as neutrophils, eosinophils and mononuclear phagocytes are activated to kill microbes. It also 
has other effects on endothelium, including stimulation of prostaglandin and nitric oxide production 
and induction of platelet activating factor expression. Chronic low production of TNF-a can cause 
tissue remodelling including angiogenesis and fibroblast growth factor production which allows 
connective tissue deposition. This may be through indirect actions dependent on leukocytes,
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although there is also some in vitro data that suggests a direct angiogenic activity for this cytokine. 
At sufficiently high levels, TNF-a acts on the hypothalmic region of the brain to induce fever and on 
hepatocytes to increase synthesis of serum amyloid proteins that are one component of the acute 
phase reaction (Baumann and Gauldie 1994). The actions of TNF-a on mononuclear phagocytes 
and endothelial cells initiate secretion of IL-1 and IL-6 into the circulation and induce activation of 
the coagulation system by altering pro and anti coagulant properties of the endothelium.
Although many TNF-a activities are indistinguishable from those of IL-1, TNF-a and IL-1 activities 
are often additive and always appear to be independent (i.e. not mediated through IL-1 synthesis). 
Through its effect on MHC I antigen expression, TNF-a may promote lymphocyte dependent 
inflammation (an action which is not shared by IL-1). IFN-y, produced by T cells augments TNF-a 
synthesis by lipopolysaccharide (LPS) stimulated mononuclear phagocytes (Doukas and Pober 
1990). Thus TNF-a is an important link between specific immune responses and acute 
inflammation.
1.1.3.2 Interferon (IFN)
Interferons are a family of proteins encoded by different genes all sharing a capacity to inhibit viral 
infections, though they have many additional biological activities. They have been subdivided into 
IFN-a, IFN-p, and IFN-y. IFN-a consists of several (over 20) homologous 18 kDa proteins produced 
by mononuclear phagocytes, IFN-p is a 21 kDa glycoprotein which is derived from tissue cells and 
IFN-y which is a 20 or 25 kDa glycoprotein which in its native form is a dimer. They are only related 
to each other by their induction of an antiviral state. IFN-y is synthesised only by ThI cells and NK 
cells in response to antigen.
IFN-y acts via specific interferon receptors and has many effects both on leukocytes and on 
endothelium (Novick et al. 1987; Fischer et al. 1988; Cofano et al. 1990). It stimulates B cells to 
mature and switch isotype and also acts as a maturation factor for cytotoxic T cells. It is an 
important activator of macrophages and is able to stimulate the alternative complement pathway, 
which leads to phagocytosis of infected cells. In addition to these effects it has many important 
consequences for endothelium. Knockout mice demonstrate an impaired response to microbial 
pathogens, but exhibit no problems in the absence of pathogens (Flynn et al. 1993).
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IFN-y induces endothelial cell expression of ICAM-1, MHC II antigens and angiostatic chemokines 
including IP-10, Mig and l-TAC (see Table 1.1). It enhances expression of MHC class I and CD40 
and acts in synergy with TNF-a to increase the levels of adhesion molecules expressed on the 
endothelial cell surface. It has also been shown to have a similar effect on chemokine production 
as well as augmenting LPS induced production of IL-1.
1.1.3.3 Transforming growth factor (TGF)
TGF-p was originally described as a component of tumour cell conditioned medium that when 
combined with TGF-a could cause cell growth (Todaro et al. 1980). It has since been shown that 
TGF-a promotes cell growth while TGF-p has cell modulatory functions. Many cell types produce 
TGF-p, including activated T cells, macrophages and cytokine stimulated endothelial cells. The 
protein is formed of two separate, but closely related 14 kDa polypeptides from different genes 
making two different forms TGF-pi and TGF-p2 which then normally homodimerise, although 
heterodimers do exist. These dimers then reassociate with the precursor to create a latent form. 
This can be activated by several different factors. These include acidic conditions, thrombospondin, 
plasmin and enzymes such as transglutaminase. TGF-p binds to specialised receptors TGF-pR 
type I and TGF-pR type II as well as to proteins of the extracellular matrix including fibronectin, 
collagen and heparin, it is thought to exert some of its effects through heparin binding.
Effects of TGF-p include the inhibition of endothelial proliferation and migration (Heimark et al. 
1986; Bell and Madri 1989; Pepper et al. 1993; Pepper 1997), this is associated with increased 
extracellular matrix and proteoglycan synthesis. It also stimulates the synthesis of VEGF and 
PDGF-B (platelet derived growth factor-B) and allows the release of bFGF into the subendothelial 
matrix. In this way it exerts much control over angiogenesis, in particular it appears to be important 
in the later stages of reducing proliferation and remodelling as it has been found to cause tubule 
formation in matrix embedded EC. Treatment of endothelial cells with TGF-p hinders leukocyte 
migration, this is associated with decreased expression of E-selectin on the cell surface and 
lowered secretion levels of IL-8 (Gamble and Vadas 1988; Gamble et al. 1993).
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1.2 Heterogeneity of endothelium
Endothelial cells throughout the vasculature share certain common functions, but heterogeneity 
exists structurally and functionally both along the vascular tree and in the microvascular beds of 
various organs (Gerritsen 1987; Turner et al. 1987; Page et al. 1992; Swerlick et al. 1992a; Risau 
1995). The differences observed are thought to be adaptations to the different functions of each 
tissue and the pressures of the local microenvironment, so the needs of a particular tissue will 
determine what is required of the endothelial cells in its blood vessels (Garlanda and Dejana 1997). 
Endothelium can be classified into three general types; continuous, discontinuous and fenestrated. 
Continuous endothelium forms a tight monolayer as in the brain or the lungs, while discontinuous 
and fenestrated endothelium form a less tight surface because of the transport functions requiring it 
to allow cells or molecules to pass more freely between different compartments (e.g. kidney, bone 
marrow, capillaries).
Endothelial cells share several common markers, which can aid identification in vitro and In vivo. 
These include the presence of von Willebrand Factor (vWF or factor VIII) and binding to the lectin 
Ulex europeaus -1 (UEA-1) (Holthofer et al. 1982). Many of the specialised characteristics of 
endothelium are induced during differentiation, whereas adult endothelium is not so susceptible to 
proliferation and differentiation. It however, does react to the pressures of the different 
microenvironments that it might be exposed to. It is in this way that differences between organs are 
maintained. This makes it difficult to maintain the phenotype of the specific endothelium in vitro, in 
particular for a cell type as specific as bone marrow endothelium (Masek and Sweetenham 1994; 
Candal et al. 1996; Rood et al. 1999). This is why the production of a cell line for this cell type is so 
important and culture conditions have to be carefully maintained (Schweitzer et al. 1997).
The earliest studies identifying heterogeneity of endothelium used tracers to assess the surface 
charge (Simionescu et al. 1982; Vorbrodt et al. 1986), then lectins were found to bind to 
endothelium and via conjugation to radioactive molecules or biotin were used to detect endothelial 
surface glycoconjugates. There have been several recent developments in techniques, which have 
allowed more selective identification of markers on the endothelial cell surface, although as yet only 
one molecular marker for specific endothelium has been identified (a zinc metalloproteinase is 
found only on lung endothelium).
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Phage display peptide libraries can be used to probe for defined peptide sequences which interact 
with a particular molecule (reviewed in Ruoslahti and Rajotte 2000). In this method up to a biilion 
permutations of different peptides are expressed on the coat of phages. The desired peptides are 
chosen by their ability to bind a specific target molecule. The advantage of this is that it allows 
selective binding to only the exposed region of the molecule without being hampered by 
conformational problems. Phage libraries can be used to seiect for proteins, carbohydrates and 
peptides on cultured cells. Rajotte et al. (1998) have studied organ specific differences in the 
vasculature and have been able to identify phages that homed to specific organs. They then 
identified the peptide sequences, but the identity of the molecules recognised by these peptides is 
only beginning to be addressed. One distinct marker has been detected so far by this method, that 
is membrane dipeptidase, found only on lung endothelium, it is a cell surface zinc metalloprotease 
involved in the metabolism of glutathione, leukotriene D4 and certain antibiotics. A more recent 
study has identified several more potential molecules that show differential expression throughout 
the vasculature (Arap et al. 2002).
Recent studies have demonstrated that it is possible to isolate and purify just the blood front of the 
endothelial cell surface (Ghitescu and Robert 2002). Patterns of 2D electrophoresis staining 
showed that while there were similarities in some proteins expressed, there were also some 
interesting differences between endothelium derived from brain, heart and lung of adult male 
Sprague Dawley rats. Differences between organs were also observed in the binding profiles of 
various lectins to the membrane preparations, with similarities observed between the heart and the 
lung, neither of which shared any simiiarities with the patterns of staining of the brain endothelium. 
Although differences between organs have been detected using this technique, the specific 
molecules which are different from organ to organ have not yet been identified. Further 
development of this technique couid prove useful in the identification of specific markers for 
endothelium.
Because chemokines and their receptors are fundamental to leukocyte recruitment, their varied 
expression by different endotheiiai celis, both during normai function and during inflammatory 
reactions could help determine which particular cell types will be recruited into which tissues. 
Adhesion molecules and the type of molecules in the proteoglycan layer are also important in 
recruitment, so specificity seems to be determined by a combination of factors. The fact that 
chemokines are produced during so many immunological events suggests that they could be very
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useful targets for drug intervention and other therapies (Saunders and Tarby 1999; Schwarz and 
Wells 1999).
Despite the realisation that there may be physiological differences between various vascular beds, 
the majority of in vitro investigations into chemokine expression by endothelium have been 
performed using Human Umbilical Vein Endothelial Cells (HUVEC) because of the relative ease 
with which they can be obtained. HUVEC have over the last couple of decades been put to good 
use in identifying many of the functions of endothelium during the inflammatory response. Much of 
the data shown in Table 1.1 has been described in HUVEC. However, the principle site of 
neutrophil adhesion and emigration is not at the level of the large veins such as HUVEC and 
Saphenous Vein Endothelial Cells (SVEC), but at the level of the postcapillary venule. Since the 
isolation of microvascuiar endothelium is becoming easier, more researchers are investigating 
other types of endothelium. I will now discuss in further detail some of the major differences found 
so far between the different endothelial cell types used in this study.
1.2.1 Human Umbilical Vein Endotheiiai Ceils
HUVEC isolated by collagenase digestion of umbilical veins have been used for many years as a 
standard endotheiiai celi type (Jaffe et ai. 1973). They have a familiar cobblestone appearance, 
bind UEA-1 on the cell surface and VWF in vesicies. HUVEC are formed during pregnancy and are 
hence considered to be foetal in origin -  not adult. The function of the vessel is simply to transport 
waste substances away from the foetus and back to the mother for breakdown or disposal. 
However there is a huge amount of information available on these cells -  including analysis of all 
the molecules shown in table 1.1.
1.2.2 Saphenous Vein Endothelium
The enzymatic isoiation of human SVEC was first described by Watkins et ai. (1984). The 
saphenous veins are large vessels taken from the leg, they are commonly used in bypass surgery, 
so knowledge of their distinct phenotype is important. In culture, they demonstrate a slightly more 
elongated form than HUVEC, but still express similar amounts of VWF in their Weibel-Palade 
bodies. In some early experiments, before it was realised that there are differences between 
endothelium, these were used interchangeabiy with and in mixed cuitures with HUVECs.
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1.2.3 Dermal Microvascuiar Endothelium
The skin is a barrier and protective structure for the body, and as such forms one of the first lines of 
defence against toxins and infectious agents. The skin is formed of an epidermis (outermost layer) 
and the underlying dermis.
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Figure 1.1 Structure of the skin
The overall structure of the skin (A.), a histology section of the skin (B.) showing the layers of epidermis (E), 
dermis (D) and hypodermis (H). Sweat glands (8), sweat ducts (Dt), and a pacinian corpuscle (Pc) are also 
shown (from Wheater et a!. 1985). Figure C. shows the morphology of confluent DMVEC (from Clonetics).
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The dermal microvascuiar endothelial cells (DMVEC) are isolated from the dermal layer of the skin 
(shown in fig. 1.1 a and b). This is the protective layer, and consists of a strong mesh like structure 
that is created by fibroblasts. Most of the fibres in the dermis are collagen and elastin fibres, which 
maintain the strength and elasticity of the skin. It is also in this layer that the blood microvessels are 
found. These capillaries function to regulate body temperature as well as to supply nutrients to the 
avascular epidermis. DMVEC are extracted first by dissection, then enzymatic digestion and 
selection either on magnetic beads coated with UEA-1 or by cell sorter. When these cells are 
contact inhibited, they exhibit the cobblestone type morphology (fig. 1 .1c), however at lower 
densities, they have a much larger, rounder morphology (see fig. 2 .1 ).
Common processes in the skin in which endothelial cells play an important role include wound 
healing and allergic reactions. In wound healing, the physical damage to the skin must be repaired 
and infectious agents neutralised. The first cell type to appear after wounding is the neutrophil, at 
one day after injury, these cells can form as much as 50% of the cells at the injured site. 
Monocytes are also recruited to the wound site at the same time as neutrophils, and become 
activated, they are important in the later stage of the reaction and in the production of growth 
factors and chemokines for the remodelling of the tissue. Lymphocytes and mast cells are also 
recruited during this type of reaction, lymphocytes not only because they act as effector cells, but 
because of their cytokine producing properties.
1.2.4 Lung Microvascuiar Endothelium
Lung capillaries are a highly selective conduit for the exchange of gases between the blood system 
and the alveolar air space. To aid in this exchange, there is very low blood pressure, very thin 
vascular walls and a high capillary density with low levels of smooth muscle cells. In this way, the 
vessels within the lungs are very different from the rest of the vasculature (see fig. 1 .2 ).
Lung microvascuiar endothelial cells (LMVEC) are isolated in the same way as dermal 
microvascuiar cells, and demonstrate a very similar morphology, cobblestone at confluence, but 
bigger and flatter sub-confluence (Carley et al. 1992). vWF staining in the lung has been found to 
be more diffuse and cytoplasmic than seen in other cell types, it does not appear to be attached to 
the Weibel Palade bodies in any way (fig. 2.1 ).
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Figure 1.2 Structure of the lungs
A. is a cross section through an area of the lungs showing the structure of the alveoli, B. shows an 
enlargement of one portion of an alveolus showing the structure of the capillaries in relation to the air spaces 
modified from Vander et al. (1994).
The lungs are an important filter for pathogens, the types of infection often found here include 
bacteria and viruses. The lungs are also a site for hypersensitivity reactions such as asthma. 
During allergic inflammation, Th2 cells recognise the allergen, then produce cytokines such as IL-4, 
IL-5, IL-10 and IL-13, which involve IgE producing B cells, eosinophils and mast cells. They have 
various effects including stimulating production of chemokines and other cytokines, inducing 
adhesion to endothelium and stimulating mast cell degranulation.
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1.2.5 Bone Marrow Endothelium
Bone marrow is a primary lymphoid tissue and is the site of origin of all leukocytes, platelets and 
erythrocytes in the adult human. Bone marrow stroma is composed of monocytes, reticular cells, 
adipocytes, osteoblasts and fibroblasts as well as endothelial cells (fig. 1.3).
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Figure 1.3 The structure of bone marrow
The bone marrow microenvironment, showing the position of the endothelial cells lining the sinuses (A. 
modified from Weiss and Greep 1977) . B. shows the movement of haematopoietic progenitor cells during 
differentiation and maturation. Mature cells migrate across the endothelium (light green) into the blood stream.
The stromal cells produce cytokines and matrix proteins forming a complex microenvironment in 
which haematopoietic cells can proliferate, differentiate and mature. The endothelium situated at 
the interface between the blood and bone marrow microenvironment can regulate the transport of 
naïve and mature blood cells into the circulation. In vivo, bone marrow endothelium has fenestrated 
sinusoids, which facilitate this transport.
Because of the scarcity of bone marrow, it was only recently that bone marrow endothelial cells 
(BMEC) were first isolated and characterised (Masek and Sweetenham 1994; Rafii et al. 1994; 
Rafii et al. 1995). It has been found that G-CSF, GM-CSF and IL-6 are all constitutively produced 
by BMEC. They also express CD34, PECAM (CD 31) and thrombospondin. One of the major 
differences between bone marrow endothelium and endothelium from the rest of the vasculature is 
that VCAM-1 and E-selectin are continually expressed both in vivo and in vitro. It appears that this
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is a property of the local microenvironment as after several passages in cuiture, this phenomenon 
is lost.
It is because of the difficulty of obtaining BMEC, that recently several different cell lines have been 
described, each with slightly differing characteristics. The ceil line that we have used in this study 
was first produced by Schweitzer et al. (1997). Although it highly expresses CD34, it appears that 
the VCAM-1 and E-selectin are not expressed unless the cells are cytokine stimulated. Both vWF 
and UEA-1 are present in these ceils -  confirming the endotheiiai phenotype. vWF is present in 
large granules. Bone marrow is not normally the site of Inflammation, but is part of the normal 
recirculation of leukocytes.
1.2.6 Liver Endothelium
The human liver has many different functions, it acts as a secretory organ for bile and is important 
in metabolism, but it also has important functions in secretion of hormones, plasma clotting factors, 
acute phase proteins, binding proteins for steroid hormones as well as many other molecules. The 
liver consists of a large number of lobules, which usually in section look hexagonal, each lobule 
contains a central vein that eventually drains to the hepatic vein (fig. 1.4). The cells of the lobule 
are parenchymal or epithelial glandular cell (hepatocytes) which are arranged in plates, with each 
plate only being one ceil thick and radiating from the centre of the lobule towards the periphery. 
These plates are separated by sinusoids that are lined by sinusoidal endotheiiai cells and Kupffer 
cells (phagocytes).
There are many different types of liver EC -  portal vein and sinusoidal being the most common. 
Those that we are using have been shown to have I CAM-1 and MHC I expressed on their ceil 
surface when resting, but not VCAM-1 or MHC II (see table 1.2). High ICAM-1 is indicative of 
sinusoidal endothelium.
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Figure 1.4 Structure of a lobule of human liver
A. diagrammatic representation of the structure of the human liver (taken from Vander et al. 1994), B. a liver 
lobule stained with haematoxylin and eosin showing the portal triad including the portal vein (V), the bile duct 
(D), and a branch of the hepatic artery (A). Also shown are the hepatocytes of the parenchyma (P) and the 
central vein (C) picture from Berman etal. (1993).
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1.3 Leukocyte migration
A crucial step in an effective inflammatory response is the promotion of leukocyte adhesion to the 
vascular endothelium (Springer 1994; Imhof and Dunon 1995). Leukocytes usually pass through 
the blood stream as non-adherent ceils, but they become adherent in order to migrate into the 
tissues during normal leukocyte recirculation or during an inflammatory response. Endotheiiai ceils 
lining the postcapillary venules are the primary site of leukocyte migration.
At sites of inflammation, leukocyte migration is mediated by a sequence of adhesive interactions 
between endotheiiai celis and the emigrating leukocyte (summarised in fig. 1.5 and table 1.2). This 
adhesive cascade allows the circulating immune cell to slow down and finally stop on the vessel 
wall at the point where the target tissue requires it. Specific stimulatory signals are presented to the 
recruited leukocyte to enable the cell to generate shear-resistant adhesion to the vessel wall.
1.3.1 Capture and rolling on Selectins
Localisation of leukocytes to specific sites of tissue injury is aided by at least three families of 
adhesion molecules expressed by the cells involved. These are the selectins, the integrins and the 
Immunoglobulin (Ig) superfamily (Springer 1995). The first step in this process is margination, 
where leukocytes leave the central stream of fast flowing cells in the blood vessel and begin 
interactions with the endothelium. The selectins mediate the initiation of cell contact between 
leukocytes and endotheiiai ceils, forming weak interactions with the leukocyte which leads to a 
roiling of the ceil along the vessel wall (Lawrence and Springer 1991).
The seiectin family consists of three molecules, L-seiectin (on leukocytes), P-seiectin (on activated 
endothelium and platelets) and E-selectin (on activated endothelial cells). They are ail single chain 
transmembrane glycoproteins, which project up above the surrounding giycocalyx. They recognise 
structures containing siaiylated carbohydrate residues via their C-type lectin domain found at the N- 
terminus of the molecule. The ligands of selectins include GIyCAM-1, CD34, MAdCAM-1 and 
PSGL-1, which are all composed of a protein backbone that is then glycosylated. This means that 
not only is the specific molecule that selectins bind to required, but the correct enzymes need to be 
present in the environment of the cell for glycosylation.
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1.3.2 Activation of the leukocyte
Once rolling along the wall of the vessel, the leukocytes are able to sense signals from the 
endothelium, the longer a celi is held roiling along the vessel wall; the more likely it is to receive 
migration signals. If it is not activated, then it will return to the circulation immediately, however, 
interactions with chemokines, leukotriene B4 or complement components can activate leukocyte 
integrins and trigger firm adhesion. Chemokines are produced by inflammatory ceils and 
endothelial cells and have been shown to have binding sites for glycosaminogiycans (GAGs) in 
addition to those for their specific receptors (Webb et al. 1993; Tanaka et al. 1993a; Witt and 
Lander 1994). It is thought that they can pass onto the lumenal side of the endothelium where they 
bind to the proteoglycan layer from which point they can be presented to rolling leukocytes (Tanaka 
etal. 1993b; Middleton etal. 1997).
1.3.3 Firm adhesion
Binding then proceeds to a second class of adhesion molecule -  the integrins, which via their 
interactions with cell adhesion molecules of the Immunoglobulin superfamily, mediate firm 
adhesion, integrins are heterodimers, which are formed by a combination of one of 17a and 8 p 
chains in humans. Integrins contain large (a) and small (p) subunits of sizes 120-170 kDa and 90 
-100 kDa, respectively. They fall into three major families depending on which p chain they have.
The integrins a4pi (VLA-1), a4P? (LPAM-1), a%p2 (pi 50,95) auPz (LFA-1 ), and Mac-1 (awp2) have 
major functions in regulating leukocyte -  endothelial interactions. Firm adhesion of leukocytes to 
endothelium via integrins can occur by two possible mechanisms. The first is increased affinity, of 
integrins for their ligands which is mediated by the binding of divalent cations such as Mg^  ^and 
Ca^  ^ resulting in rapid conformational changes. The second is an increase in avidity through 
integrin clustering (Stewart et al. 1996). This has been shown to strengthen adhesion to 
immobilised integrin ligands, it works by an enzyme dependent mechanism which releases the 
integrins from the cytoskeieton of the leukocyte so they can move together.
Chemokines were first suspected of signalling integrin activation, because it was found that adding 
pertussis toxin (a G-protein signalling inhibitor) couid block leukocyte arrest. Several studies have 
since confirmed this finding for different cell types (Tanaka et al. 1993a; Campbell et al. 1998; 
Kitayama et al. 1998). A similar effect has also been observed by cross-linking seiectin molecules.
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The activation, movement and conformational change of the integrins leads to firm arrest of cells 
on the vessel wall and then transendothelial migration.
The ligands for integrins on endothelial cells are five cell adhesion molecules of the Ig superfamily 
whose expression on the endothelial cell surface can be regulated by cytokines and also by shear 
forces (reviewed in Wang and Springer 1998; Yang et al. 2002). To be included in this family, one 
or more immunoglobulin domains should be present, each domain is usually encoded by a discrete 
exon and consists of a primary sequence of 60 - 70 amino acids with a disuiphide bridge spanning 
50 - 70 residues. This sequence permits folding into particular tertiary structures consisting of a 
sandwich arrangement of p pleated sheets known as an antibody fold. The Ig superfamily adhesion 
molecules involved in migration are all single chain glycoproteins with differing numbers of 
extracellular Ig-like domains, followed by a transmembrane sequence and a short cytoplasmic 
domain.
The a4 integrins involved in leukocyte migration bind to endotheiiai VCAM-1 and MAdCAM-1 with 
a4p1 preferentially binding VCAM-1 while a4p7 preferentially binds MAdCAM-1. p2 integrins 
recognise the Intercellular adhesion molecules (ICAMs), aLp2 will bind ICAM-1,2 and 3, while Mac- 
1 will bind ICAM-1. ICAM-2 is constitutively expressed on endothelium and is involved in binding to 
resting endothelium and normal leukocyte recirculation, while ICAM-1, VCAM-1 and MAdCAM-1 
are all inducible with the pro-inflammatory cytokines TNF-a, IL-1 as well as LPS. IFN-y is only a 
weak inducer of ICAM-1 alone, however it shows strong synergy with TNF-a or IL-1.
1.3.4 Transendothelial migration
Once activated, integrins interact with members of the Ig superfamily (Ruoslahti, 1991; Hynes, 
1992), these interactions allow the leukocytes to squeeze through or between the endothelial cells 
and cross the vessel wall in a process known as diapedesis. This is the final step in leukocyte 
transmigration. It is at this stage that adherent ceils can extend pseudopodia into the interceiluiar 
junctions between endotheiiai ceils, then squeeze through the gap, digest the basement membrane 
and migrate out into the tissues.
Much less is known about the precise mechanisms of this stage than is known about the first three 
steps in this cascade. Chemokines have been discovered to be important in this step (Randoiph 
and Furie 1995) and have been found to drive neutrophils to migrate. Other chemokines invoived in
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recruitment are important for later steps -  such as guiding ieukocytes through the interstitium to the 
site of infection etc. There is aiso evidence for many of the junctionai proteins and proteolytic 
enzymes playing an important role.
It is stiil controversial as to exactly how the leukocyte transmigrates and whether it passes through 
the ceil or through the intercellular junctions. It is iikely that different ieukocytes migrate by different 
methods, which also depend on the type of endothelium and whether it is continuous or 
discontinuous.
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Figure 1.5 Leukocyte migration
Showing the different stages of leukocyte migration; 1. Capture and rolling on selectins, 2. Activation of the 
leukocyte and tight binding by integrins, 3. Transendothelial migration, 4. Migration through the tissues and 
ECM to the injury site, (from Janeway and Travers 1997)
Table 1.2 Adhesion Molecules involved in Leukocyte Recruitment
ADHESION
MOLECULE
EXPRESSION LIGAND EXPRESSION OF LIGAND
E-selectin
Cytokine activated 
endothelium
Siaiylated Lewis X and 
similar structures, E 
seiectin ligand
Neutrophil, Monocyte, Eosinophil, 
Basophil, some lymphocytes, NK 
cells
L-selectin
Monocytes, 
Neutrophils, 
Eosinophils, some 
Lymphocytes
Siaiylated, fucosylated, 
sulphated carbohydrates 
found on; GlyCAM-1, 
CD34, MAdCAM-1
HEV, Activated endothelium
P-selectin
Activated Endothelium, 
platelets
Sialomucin side chains of 
PSGL
Neutrophils, Monocyte, 
Eosinophil, Basophil, NK cells, 
some lymphocytes
aL(32 (LFA-1)
All lymphocytes, 
monocytes, neutrophils.
ICAM-1, 2 Endothelium and other cell types 
(constitutive and cytokine 
inducible)
aMp2 (Mac-1) Monocytes, neutrophils ICAM-1, C3b, fibronectin, factor X
Endothelium (and others)
aXp2 (pi 50,95)
Monocytes,
Neutrophils,
Eosinophils
C3b, fibronectin
a4p1 (VLA-4)
Lymphocytes, 
monocytes, basophils, 
eosinophils
VCAM-1, fibronectin. Endothelium, macrophages and 
dendritic cells (constitutive and 
cytokine inducible)
a4p7 (LPAM-1) Lymphocytesubpopulations
MAdCAM-1, VCAM-1, 
fibronectin
Mucosal endothelium
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1.4 Chemokines
Chemokines are a family of small molecular weight proteins (8 -1 4  kDa) with 20 -  70% homology 
in amino acid sequences. In 1977, Platelet factor 4 (PF-4) was first described, but it was a further 
10 years before IL-8  was Isolated from culture supernatants of stimulated human blood monocytes 
and identified as a chemoattractant for leukocytes (Walz et al. 1977; Walz et al. 1987; Yoshlmura 
et al. 1987). Since then many more chemokines have been identified and have been found to 
function as regulatory molecules in immunosurveillance, homeostasis, traffic and homing of 
lymphocytes and the development and differentiation of naïve cells of the immune system. To date, 
more than 40 different human chemokines have been discovered (Baggiolini etal. 1994; Baggiolini 
et al. 1997; Zlotnik et al. 1999). They are classified into four distinct groups, CXC, GO, 0  and 0X30 
chemokines, which depend on the number and positioning of the cysteine residues at the N- 
terminus. The 0X0 and 0 0  are the largest families and the most characterised. The 0X0 group 
has one amino acid between the first and second cysteines while In the 0 0  group the cysteines are 
next to each other. There are two other chemokines that do not fit into these classes and map to 
different loci, so each forms their own class. Lymphotactin (0 class) has lost the first and third 
cysteines, and hence has only one cysteine at the N-terminus (Kelner et al. 1994) but fractalkine 
(0X30) is a membrane spanning protein that has 3 amino acids between the first and second 
cysteine (Bazan et al. 1997). The 0X0 chemokines can be further classified into ELR+ or ELR- 
chemokines according to the presence or absence of the glutamate - leucine -  arginine motif 
between the N-terminus and the first cysteine. ELR+ chemokines are specific for monocytes and 
granulocytes, while ELR- attract a variety of leukocytes. It has been shown that IL-8  loses its 
activity when the ELR motif is removed or mutated. PF4, which is normally ELR-, can Induce 
degranulation and chemotaxis of neutrophils when the ELR motif is inserted. So it appears that this 
motif is particularly important in the binding of neutrophils through the 0X0R1 and 2 receptors. The 
nomenclature has recently been updated to reduce problems with the numerous names that had 
come into being for each different chemokine (Zlotnik and Yoshie 2000). This is shown in table 1.3.
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Table 1.3 Chemokine classification and nomenclature
FAMILY SYSTEMATIC NAME COMMON NAME RECEPTOR ELR STATUS
0X0L1 Gro-a / MGSA-a 0X0R1,2 ELR+
0X0L2 Gro-3 / MGSA-3 0X0R2 ELR+
0X0L3 Gro-y / MGSA-y 0X0R2 ELR+
0X0L4 PF-4 Unknown ELR+
0X0L5 ENA-78 0X0R2 ELR+
0X0L6 GOP-2 0X0R1,2 ELR+
CXC 0X0L7 NAP-2 0X0R1, 2 ELR+0X0L8 IL-8 0X0R1, 2 ELR+
0X0L9 Mig 0X0R3 ELR-
OXOL10 IP-10 0X0R3 ELR-
0X0L11 l-TAO 0X0R3 ELR-
0X0L12 SDF-1a/-13 0X0R4 ELR-
0X0L13 BLO / BOA-1 0X0R5 ELR-
0X0L14 BRAK / bolekine Unknown ELR-
xc X0L1 Lymphotactin / SOM-1 a X0R1X0L2 SOM-1 3 X0R1
CX3C 0X30L1 Fractalkine 0X30R1
00L1 1-309 00R8
00L2 MOP-1 / MOAF 00R2
00L3 MIP-1a 00R1,5
00L4 MIP-1 3 00R5
00L5 RANTES 00R1,3, 5
(00L6) Mouse 0 1 0  / MRP-1 Unknown
00L7 MOP-3 00R1,2, 3
00L8 MOP-2 00R3
(00L9) reserved -
(OOL10) reserved -
00L11 Eotaxin 00R3
(00L12) Mouse MOP-5 00R2
00L13 MOP-4 00R2, 3
0 0 00L14 HOO-1 00R1
00L15 H00-2/Lkn-1 /MIP-1Ô 00R1,3
00L16 HOO-4/LEO/LOO-1 00R1
00L17 TARO 00R4
00L18 DO-OK-1 / PARC / AMAO-1 Unknown
00L19 M IP-33 / ELO / Exodus-3 00R7
OOL20 MIP-3a / LARO / Exodus-1 00R6
00L21 60kine / SLO / Exodus-2 00R7
OOL22 MDO/STOP-1 00R4
OOL23 MPIF-1 / MIP-3 00R1
OOL24 MPIF-2 / Eotaxin-2 00R3
OOL25 TEOK 00R9
OOL26 Eotaxin-3 00R3
OOL27 OTAOK OOR10
Processing from a longer protein of 9 2 -  125 amino acids to a shorter version of 7 0 -  100 amino 
acids is common to many chemokines. For example, the open reading frame of IL-8  cDNA codes 
for 99 amino acids, while the mature form has been processed to a 72 amino acid protein.
In general, CC chemokines exhibit attraction for monocytes, lymphocytes, eosinophils and 
basophils while CXC chemokines are chemoattractant for neutrophils and the CXCR3 binding
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chemokines are specifically attractant for activated T cells. The effects of chemokines are mediated 
by their specific G-protein coupled receptors and cellular responses depend on the presence of the 
relevant receptor, which determines the spectrum of action of the chemokines (Horuk 2001). 
Chemokines not only mediate chemotaxis, but also have many other functions including mediator 
release by triggering degranulation of intracellular vesicles or upregulation of integrins. Until 
recently, leukocytes were thought to be the only sites of chemokine action, but there is increasing 
evidence that other cell types are capable of binding and responding to various chemokines.
As I have previously described, chemokines are a key element In the multistep process of 
leukocyte recruitment (Springer 1994; Baggiolini 1998; Olson and Ley 2002) and are produced by 
endothelial cells in response to molecules involved in inflammatory reactions, immunity and 
thrombosis. The chemokine repertoire of the EC includes members of both the CXC (IL-8, IP-10, 
ENA-78 and gro-a) and CC (MCP-1, MCP-3 and RANTES) families of chemokines. Most studies 
so far have focussed on IL-8 and MCP-1.
Chemokines have also been found to have a separate and very distinct heparin-binding site, which 
allows them to bind to heparan sulphate present on the proteoglycan layer (Lortat-Jacob et al. 
2002). They are highly basic molecules and can be immobilised by interacting with the negatively 
charged GAGs. Binding of chemokines to HSPG is thought to assist in dimerization and orientation 
of the chemokine (Hoogewerf et al. 1997). Chemokines have been found to have enhanced 
activities when bound to GAGs. Specific chemokines have been found to bind different types of 
GAGs with different affinities (Kuschert et al. 1999). Since GAG type can vary with cell type, 
location and inflammatory status, the regulation of GAG expression by different endothelial cell 
types could be important within the cascade of leukocyte migration. The involvement of both 
adhesion molecules and chemokines in leukocyte extravasation means that selectivity for a tissue 
is determined combinatorially, with selectins, integrins, chemokines and GAGs all taking part 
(Mackay 2001).
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1.5 Chemokine receptors
The specific effects of chemokines on their target cells are mediated by seven-transmembrane- 
spanning, G-protein coupled receptors (specifically Gal coupled receptors)(Gerard and Gerard 
1994; Murphy et al. 2000). The extracellular loops and NH2-terminus are responsible for ligand 
binding, while the intracellular loops and carboxy-termlnal tail are involved in G-protein interactions 
and signal transduction (see fig. 1.6). Chemokine receptors are defined by their ability to signal on 
binding one or more chemokines. These receptors are part of a much larger family of G-protein 
coupled receptors which can react to many other molecules including hormones, neurotransmitters, 
paracrine substances and other inflammatory mediators. Although each of these chemokine 
receptors binds only a single class of chemokines, they can bind to several different members of 
the same class with high affinity. For example CXCR3 binds to IP-10, l-TAC and Mig with high 
affinity, though it has been shown to bind l-TAC better than the other two. Only the promiscuous 
chemokine binding proteins DARC and D6 (not true chemokine receptors as they do not signal) 
have been shown to bind both CC and CXC chemokines.
Chemokine receptor binding initiates a cascade of intracellular events which culminates in specific 
biological effects. When the chemokine binds to its receptor, it induces a conformational change in 
the G-protein and splits off the a subunit off from the Py subunit. These subunits can act as second 
messengers and activate several enzyme cascades, which induce calcium mobilisation and protein 
kinase activation. These reactions can have many different cellular functions depending on the 
particular cell type that they take place in, including increased adhesion molecule expression, 
stimulation of the respiratory burst, degranulation or phagocytosis.
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Figure 1.6 Chemokine receptor structure
Showing the seven transmembrane domains of the receptor and the position in which the chemokine binds, 
(modified from Murdoch and Finn 2000 with thanks to J.L. Wood for help with this image).
The first chemokine receptor to be cloned was the IL-8 receptor in 1991 (Beckmann et al.), to date 
a total of 18 chemokine receptors have been discovered (Table 1.4). Five receptors selectively bind 
certain CXC chemokines (CXCR1-6), whilst the CC receptor family consists of a further eleven 
receptors (CCR1-10). There is one receptor (XCR1) for lymphotactin -  the one representative of 
the C family and one receptor for fractalkine (CX3CR1). A further two chemokine binding proteins 
have also been identified, the first is known as the Duffy antigen receptor for chemokines (DARC) 
which has been shown to bind promiscuously to both CXC and CC chemokines. The second is 
known as D6 and has been shown to bind several CC chemokines (Nibbs et al. 1997). DARC has 
a possible role as a sink for some chemokines to maintain gradients of more important chemokines 
(Horuk et al. 1994). These two binding proteins apparently do not signal and so are excluded from 
the standard nomenclature.
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Table 1.4 Characteristics of chemokine receptors currentiy known
RECEPTOR HIGH AFFINITY LIGANDS CELLULAR DISTRIBUTION
CXCR1 IL-8, GCP-2, Neutrophils, Monocytes, Macrophages, Mast cells
CXCR2 IL-8, Gro-a,Gro-p, Gro^, NAP-2, 
ENA-78, GCP-2
Neutrophils, Monocytes, Macrophages, 
Eosinophils, Mast cells
CXCR3 IP-10, ITAC, Mig Activated T cells, B cells, NK cells
CXCR4 SDF-1 Neutrophils, Monocytes, Macrophages, Dendritic 
cells. Resting T cells, B cells. Progenitor cells
CXCR5 BCA-1 B cells, memory T cells
CXCR6 SexCKine Dendritic cells, T cells
CCR1 RANTES, MIP-1a, MCP-3, 
HCG-1, Lkn-1, MCP-2, MPIF-1
Neutrophils, Macrophages, Eosinophils, Basophils, 
Immature dendritic cells. Memory T cells, NK cells
CCR2 MCP-1 - 4 Neutrophils, Macrophages, Activated T cells, B 
cells, NK cells
CCR3 Eotaxin, Eotaxin-2, MCP-2-4, 
Lkn-1, RANTES, Eotaxin-3
Eosinophils, Basophils, Th2 cells
CCR4 TARC, MDC Immature dendritic cells, Th2 cells, NK cells
CCR5 MIP-1a, MIP-ip, RANTES Monocytes, Macrophages, Dendritic cells, T cells 
(ThO, Thi)
CCR6 LARC Immature dendritic cells. Memory T cells, B cells
CCR7 ELC, SLC Mature dendritic cells, T cells, B cells
CCR8 1-309 Monocytes, Macrophages, Th2 cells. Thymus
CCR9 TECK a4p7+ T cells. Thymus
CCR10 Eotaxin-3, CTACK, MEC T cells, Langerhans cells
CX3CR1 Fractalkine Monocytes, Macrophages, T cells, NK cells
XCR1 Lymphotactin T cells, NK cells
DARC IL-8, Gro-a, RANTES, MCP-1, 
NAP-2
Erythrocytes
D6 MCP-1-4, MIP-ip, RANTES, 
HCC-1
T cells
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1.6 The Proteoglycan Layer
The endothelial cell surface is coated with a thick giycocalyx (15 -  40 nm thick); this is a 
carbohydrate rich zone, which on endothelial cells Is composed of glycoproteins (Simionescu et al. 
1982; Simionescu and Simionescu 1986). Most of the carbohydrates present are attached to 
membrane proteins, but a small proportion are secreted glycoproteins which have been adsorbed 
onto the celi surface.
Proteoglycans are a specific class of glycosylated proteins, which consist of a core protein with 
unbranched glycosaminoglycan (GAG) chains attached to it (reviewed in Kjellen and Lindahl 1991). 
There are more than 20 different core proteins, but those present on human endothelium, include 
the syndecans, the glypicans and CD44. GAGs are sulphated polysaccharide chains made up of 
repeating disaccharide subunits (usually 40 to 100 repeats). The GAGs that are commonly 
encountered in human tissues include chondroitin sulphate, dermatan sulphate, heparan sulphate 
and keratan sulphate, they each consist of different disaccharides with different sulphation 
patterns.
Table 1.5 Composition of glycosaminogiycans
DISACCHARIDE GLYCOSAMINOGLYCAN SULPHATION PATTERN
Glucuronic acid / iduronic acid-N- 
acetylgalactosamine
Dermatan sulphate Irregular spaced pattern
Chondroitin sulphate Regular pattern
Glucuronic / iduronic acid-N- 
acetyl glucosamine
Heparan sulphate Irregular spaced pattern
Heparin Regular pattern
Galactose-N-acetylglucosamine Keratan sulphate
1.6.1 Proteoglycan synthesis
The core protein is made on membrane bound ribosomes and is then threaded into the lumen of 
the endoplasmic reticulum, but it is turned into a proteoglycan when the polysaccharide side chains 
are attached in the golgi. The synthesis of GAGs in the golgi is quite complex, but basically a 
special link tetrasaccharide is attached to serine residues on the core protein. This serves as a 
primer for polysaccharide growth as glycosyl transferases add one sugar residue at a time. While
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still in the golgi, the molecule is modified by sulphation (which gives the molecule its negative 
charge) and épimérisation, which alters the configuration of the molecule around individual carbon 
atoms.
Proteoglycans have potentially unlimited heterogeneity. The core proteins can range from 10 to 
600 kDa and have a great variety of numbers and types of GAG chains, which can be modified by 
different amounts of sulphation. This makes it difficult to accurately identify the proteoglycans In 
particular In terms of their sugars although the core proteins can be identified. There have been no 
particular structural motifs found which could aid in identification.
1.6.2 Biological effects of proteoglycans
Proteoglycans can be attached either to the basement membrane or to the surface of cells -  via a 
transmembrane protein core (e.g. syndecans) or via covalent binding to phospholipids (e.g. 
glypicans). They have many functions in cells, where they perform a major role In cell to cell 
signalling and can also bind to and regulate the activity of secreted proteins including growth 
factors, proteases and protease inhibitors. They are also hydrophilic and can trap water, hence 
providing hydrated space around and between cells.
Heparan sulphate Is the major GAG expressed on cell surfaces and is usually present as heparan 
sulphate proteoglycan (HSPG). In this form, it is important in cell growth and adhesion and also 
maintains a non-thrombogenic surface on the lumen of blood vessels (Gallagher 1995). Other 
important effects include aiding the dimérisation of certain protein mediators.
One of the most important roles of HSPG on the endothelial surface is in the regulation of anti­
thrombin -  an inhibitor of pro-coagulant proteases in blood and vascular tissues. HSPG 
accelerates the inhibition of thrombin and activated factor X by anti-thrombin, hence exerting 
effects on the coagulation pathway. Binding of heparan sulphate to anti-thrombin causes a 
conformational change, and exposes the reactive site for thrombin.
Heparan sulphate can also be Involved In the activation of bFGF. By binding to heparan sulphate, 
binding to its specific FGF receptor is mediated. Similar HSPG binding properties also exist for 
other cytokines including TGF-p, IFN-y, IL-3, GM-CSF and VEGF.
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1.7 Chemokines involved in inflammation
The major role of chemokines is in the control of leukocyte migration. Today -  fifteen years after 
the discovery of IL-8, numerous chemokines have been identified as attractants of different types of 
blood leukocytes to sites of infection and inflammation. They are produced locally in the tissues, by 
many cell types, and act on leukocytes and other cell types through selective receptors.
Many peptide chemoattractants may be produced in one place -  for example if a bacterial infection 
occurs. It is thought that leukocytes can follow complex chemokine gradients in a step by step 
manner - from one gradient to the next and can integrate many signals. Chemokines in this 
situation act in an overlapping and sequential fashion on each cell (Foxman et a/. 1997), and this 
may explain how receptor promiscuity and specificity are combined in vivo.
The effects of chemokines on cells are very rapid, the most impressive effect being the immediate 
shape change caused by the polymerisation and breakdown of actin. This leads to the formation 
and retraction of lammellipodia, whose function is in moving the cells during migration. Another 
rapid effect is the upregulation and activation of integrins on the leukocyte which enable the cell to 
tightly adhere to the blood vessel wall and subsequently migrate through the wall of the vessel. 
Adhesion via integrins has recently been shown to require a higher threshold concentration of 
chemokine present than that required for chemotaxis, therefore receptor expression may not 
necessarily mean that adhesion triggering will occur. There are several other effects of chemokines 
which can be observed on different celi types -  including a rise in intracellular calcium levels, the 
production of microbicidal oxygen radicals and the release of the contents of certain cytoplasmic 
storage granules.
Many chemokines are produced under conditions of inflammation or infection by tissue cells and 
infiltrating leukocytes, however some chemokines are constitutively expressed by certain cell types 
and seem to fulfil housekeeping functions. Some chemokines (e.g. SDF-1 a, SLC, MIP-Sp) are 
capable of triggering adhesion of most lymphocytes, others are more specialised and only activate 
particular subsets (e.g. MIP-3a - memory CD4+ T cells). This suggests that only certain cell types 
will be activated -  that are specific to the process in hand.
The effector phase of an immune response involves the secretion of cytokines by antigen 
stimulated leukocytes, which serve to recruit and activate the various responsive cell populations
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that comprise the inflammatory Infiltrate, among them the mononuclear phagocytes which in turn 
secrete additional cytokines that influence the reaction. Under certain circumstances, the immune 
response can be activated inappropriately and targeted at normal healthy tissue. Chemokines are 
associated with these problems as much as with a normal immune response for example in allergic 
diseases such as asthma or dermatitis and in autoinflammatory diseases such as multiple sclerosis 
or rheumatoid arthritis. In recent years, there has been much Interest in the therapeutic potential of 
chemokines and chemokine antagonists (Saunders and Tarby 1999; Schwarz and Wells 1999; 
Cascieri and Springer 2000; Power and Proudfoot 2001 ; Ajuebor et al. 2002).
In this thesis I will be concentrating specifically on differences between cell types in chemokine 
activities during inflammation. To do this, I have chosen a panel of pro-inflammatory chemokines to 
examine, which will now be discussed in greater detail.
1.7.1 IL-8 (CXCL8)
IL-8 is a member of the CXC chemokine family and was purified as a monocyte derived factor that 
attracts neutrophils, but not monocytes (Yoshlmura et al. 1987). It acts via two receptors, CXCR1 
and CXCR2 and is the most potent neutrophil chemotactic agent known. The ELR motif Is 
particularly important in neutrophil chemotaxis. Many other cell types produce IL-8 as well as 
monocytes -  In particular T cells, neutrophils, fibroblasts, endothelial and epithelial cells. It triggers 
(32 integrin mediated firm adhesion of monocytes to endothelium, stimulates the respiratory burst in 
neutrophils, induces degranulation and promotes attachment and transendothelial migration of 
neutrophils (Huber et al. 1991). IL-8 also induces histamine release from basophils (White et al. 
1989), has chemotactic activity for lymphocytes and eosinophils and has important functions in 
angiogenesis.
IL-8 in its final form can be either 72 or 77 amino acids in length depending on which cell type 
produced it and exactly which enzymes are used in processing (Hebert et al. 1990). The 72-amino 
acid form is predominant in cultures of monocytes and macrophages, while the longer form is 
common in supernatants from tissue cells such as endothelial cells. The longer form is 
considerably less potent as a neutrophil chemoattractant in vitro, but in vivo it shows similar 
chemotactic activity to the shorter form, perhaps due to processing mechanisms which are present 
in vivo, but not in vitro. IL-8 is expressed early in many types of infection and wounding, bringing 
neutrophils to the damaged site.
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1.7.2 MIP-1a(CCL3)
Macrophage inflammatory protein - la  (MIP-1 a) is a 69 amino acid CC chemokine produced by 
fibroblasts, monocytes, lymphocytes, neutrophils, eosinophils, smooth muscle cells and mast cells. 
It was first purified from LPS treated monocytic cell lines (Wolpe et al. 1988). It binds to CCR1 (Gao 
et al. 1993; Neote et al. 1993b) and CCR5 (Raport et al. 1995; Raport et al. 1996) and has been 
found to have effects on most leukocytes with the exception of B cells, but the predominant cell 
type that it chemoattracts is CD8‘" T cells. MIP-1a production is inducible in many cell types by 
TNF-a, IL-1 and LPS and on neutrophils by IFN-y. TGF-p appears to downregulate the production 
of MIP-1a by macrophages (Sherry et al. 1998). Its effects, apart from chemotaxis of most cells of 
the immune system, include stimulating histamine release by basophils and mast cells, triggering 
p2 integrins on monocytes, stimulating degranulation of eosinophils, the oxidative burst in 
neutrophils and enzyme release by macrophages. It also increases cytokine production and 
proliferation of monocytes, however it has opposing effects on T cells -  decreasing levels of 
cytokines produced and inhibiting proliferation, but increasing adhesion.
MIP-1a is expressed in bronchoalveolar lavage fluid harvested from patients with lung diseases or 
hypersensitivity reactions (Alam et al. 1996; Capelli et al. 1999) and is found at increased levels in 
the cerebrospinal fluid of patients with multiple sclerosis (Miyagishi et al. 1995).
1.7.3 RANTES (CCL5)
RANTES (regulated upon activation, normal T-cell expressed, and secreted) is 68 amino acids long 
and induces leukocyte migration by binding CCR1, CCR3 and GCR5 (Schall 1991; Appay and 
Rowland-Jones 2001). RANTES is specifically chemotactic for T cells of the memory subtype, 
monocytes and eosinophils (Schall et al. 1990; Alam et al. 1993). It is produced In vivo during 
allergic reactions and is thought to play an important role in accumulation of CD4+ memory T celis 
during delayed type hypersensitivity (DTH) reactions. Induction of RANTES gene expression and 
production of RANTES protein has been shown to be optimally produced by a combination of TNF- 
a and IFN^ (Marfaing Koka et al. 1995). Gene induction by TNF-a or IFN-y has also been reported 
in other cell types -  IFN^ stimulates RANTES production in monocytes (Devergne et al. 1994), 
while TNF-a and IL-1 (3 stimulate RANTES gene induction in fibroblasts and renal tubular epithelial 
cells (Rathanaswami et al. 1993; Pattison et al. 1994). RANTES induces calcium mobilisation and
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migration in dendritic cells and mediates the trafficking of many different cell types including T cells, 
monocytes, basophils, NK cells, DC and mast cells. It is produced by CD8+ T cells, epithelial cells, 
fibroblasts and platelets.
RANTES has been implicated in a wide range of diseases and disorders -  usually by the promotion 
of infiltration of leukocytes e.g. in arthritis, atopic dermatitis, asthma and DTH reactions 
(Rathanaswami et al. 1993; Alam et al. 1996; Thornton et al. 1999). It is also important in the 
response to viral infection as it is degranulated from activated cytotoxic T cells along with perforin 
and granzyme A. It is of particular interest for researchers because of its ability to suppress 
replication of HIV and because of its binding to OCRS which is now know to be an HIV co-receptor 
(Lehner 2002). The precise role of RANTES In suppression of HIV is still not known, but it appears 
to be critically dependent on the GAGs present on the surface of the Infected cells.
RANTES Is known to form dimers, but this does not appear to be essential for receptor binding. 
However the binding to GAGs plays a central role in trafficking and migration of leukocytes as this 
appears to be the way in which dimers and concentration gradients are formed.
1.7.4 MCP-1 (CCL2)
Monocyte chemoattractant protein -  1 (MCP-1) was one of the first discovered and is now the most 
extensively studied of the CC chemokines. Human MCP-1 was purified from culture supernatants 
of blood mononuclear cells, glioma and myelomonocytic cell lines as a monocyte (but not 
neutrophil) chemoattractant (Matsushima et al. 1989). It has now been found to be active on 
several other leukocyte subsets. MCP-1 Is produced by many different cell types including 
leukocytes, endothelial cells and fibroblasts after stimulation. The mature protein is 76 kDa (once 
its signal sequence has been cleaved) and can be glycosylated with a slight reduction in 
chemotactic activity as a result (Proost et al. 1998). MCP-1 has several closely related family 
members (MCP 2-4 and 3 eotaxins) with 56 -  71% sequence homology. MCP-1 binds strongly to 
CCR2, which is widely expressed in different cells of the Immune system such as basophils, 
monocytes, activated memory T cells, NK cells and blood derived dendritic cells. CCR2 receptors 
are upregulated on the surface of T cells after stimulation with IL-2, but are constitutively expressed 
on the monocyte cell surface. LPS and IFNy have been found to downregulate the CCR2 receptor 
on monocytes -  hence reducing the effects of MCP-1. At physiological concentrations MCP-1 is 
present as a monomer, but will form dimers at high (100 pM) concentrations. CCR2 receptor
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triggering may require dimérisation (Rodriguez-Frade et al. 1999), which is thought to be mediated 
by binding to heparan sulphate.
As its name suggests, the most important function of this chemokine is as a mononuclear cell 
chemoattractant. MCP-1 chemoattracts T cells and monocytes at very low concentrations (0.1 - 0.3 
nM and 0.01 - 0.1 nM respectively) (Van Damme et al. 1992; Taub et al. 1995a; Uguccioni et al. 
1995). At higher concentrations (>3 nM) it can attract basophils, stimulated NK cells and DC (Taub 
et al. 1995b). MCP-1 also induces enzyme release by T cells, monocytes and NK cells which 
allows digestion of the ECM as part of migration toward an injury or infection. It also stimulates 
basophils to release histamine and leukotrienes and monocytes to upregulate integrins CD IIb and 
CDIIc.
In vivo, transgenic mice with promoters that allow selective expression of MCP-1 in different organs 
all showed similar accumulation of mononuciear cells in the particular organ that was over 
expressing this chemokine. Knockout models have shown defects in monocyte recruitment in 
response to inflammatory stimuli or antigen chaiienge. CCR2 -/- mice had defects in DIM 
responses and in IFN-y production (Boring et al. 1997).
Increased expression of MCP-1 is evident in many disease processes in humans; atherosclerosis 
is the best studied, where it is thought to be crucial in disease initiation, but it is also found In 
psoriasis and several types of hypersensitivity reactions in the skin. MCP-1 is increased in the 
synovial fluid of those patients with rheumatoid arthritis and is found in many lung diseases 
particularly allergic reactions where it stimulates release of histamine. It also Is implicated in MS 
and the response to microbial infection.
The control of MCP-1 expression has been extensively studied unlike other chemokines and has 
proven quite complicated due to the number of different inputs that stimulate and repress its 
expression. There is one responsive element that appears to regulate basal promoter activity, 
another that responds to shear stress, a GC box that regulates basal transcriptional activity (Ueda 
et al. 1994; Shyy et al. 1995; Ueda et al. 1997). Several NFkB elements as well as an AP-1 
sequence have been found at different sites in different cell types, which respond specifically to 
TNF-a and IL-1p. Some cells can respond to IFN-y which induces the MCP-1 promoter via a 
gamma activated sequence (Majumder et al. 1996). Only the NFkB and AP-1 sites have been 
shown to be implicated in endothelial production of MCP-1 so far (Martin et al. 1997).
50
1.7.5 IP-10 (CXCL10)
IP-10 was identified by Luster et al. (1985) as an interferon inducible gene. They subsequently 
characterised its production by HUVEC (Luster and Ravetch 1987a; Luster and Ravetch 1987b). It 
lacks the ELR motif and hence has angiostatic effects, which are mediated by its sole receptor 
CXCR3 (Strieter et al. 1995a). Other functions of this molecule Include acting as a chemoattractant 
for monocytes, NK cells and IL-2 activated T cells. It is synthesised in monocytes, endothelium, 
fibroblasts and kératinocytes as a 98 amino acid precursor protein, which is then cleaved to the 77 
amino acid mature form. The expression of IP-10 is distinct from the other chemokines that we are 
investigating in that it does not respond to either TNF-a or IL-1 on their own, but when either or 
both of these are used in combination with IFN-y, then a massive response is observed. Angiostatic 
chemokines and cytokines are thought to be required in the later stages of wound healing as an 
‘ofT signal for angiogenesis (Belperio et al. 2000).
1.7.6 Gro-a(CXCLI)
Gro-a was originally described as a product of a gene differentially expressed in transformed 
hamster cells that had suffered loss of growth control (Anisowicz et al. 1987) and In human cells as 
melanoma growth stimulatory activity (Richmond et al. 1988; Richmond and Thomas 1988). It was 
later shown to activate human neutrophils (Moser et al. 1990; Schroder et al. 1990) and to have a 
similar neutrophil chemoattractant potency to IL-8. Gro-p and Gro-y are structurally very similar 
(approx. 90% homologous) and show very similar properties. All three Gro chemokines are ELR+ 
and bind to CXCR2, which is found on monocytes and macrophages, eosinophils, mast cells and 
lymphocytes. A major function of these chemokines is in angiogenesis where they stimulate the 
proliferation of endothelial cells. Gro-a is produced by monocytes, neutrophils, endothelial cells and 
macrophages and its production is stimulated by IL-1, TNF-a and LPS as well as thrombin.
1.7.7 Eotaxin (CCL11)
Eotaxin was first found in guinea pig and mouse as an eosinophil chemoattractant before it was 
cloned in humans (Garcia-Zepeda et al. 1996; Kitaura et al. 1996; Ponath et al. 1996). It Is a 97 
amino acid protein which when the signal protein of 23 residues is cleaved forms a mature protein 
of 74 amino acids. This mature protein is 66% identical to MCP-1 and belongs to the same sub 
family of chemokines. It is present both as a monomer and as a dimer at physiological
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concentrations. Eotaxin binds only CCR3, however many other chemokines have also been found 
to bind to this receptor (table 1.5). CCR3 Is expressed on eosinophils, basophils, T cells and DC. 
Eotaxin is produced by connective tissue ceils as well as by subsets of leukocytes. The expression 
of eotaxin by epithelial cells, endothelial cells and fibroblasts has been demonstrated, results 
indicate that induction occurs after stimulation with pro-inflammatory cytokines such as IL-1, 
TNF-a, IFN-y and IL-4 or by combinations of more than one of these. Monocytes and T cells are 
also sources of eotaxin, but it is not known what induces them.
Eotaxin functions in the directional migration of eosinophils and basophils at 0.1 -  1 nM. It 
stimulates calcium mobiiisation, the respiratory burst and upregulates C D IIb  in eosinophils as well 
as stimulating leukotriene C4 release from both eosinophils and basophils (reviewed in Van Coillie 
et al. 1999). It has also been shown to upregulate ICAM-1 and 2 levels on endothelium. Eotaxin -/- 
mice showed reduced numbers of eosinophils in the jejunum and thymus, which suggests that 
eotaxin is required for normal recirculation in a healthy individual (Matthews et al. 1998). It has also 
been shown that when a mouse is challenged with antigen in a model for asthma eotaxin is 
important in the eariy response to challenge (Rothenberg et al. 1997).
Eotaxin has been implicated in asthma and other lung diseases such as allergic rhinitis as well as 
in diseases of the digestive tract such as Crohns disease and ulcerative colitis. It contributes to the 
inflammatory infiltrate and also activates basophils and mast cells to degranulate and release 
histamine (Nickel etal. 1999; Broide and Sriramarao 2001; Lloyd 2002; Romagnani 2002).
52
1.8 Aim
An effective inflammatory response requires cells of the immune system such as leukocytes to 
migrate across the endothelial cell layer into damaged and diseased tissues. This involves 
molecular mechanisms, which enable leukocytes to recognise sites of injury and infection from 
within the vasculature and form contact with the endothelium in order to exit the blood stream and 
migrate through the blood vessel wall and interstitium. Chemokines are necessary for many of 
these steps, and our research is concerned with how they might exert control over the process of 
leukocyte migration in different tissues.
The aim of this study is to investigate how leukocyte migration might differ between vascular beds. 
To do this we particulariy want to concentrate on the chemokines as these are thought to be the 
major controlling molecules in the selective recruitment of different subsets of leukocytes to 
different tissues during inflammation. Several studies have demonstrated chemokine production 
and receptor expression by different endothelial cell types and under differing conditions. In this 
study we provide a comparison between many different endothelial cell types from different 
vascular beds under the same conditions. We investigate how they vary in their ability to produce 
and express different chemokines and receptors as the signalling involved in leukocyte recruitment 
and homing is thought to vary between different tissues. We will also investigate the role of the 
proteoglycan layer in presentation of chemokines on the surface of different endothelia.
1.8.1 Hypotheses
1. Endothelial chemokine production wiil depend on the origin of the endothelium
2. The binding of inflammatory chemokines to endothelium depends on the tissue of origin of the 
endothelium
3. The resting expression of chemokine receptors wili be different depending on the type of 
endothelium
4. The composition of the proteoglycan layer differs between endothelial cell types
5. The effects of chemokines on endothelial functions wili depend on the vascular bed from which 
the celis are derived
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2. Methods
2.1 Isolation and culture of cells
Endothelial ceils were isolated from human umbilical veins and human adult saphenous veins by 
digestion with 0.1% coliagenase (Sigma, Poole, England) as described previously (Jaffe et al. 
1973; Marin et al. 2001). Isolated cells were expanded in Medium 199 with 2 mM glutamine 
(Gibco, Paisley, Scotland) supplemented with 10% Foetal Calf Serum (FCS, Gibco), 100 U/ml 
Penicillin, 100 pg/ml streptomycin (Gibco), 2.5 pg/ml amphotericin-B (fungizone, Gibco) and 30-50 
pg/ml endothelial cell growth supplement (Sigma). Note that endothelial cells are particularly 
sensitive to amphotericin-B and the concentration in these cultures is lower than generally used on 
other cell types.
Dermal and lung endothelium were purchased from Cionetics/Biowhittaker (Wokingham, Berks. 
England) and expanded according to recommendation of the supplier in EGM-2-MV medium 
(Clonetics).
The human BMEC line was kindly donated by Babette Weksler of Cornell University (Schweitzer et 
al. 1997). To produce this ceil line, primary human bone marrow endothelial cells were transfected 
using a construct containing simian virus 40 (SV40) large T antigen under the control of a portion of 
the human vimentin gene promotor. The resulting transformed ceils were cultured in Dulbeccos 
modified eagle medium (Gibco) with low glucose (1 mg/ml) and 2 mM glutamine, supplemented 
with 10% FCS, 100 U/ml penicillin, 100 pg/ml streptomycin and 2.5 pg/mi amphotericin-B.
Liver endothelial ceils were kindly donated by Adam Linke (Kings College, London) and were 
maintained in Medium 199 with 2 mM glutamine supplemented with 10% Foetal Calf Serum (FCS), 
100 U/ml Penicillin, 100 pg/ml streptomycin and 2.5 pg/mi amphotericin-B until assayed for 
chemokine production. There are several different types of endothelial cell found in the liver, which 
can be distinguished by phenotype, those we are using appear to show a sinusoidal phenotype. 
There were two distinct populations of EC in our cultures. They can be distinguished by size as 
shown in fig. 2.3 but ail express CD31 and ICAM-1 (also shown in fig. 2.3, data courtesy of Adam 
Linke). As sinusoidal endothelial cells do not have Weibel-Palade bodies, they do not express P-
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selectin. They also show reduced E-selectin (Daneker et al. 1998) perhaps because the slowing of 
leukocytes is iess important in the already slow-flowing environment of the liver.
All endothelial cells were grown to near-confluence and passaged by exposure to trypsin 
0.025%/EDTA 0.01% in calcium and magnesium free HBSS (Gibco or Clonetics) and were then 
cultured in 75 cm^ tissue culture flasks. BMEC and HUVEC were grown on 0.2% gelatin. Note that 
although the cells were expanded using protocols and media that had been optimised and 
recommended for growth of that cell type, they were rested and switched Into assay medium before 
the start of each experiment. All experiments were performed on subcultures of confluent cells 
between the second and seventh in vitro passage with the exception of the immunocytochemistry, 
which was performed on subconfluent cells. All the cells tested (liver EC were not examined) 
expressed von Wiiiebrand factor (figs. 2.1 and 2.2) and retained their distinctive morphology. At 
confluence, SVEC were predominately bipolar, umbilical vein endothelium had a cobblestone 
appearance while lung, dermal and liver endotheiium appeared intermediate. All cells showed 
contact inhibition, but the bone marrow endothelial cell line grew to higher densities than the 
primary cultures.
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Figure 2.1 Immunocytochemistry staining of permeabiiised endothelial cells showing iocalisation of 
vWF within different endothelial cell types
Left column stained with anti vWF followed by goat anti rabbit cy3 conjugated secondary. Right column 
stained with goat anti rabbit cy3 alone as a control. Scale bar = 40p.m.
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Figure 2.2 Flow cytometry histograms of vWF immunofluorescence on resting endothelial cells
Different endothelial cell types were harvested by trypsinisation, then the level of vWF detected using a human 
vWF specific antibody followed by goat anti rabbit Ig FITC conjugated secondary antibody. Filled peaks show 
vWF, unfilled show secondary alone.
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Figure 2.3 Flow cytometry data showing the phenotype of liver endothelial cells
There are two distinct populations of liver endothelial cells which can be seen in A. marked R1 and R2, they 
are showing differences in size, but less difference in surface granularity. The two populations both exhibit a 
similar overall level of CD31 (PECAM) shown in B and C. (data courtesy of Adam Linke).
Table 2.1 Markers detected on liver endothelium used in this study
Data courtesy of Adam Linke
MARKER PERCENT POSITIVE
CD31 89.65%
CD14 2.85% (negative)
VCAM-1 4.15% (negative)
ICAM-1 16.5%
CD4 3.55% (negative)
HLA-DR 0.00% (negative)
CD80 0.20% (negative)
CD86 0.10% (negative)
HLA-ABC 100%
59
2.2 Cell based assays
A cell based binding assay system was used for severai different experiments with various 
modifications, which wiil be described iater in detaii.
2.2.1 Solutions used
Assay medium: M199 with 2 mM glutamine, suppiemented with 10% FCS and 100 U/mi peniciiiin, 
100 pg/ml streptomycin.
ELISA diluent: HBSS (Gibco) with 4 mg/mi BSA (Sigma), 100 pg/mi rabbit IgG (Sigma) and 0.1% 
tween 20 (Sigma).
Wash buffer: PBS with 0.1 % tween 20
2.2.2 Cell culture
Ceils were plated onto the central 60 wells of a 0.2% gelatin coated 96 weli plate at 3.5 x lO'  ^cells 
per well in 200 pi of growth medium. Cells were grown overnight to confluence, then rested for 24 
hours in assay medium (see 2.2.1).
2.2.3 ELISA assay
The monoiayer was washed four times in HBSS, then fixed for 10 mins. at room temp, using 100 pi 
of 0.1% giutaraldehyde in PBS. The giutaraidehyde was removed, then 200 pi of 0.05 M tris/HCi 
(pH 7.5) was used to biock the pi ate for 20 mins. at room temp, before washing three times in 0.1% 
tween 20 in PBS. 100 pi per weli of appropriate anti human antibody or lectin was added for 1 hour 
at 37°C, in ELISA diluent (see 2.2.1 for details). 10 pg/ml of MHC class I antibody (Serotec, Oxford, 
UK) was used in each experiment on unstimulated cells to standardise between experiments as 
there have been shown to be approximately the same levels of MHC class I molecules across 
different cell types when unstimulated (Lidington et al. 1999). This has also been previously 
demonstrated on different strains of rats (personal communication D. Male). At the end of 1 hour, 
the plate was washed three times in 0.1% tween 20 in PBS and 100 pi of appropriate biotin labelled 
secondary antibody was added in ELISA diluent for those weiis where it was necessary. Biotin 
labelled rabbit anti mouse immunoglobulins (Dako, Ely, Cambs. UK) added at 1:700 dilution in 
ELISA diluent was used for those wells containing MHC class I primary antibody. The ceils were 
incubated at 37°C for 45 mins, then washed again in wash buffer. 100 pi of streptavidin
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horseradish peroxidase compiex (Amersham, Littie Chalfont, Bucks.) was added at 1:700 in ELISA 
diiuent for 45 mins. at 37°C. The reaction was visualised using 100 pi of 0.1 mg/mi of 
tetramethyibenzidine (Sigma) in 0.1 M citrate acetate buffer containing 0.03% hydrogen peroxide 
(Sigma). It was stopped with 50 pi of 10% sulphuric acid and then read at 450 nm.
2.3 Enzyme digestions
Enzyme digestions were performed in two different experiments to investigate the composition of 
the proteoglycan layer, in both cases, the confluent monolayer was washed three times in HBSS, 
then 65 pi of 10 U/mi heparinase III from Flavobacterium heparlnum, 1 U/mi chondroitinase ABC 
from Proteus vulgaris or 1 U/mi neuraminidase from Clostridium perfrlngens (diluted in HBSS, ail 
from Sigma) was added to triplicate weiis for 1 hour then washed off prior to commencing the 
chemokine binding or lectin assays. Digestions using these enzymes at these concentrations have 
previously revealed that neuraminidase is selective only for sialic acid, chondroitinase ABC is 
selective for chondroitin 4 and 6 sulphate, dermatan sulphate and hyaluronic acid while heparinase 
Hi was only effective against heparan sulphate (Dos Santos 1995).
2.4 Statistical Analysis
In ail experiments statistical significance was determined by the performance of a one or two way 
AN OVA followed by a post hoc t-test (T ukeys unless otherwise stated).
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3. Chemokine production by endothelial cells 
3.1 Introduction
Activation of EC induces a muiti-step cascade of events, which resuits in leukocyte recruitment. 
These events include upregulation of selectins and other adhesion molecules on the lumenal 
surface of the endothelium, thus allowing leukocytes to roll along the surface of the endothelia 
using the selectins. Then chemokines activate firm adhesion using the integrins and finally the 
leukocyte will transmigrate (Springer 1994). Chemokines are a key element in the muiti-step 
process of leukocyte recruitment (Baggioiini 1998; Mackay 2001) in particular in the co-ordination 
and control of the process. They are thought to exert their effect while immobilised on endothelial 
cell surface proteoglycans. This immobilisation is necessary, as in vivo the forces exerted on free 
chemokines by the flow of blood would easily remove them from the site where they are required.
Chemokines are important not only for their chemotactic properties, but also for their activation of 
firm leukocyte binding by integrins (Shimaoka et ai. 2002). However, their chemotactic properties 
ensure that specific subsets of leukocytes will be recruited. This effect is often described as 
combinatorial as more than one chemokine can be involved in the recruitment of each cell.
Chemokines are produced by endothelial cells in response to various molecules involved in 
inflammatory reactions, immunity and thrombosis. The chemokine repertoire of the endotheiium 
includes members of both the CXC and CC families of chemokines. Most studies so far have 
focused on IL-8 and MCP-1.
Most of the data concerning endothelial cell functions has been obtained by studying HUVECs. 
These have great advantages in their ease of isolation and ready availability, however they are not 
necessarily the best representative of ail endothelia. The primary site of leukocyte migration across 
the blood vessel walls is the post capillary venules, but in the dermis and lung, leukocytes migrate 
directly across the capillary wall. HUVEC are taken from large vessels of the umbilical vein and are 
foetal in origin and have hence undergone iess cell division than EC found within the adult body. Ail 
endothelial cell types show induction of certain chemokines after cytokine stimulation and there is 
increasing evidence which shows structural and functional differences between endothelium 
obtained from different sites (Sweriick et ai. 1992a; Swerlick et ai. 1992b; Petzelbauer et ai. 1993;
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Swerlick and Lawiey 1993; Groger et al. 1996). More recently, studies investigating microvascuiar 
endothelium show distinct differences in chemokine production profiles in response to cytokines.
Differences between endothelial cell types in cytokine regulation of adhesion molecules have been 
observed (Sweriick et ai. 1992b). it is therefore important to compare the chemokine secretion 
patterns of different endothelial celis.
Severai chemokines have been found to be produced by HUVECs, these include MCP-1, 
RANTES, Gro and IL-8 (Schroder and Christophers 1989; Rollins et ai. 1990; Marfaing Koka et ai. 
1995).
in this study, BMEC, SVEC, DMVEC, LMVEC and Liver EC were examined and compared to 
HUVECs. We measured the secretion of five pro-infiammatory chemokines (IL-8, RANTES, MCP- 
1, IP-10 and MIP-1a) unstimulated, and in response to TNF-a, IFN-y, TGF-p and combinations of 
these cytokines.
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3.2 Methods
3.2.1 Collection of cell culture supernatants
The six different types of endotheiiai ceiis were grown in their normal culture medium to confluent 
monolayers on 0.2% gelatin in 24 weli plates. They were then rested for 24 hours in assay medium 
(M l99 with 10% FCS and peniciiiin streptomycin) before being stimulated. To do this, the medium 
was removed and replaced with fresh assay medium containing either TNF-a (25 ng/mi), IFN-y 
(200 U/ml), TGF-p (25 ng/ml), combinations of these or left unstimulated. The supernatant was 
collected from unstimulated wells at 0, 5, 24 and 48 hours and from stimulated wells at 24 and 48
hours. The supernatants were stored at -20®C before measuring the amounts of chemokines
present by ELISA.
3.2.2 Detection of chemokines by ELISA
Wash buffer: 0.05% tween 20 in PBS
ELISA diiuent: 0.1% BSA, 0.05% tween 20 in tris buffered saline (pH 7.3)
A 96 weli ELISA plate (Nunc, Maxisorb) was sensitised overnight at room temperature with 100pi 
per well of mouse anti human chemokine moncionai capture antibody (R & D systems, Abingdon, 
England) diluted to the appropriate concentration in PBS (2-4 pg/mi, see table 3.1). After 3 washes 
with wash buffer, the non-specific reactions were blocked for 1 hour at room temperature using 200 
pi per well of PBS containing 1% BSA and 5% sucrose. The weiis were then washed and incubated 
for 2 hours at room temperature with 100 pi of samples in duplicate at an appropriate dilution (1:5, 
1:25 or 1:100) in ELISA diiuent or standards at 0 -  8000 pg/mi in ELISA diiuent. The plates were 
washed three times, then 100 pi of biotinyiated goat anti human chemokine detection antibody (R & 
D systems) was added in ELISA diiuent for 2 hours at room temperature (for concentrations used 
see table 3.1). After 3 more washes, 100 pl/well of streptavidin -  biotin horseradish peroxidase 
(Amersham) diluted 1:700 in ELISA diluent was added for 1 hour at room temperature. Finally, the 
plate was washed 3 times, then developed, stopped and read as described previously (section 
2.2.3).
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Table 3.1 Optimal concentrations of antibodies for detection of chemokines in supernatants by 
sandwich ELISA
CHEMOKINE CAPTURE ANTIBODY CONCENTRATION (pg/ml)
DETECTION ANTIBODY 
CONCENTRATION (ng/ml)
IL-8 4 20
MIP-1a 4 40
RANTES 4 5
MCP-1 2 50
IP-10 2 100
3.2.3 Standard curve properties
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Figure 3.1 Standard curves for IL-8
This represents a typical standard curve produced using the protocol outlined in section 3.2.2 (A). B. Log 
standard curve for IL-8 showing fitted curve from which our data has been extracted for table 3.3.
Table 3.2 shows the range, sensitivity and variance of the assay, but the detection threshold is 
determined by the dilution factor used to detect the chemokine. This means that in the results table, 
where we have shown a result of 0, this data point is below the sensitivity of the assay, which is < 
0.5 ng/ml. The maximum standard error shown here is that determined by reading three different 
values off the linear region of the standard curve (fig. 3.1a between 100 and 1000 pg/ml).
Table 3.2 Properties of the standard curves produced for each chemokine
CHEMOKINE RANGE SENSITIVITY STANDARD
ERROR
IL-8 30 - 4000 pg/ml 30 pg/ml 60 pg/ml
MIP-1a 30 - 4000 pg/ml 100 pg/ml 50 pg/ml
RANTES 30 - 4000 pg/ml 60 pg/ml 43 pg/ml
MCP-1 30 - 4000 pg/ml 100 pg/ml 120 pg/ml
IP-10 30 - 4000 pg/ml 100 pg/ml 26 pg/ml
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3.3 Results
In order to determine how endothelia vary in their chemokine secretion profiles, the production of 
IL-8, RANTES, MCP-1, IP-10 and MIP-1a was measured by ELISA, on duplicate samples of 
supernatants from cells treated with different combinations of cytokines. The data for IL-8, 
RANTES, MCP-1 and iP-10, from one set of assays is given in table 3.3. Data showing the resuits 
of cytokines on chemokine production at 24 and 48 hours are shown in figures 3.3 and 3.4 
respectiveiy. MIP-1a was not detectabie in any of the endotheiiai culture supernatants in this 
assay,
3.3.1 Constitutive chemokine production
Production of the chemokines by resting endotheiium was measuredby harvesting tissue cuiture 
supernatants at 0, 5, 24 and 48 hours (Table 3.3, rows 1-4 and fig. 3.2). MCP-1 & IL-8 were 
produced by all resting EC tested. HUVEC was the highest producer of both chemokines of aii the 
different cell types, producing 24 ng/mi of MCP-1 and 30 ng/ml of IL-8 after 48 hours in cuiture. 
Unike the HUVECs, both the BMEC line and SVECs produced more MCP-1 than IL-8 however, 
only very low levels were detected (2.1 ng/mi or iess) for both these ceil types. In the primary 
microvascuiar cells and Liver EC more IL-8 was produced than MCP-1. RANTES was constitutively 
produced at a low level by DMVEC, but not by any other endotheiiai ceil type. IP-10 was not 
produced by any of the unstimuiated endotheiiai cells tested.
The rate of production of IL-8 by HUVEC suffered a slight lag effect at the beginning (until 5 hours), 
then was constant, while aii 5 other ceil types showed a constant rate of IL-8 production (fig. 3.2a). 
A lag effect was also shown in the rate of MCP-1 production by HUVEC and microvascuiar 
endothelium up until 5 hours, with BMEC not beginning to produce MCP-1 until after 24 hours. 
SVEC and Liver EC produced MCP-1 at a constant rate (fig. 3.2b).
We have also shown that while the SVEC are relatively consistent in the lack of production of 
constitutive chemokines, the high levels of IL-8 and MCP-1 produced by HUVECs is variable 
between individuals.
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Figure 3.2 Constitutive production of MCP-1 and IL-8 by endotheiiai ceiis over time
Supernatants were collected from confluent resting endothelial cells at 0, 5, 24 and 48 hours, then 
assayed by sandwich ELISA for IL-8 and MCP-1. A. IL-8, B. MCP-1. SVEC n=4, HUVEC n=2, all 
other cell types n=1 Error bars show SEM.
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Figure 3.3 Chemokine production by endothelial cells after stimulation by cytokines for 24 hours
Supernatants were collected from confluent cytokine stimulated endothelial cells at 24 hours post stimulation, 
then assayed by sandwich ELISA for chemokine production. A. IL-8, B. RANTES, C. MCP-1, D. IP-10. Blue = 
BMEC, Red = SVEC, Yellow = DMVEC, Green = LMVEC, Purple = HUVEC, White = Liver EC. * denotes a 
statistically significant difference between SVEC and HUVEC {p<0.05). SVEC n=4, HUVEC n=2, other cell 
types n=1, therefore no statistical tests on these cells.
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Figure 3.4 Chemokine production by endotheiiai cells after stimulation by cytokines for 48 hours
Supernatants were collected from confluent cytokine stimulated endothelial cells at 48 hours post stimulation, 
then assayed by sandwich ELISA for chemokine production. A. IL-8, B. RANTES, C. MCP-1, D. IP-10. Blue = 
BMEC, Red = SVEC, Yellow = DMVEC, Green = LMVEC, Purple = HUVEC, White = Liver EC. . * denotes a 
statistically significant difference between SVEC and HUVEC (p<0.05). SVEC n=4, HUVEC n=2, other cell 
types n=1, therefore no statistical tests on these cells.
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3.3.2 TNF-a upregulates chemokine production
The addition of 25 ng/mi of TNF-a to the tissue cuiture medium for 24 or 48 hours increased 
production of IL-8, RANTES and MCP-1 by aii 6 endotheiiai celi types tested. It aiso upreguiated 
IP-10 production but to a lesser extent. IL-8 showed the biggest increase in secretion levels upon 
addition of TNF-a across five out of the six celi types (BMEC being the exception) with HUVECs 
secreting as much as 313 ng/mi after 48 hours. RANTES production increased to only modest 
levels of 3 -  11 ng/mi after 48 hours by most celi types, however for DMVEC and BMEC, the 
increase was more pronounced -  up to 62 ng/mi on DMVEC and 51 ng/ml on BMEC after 48 
hours. MCP-1 was also produced at high levels (146 ng/ml) by BMEC; however, the DMVECs 
produced less than any other cell type (less than 20 ng/ml) at 48 hours. Upon stimulation with 
TNF-a, BMEC produced the most MCP-1, all other EC types tested produced IL-8 as their major 
chemokine after TNF-a stimulation. IP-10 production was increased slightly on addition of TNF-a in 
all cell types. Highest levels were demonstrated by BMEC as they secreted 24 ng/ml after 48 
hours, while other cell types all produced less than 10 ng/ml with virtually none produced by 
HUVEC and Liver EC.
3.3.3 IFN-y decreases production of IL-8 by endothelial cells
The addition of IFN-y had very little effect on IL-8 production by BMEC and SVEC at 24 or 48 hours 
and no effect on Liver EC production at 24 hours, though an increase from 3.4 to 7.1 ng/ml was 
observed by 48 hours. On the other hand, in the two microvascuiar endothelia and in HUVEC, IFN- 
Y reduced the high constitutive levels by approximately half e.g. LMVEC showed constitutive levels 
of 15 ng/ml of IL-8 after 48 hours, but with IFN-y added, they showed only 8.4 ng/ml, a decrease of 
44%.
3.3.4 IFN-y upregulates MCP-1 and IP-10 production
As previously reported (Luster and Ravetch 1987a) there was no constitutive expression of IP-10, 
but IFN-y induced production of IP-10 by all 6 EC types. The highest increases were observed for 
the two types of microvascuiar endothelia (26 and 34 ng/ml at 48 hours for dermal and lung 
respectively). IFN-y also increased production of MCP-1 significantly by BMEC, SVEC, LMVEC and 
to a much lesser extent by DMVEC, though not to the same degree as TNF-a. Liver EC showed 
only low levels -  a maximum of 2.0 ng/mi was produced at 48 hours. HUVEC showed a slight
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increase from constitutive ieveis at 24 hours, but by 48 hours the ieveis were decreased from 24 
ng/mi without IFN-y to 19 ng/ml when IFN-y was added to the maintenance medium. Interestingly, 
SVEC and HUVEC showed more MCP-1 than IP-10 production after IFN-y stimulation, whereas 
BMEC, DMVEC LMVEC and Liver EC showed iess.
3.3.5 Effects of TGF-p on MCP-1 and IL-8 production
Addition of TGF-p to the maintenance medium reduced the constitutive secretion of IL-8 by LMVEC 
and DMVEC. Unstimulated DMVEC secreted 10 ng/ml after 48 hours, after the same time with 
TGF-p added, only 5.9 ng/ml was secreted. The reduction was more pronounced for LMVEC as the 
constitutive levels of 15 ng/ml dropped to just 3.2 ng/ml after addition of TGF-p to the maintenance 
medium. TGF-p also reduced MCP-1 production by both microvascuiar EC and HUVECs, though 
to a lesser extent than seen for IL-8. This was particularly noticeable in the LMVEC and DMVEC as 
only low constitutive ieveis were produced. We did not have enough Liver EC to investigate TGF-p 
stimulation (marked ND on table 3.3).
3.3.6 TNF-a and IFN-y act in synergy to induce high IP-10 and RANTES production
RANTES production increased across all five ceils types upon stimulation with TNF-a, the highest 
level (62 ng/ml) being observed for DMVEC after 48 hours in culture. However all cell types 
showed some increased production in the presence of TNF-a or IFN-y and showed high levels of 
secretion in the presence of these two cytokines in combination. The levels produced by a 
combination of the two cytokines were much higher than that of TNF-a alone. Although IFN-y had 
little effect on RANTES production alone, when put into the maintenance medium in combination 
with TNF-a, there is a distinct synergistic effect. IP-10 was also produced by all EC upon 
stimulation with TNF-a or IFN-y and extremely high ieveis were produced with both together -  
again showing synergy. BMEC, SVEC and HUVEC produced over 200 ng/mi of IP-10 after 48 
hours of stimulation with 25 ng/ml of TNF-a and 200 U/ml of IFN-y together. In both the expression 
of IP-10 and RANTES, DMVEC show much higher secretion in comparison to LMVEC.
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3.3.7 IFN-y and TNF-a effects on MCP-1 and IL-8
For IL-8 production there was no synergy between TNF-a and iFN-y. In fact, IFN-y reduced the 
high chemokine produced by addition of TNF-a to endotheiiai celis. This suggests an antagonism 
between TNF-a and IFN-y with regards to IL-8 production on all EC tested. However, the levels of 
IL-8 were not reduced to constitutive ieveis, which suggests that there is stiil an overaii pro- 
inflammatory effect. MCP-1 levels were increased from those with TNF-a or IFN-y alone showing a 
possible synergy between the two cytokines on MCP-1 production by SVEC and HUVEC only. An 
antagonistic effect was seen on LMVEC and Liver EC, with little change or inconsistent effects 
shown in DMVEC and BMEC.
3.3.8 Effects of TGF-p and TNF-a in combination
There was iittle significant difference between TNF-a acting on endotheiiai ceils alone and TNF-a 
acting in combination with TGF-p for either SVEC or HUVEC. The other 4 celi types however 
appeared to show lower levels of IL-8 and MCP-1 produced after the addition of TGF-p as weil as 
TNF-a to the maintenance medium as compared to TNF-a aione. For exampie, after 48 hours 
LMVEC constitutively produce 15 ng/ml of IL-8, they produced 122 ng/ml after stimulation with 
TNF-a aione and 3.2 ng/ml with TGF-p stimulation, but when TNF-a and TGF-p act together oniy 
35 ng/mi of IL-8 was produced. This is not reduced to constitutive levels, but is a 65% reduction 
from those observed with TNF-a alone. TGF-p can reduce the effects of TNF-a on endothelial 
chemokine production by up to 75% depending on the ceii type and chemokine investigated. 
Without more samples from different individuals though, it is difficult to tell whether this might be a 
cnsistent finding. There is iittle difference in the effects of TNF with or without TGF on RANTES or 
iP-10 production by any celi type tested..
3.3.9 Effects of TGF-p and IFN-y in combination
No IP-10 was detectable after TGF-p stimulation of endotheiiai monolayers, but TGF-p was found 
to have a small downregulatory effect on IFN-y induced IP-10 secretion by aii endotheiia except 
HUVEC. TGF-p again appears to stimulate HUVECs to produce high ieveis of chemokines rather 
than reduce the effects of other cytokines. This was noticeabie when TGF-p was used in 
combination with IFN-y as high secretion of MCP-1 and IP-10 was observed. HUVEC produced
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low levels of IP-10 when stimulated with IFN^ (4.3 ng/ml) and virtually none (0.5 ng/ml) when 
stimulated with TGF-p, however with both together 20 ng/ml of IP-10 was detected. SVEC from 
some individuals also show this trend, whereas others show the opposite. IFN-y stimulates all other 
endothelia to produce 6.1 -  34 ng/ml of IP-10 after 48 hours. When TGF-p was added as well as 
IFN-y, levels of production were reduced in each individual cell type producing 4 .8 -  23 ng/ml IP- 
10.
It also appears that IFN-y and TGF-p acting together suppress much of the production of IL-8 
observed in LMVEC and DMVEC after stimulation with either cytokine alone.
3.3.10 Inter -  individual v<ariation In chemokine production
To address the question of whether there is any variation between individuals in their endothelial 
chemokine production and cytokine responsiveness, we repeated the assay using SVECs from a 
further three different donors (Tables 3.4 -  3.7). The tables show the mean results from duplicate 
wells for each individual donor, and the mean and standard error for the four donors pooled. From 
this data, we can show that there is variation between individuals with combinations of cytokines 
exhibiting greater differences between individuals than stimulation with a single cytokine. IP-10 also 
appears to have greater variation than others due to very high production by donor 4. Therefore we 
suggest that in general small differences between tissue from different donors could be due to 
inter-individual variation, where larger differences are exhibited we can conclude they are 
significant differences between cell types.
75
Treatment IL-8 production (ng/ml) Mean StandardError1 2 3 4
Control 0 hr 0 0 0 0 0 0
Control 5 hr 0 - 0 0 0 0
Control 24 hr 0 0.8 0 0.7 0.38 0.22
Control 48 hr 0 - 0.8 0.7 0.50 0.25
TNFa 24 hr 56 30 27 33 36.5 6.6
TNFa 48 hr 72 - 49 79 66.7 9.1
IFN-y 24 hr 0.6 0 0 0 0.15 0.15
IFN-y 48 hr 0 - 0.7 0 0.23 0.23
TGF-P 24 hr 14 - 4.2 0.8 6.33 4.0
TGF-P 48 hr 10 - 3.9 0.8 4.90 2.7
TN Fa& IFN ^ 24 hr 16 13 18 18 16.3 1.2
TNFa & IFN-y 48 hr 25 - 25 29 26.3 1.3
TNFa & TGF-P 24 hr 73 - 46 41 53.3 9.9
TNFa & TGF-P 48 hr 105 - 67 53 75.0 15.5
IFN-y & TGF-P 24 hr 4.1 - 5.8 0 3.30 1.7
IFN-y & TGF-P 48 hr 6.2 - 6.1 0 4.10 2.0
Table 3.4 Variation between individuals in IL-8 production by SVECs
Confluent endothelial cells from four different donors were treated with TNF-a (25 ng/ml), IFN-y (200 U/ml), 
TGF-p (25 ng/ml), combinations of these or left unstimulated. The supernatants were collected and assayed 
by sandwich ELISA for IL-8, RANTES, MOP-1 and IP-10. Means of duplicate wells for each individual donor 
are shown, with an overall mean and standard error of the mean for the four individuals pooled.
Treatment RANTES production (ng/ml) Mean StandardError1 2 3 4
Control 0 hr 0 0.7 0 0 0.18 0.18
Control 5 hr 0 - 0 0 0 0
Control 24 hr 0 0 0 0 0 0
Control 48 hr 0 - 0 0 0 0
TNFa 24 hr 0 0 0 1.2 0.30 0.3
TNFa 48 hr 1.4 - 1.5 9.3 4.11 2.6
IFN-y 24 hr 0 0 0 0 0 0
IFN-y 48 hr 0 - 0 0 0 0
TGF-P 24 hr 0 - 0 0 0 0
TGF-P 48 hr 0 - 0 0 0 0
TNFa & IFN-y 24 hr 9.8 3.4 17 14 11.1 2.9
TNFa & IFN-y 48 hr 41 - 36 67 48.0 9.6
TNFa & TGF-P 24 hr 0 - 0.5 0 0.17 0.17
TNFa & TGF-P 48 hr 2.4 - 1.5 2.1 2.00 0.26
IFN-y & TGF-P 24 hr 0 - 0.5 0 0.17 0.17
IFN-y & TGF-P 48 hr 1.0 - 1.9 0 0.97 0.55
Table 3.5 Variation between individuals in RANTES production by SVECs
Confluent endothelial cells from four different donors were treated with TNF-a (25 ng/ml), IFN-y (200 U/ml), 
TGF-p (25 ng/ml), combinations of these or left unstimulated. The supernatants were collected and assayed 
by sandwich ELISA for IL-8, RANTES, MCP-1 and IP-10. Means of duplicate wells for each individual donor 
are shown, with an overall mean and standard error of the mean for the four individuals pooled.
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Treatment MCP-1 production (ng/ml) Mean StandardError1 2 3 4
Control 0 hr 0.9 1.2 1.4 0 0.88 0.31
Control 5 hr 1.2 - 1.2 1.20 1.20 0
Control 24 hr 1.6 0.9 1.2 1.9 1.40 0.22
Control 48 hr 1.1 - 1.1 2.1 1.43 0.33
TNFa 24 hr 14 8.0 6.9 7.8 9.18 1.6
TNFa 48 hr 27 - 11 25 21.0 5.0
IFN-y 24 hr 9.5 4.2 3.2 6.8 5.93 1.4
IFN-y 48 hr 5.2 - 4.6 13 7.60 2.7
TGF-P 24 hr 4.9 - 2.1 2.1 3.03 0.9
TGF-p 48 hr 5.3 - 2.9 2.8 3.67 0.8
TNFa & IFN-y 24 hr 32 16 5.7 24 19.4 5.6
TNFa & IFN-y 48 hr 49 - 25 81 51.7 16.2
TNFa & TGF-P 24 hr 14 - 12 9.5 11.8 1.3
TNFa & TGF-P 48 hr 43 - 14 20 25.7 8.8
IFN-y & TGF-P 24 hr 31 - 26 7.7 21.6 7.1
IFN-y & TGF-P 48 hr 20 - 13 8.7 13.9 3.3
Table 3.6 Variation between individuals In MCP-1 production by SVECs
Confluent endothelial cells from four different donors were treated with TNF-a (25 ng/ml), IFN-y (200 U/ml), 
TGF-p (25 ng/ml), combinations of these or left unstimulated. The supernatants were collected and assayed 
by sandwich ELISA for IL-8, RANTES, MCP-1 and IP-10. Means of duplicate wells for each individual donor 
are shown, with an overall mean and standard error of the mean for the four individuals pooled.
Treatment IP-10 production (ng/ml) Mean StandardError1 2 3 4
Control 0 hr 0 0 0 0 0 0
Control 5 hr 0 - 0 0 0 0
Control 24 hr 0 0 0 0 0 0
Control 48 hr 0 - 0 0 0 0
TNFa 24 hr 0 0 0 0.5 0.13 0.13
TNFa 48 hr 0 - 0 4.0 1.33 1.3
IFN-y 24 hr 1.4 0 0 2.7 1.03 0.65
IFN-y 48 hr 1.3 - 1.1 8.9 3.77 2.6
TGF-P 24 hr 0 - 0 0 0 0
TGF-P 48 hr 0 - 0 0 0 0
TNFa & IFN-y 24 hr 14 4.4 13 124 38.9 28.5
TNFa & IFN-y 48 hr 31 - 19 237 95.7 70.8
TNFa & TGF-P 24 hr 0 - 0 0 0 0
TNFa & TGF-P 48 hr 0 - 0 0 0 0
IFN-y & TGF-p 24 hr 3.8 - 3.6 1.5 2.97 0.74
IFN-y & TGF-P 48 hr 5.0 - 5.6 5.9 5.50 0.26
Table 3.7 Variation between Individuals In IP-10 production by SVECs
Confluent endothelial cells from four different donors were treated with TNF-a (25 ng/ml), IFN^ (200 U/ml), 
TGF-p (25 ng/ml), combinations of these or left unstimulated. The supernatants were collected and assayed 
by sandwich ELISA for IL-8, RANTES, MCP-1 and IP-10. Means of duplicate wells for each individual donor 
are shown, with an overall mean and standard error of the mean for the four individuals pooled.
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3.4 Discussion
There are now numerous studies demonstrating important structural, biochemical, antigenic and 
functional differences in endothelial cells from different morphological areas. Here we contribute a 
large comparative study of the effects of pro- and anti- inflammatory cytokines on chemokine 
production by endothelium from different areas of the body.
Our data showed great variability between endothelia in production of chemokines -  with results 
from 0 ng/ml produced by unstlmulated endothelia, up to 430 ng/ml from cytokine stimulated 
endothelia after 48 hours. Since we have shown there to be some variability between individual 
donors (tables 3.4 -  3.7) we cannot make inferences from small differences between endothelia. 
However, in the instances where the differences were great we can conclude that these were 
significant. There was variability between experiments of less than 5%, but this was far less than 
that between individuals.
In general, chemokines are physiologically active at levels of 2 -  200 ng/ml with maximum 
chemotactic activity at 10 -  50 ng/ml depending on the chemokine and the responding cell type. So 
for instance, our data suggests that only DMVEC, LMVEC, Liver EC and HUVECs produced 
physiological levels of IL-8 constitutively.
In this experiment, we particularly need to take into account that cells are grown under static 
conditions and the levels of chemokine build up, as they would not do in vivo. Under flow 
conditions, the chemokines would be much diluted, however since production is constant, a low 
concentration would be maintained at the cell surface.
The earliest study on the production of chemokines by EC was in 1987, when Luster and Ravetch 
showed the production of IP-10 by HUVEC cultured in vitro. Other early studies identified a soluble 
molecule, at first named leukocyte adhesion inhibitor, which was secreted by endothelial cells upon 
stimulation with IL-1, TNF-a or LPS and which was found to reduce the adherence of leukocytes to 
the endothelial cell surface. This molecule was deduced to be (Ala-1 L-8)77 a form of IL-8 extended 
at the NH2 terminus, which has similar effects to IL-8 derived from other cell types (Gimbrone et al. 
1989). It has since been shown that the inhibitory effect could be due to the disruption of 
chemotactic gradients.
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At a similar time, it was demonstrated by RNA blot analysis that TNF-a, LPS and IL-1 were each 
able to induce gene expression for IL-8 in HUVEC (Strieter et al. 1989a) and studies by several 
other labs confirmed these findings (Schroder and Christophers 1989; Sica et al. 1990a). It was 
also shown that cytokines such as IL-1 and TNF-a induce the production of MCP-1 by HUVEC 
(Rollins et al. 1990; Sica et al. 1990b; Rollins and Pober 1991). Since these early experiments, 
there have been many more investigations into the different chemotactic molecules produced by 
endothelium under different conditions. In a large proportion of these studies, HUVEC were used, 
as they are the easiest endothelial cell type to obtain, isolate and culture.
3.4.1 Constitutive chemokine production
Several groups have shown that IL-8 mRNA is present at very low levels in unstimulated EC, with 
slightly higher levels of MCP-1 mRNA. This has been demonstrated in HUVEC (Rollins et al. 1990; 
Sica et al. 1990b), DMVEC by In s/fu hybridisation (Goebeler et al. 1997), LMVEC (Brown et al. 
1994) and Liver EC, but not sinusoidal cells (Afford et al. 1998) determined by In situ hybridisation 
on frozen sections. Basal levels of protein expression of these two chemokines have also been 
shown after 24 to 48 hours in culture (Rollins et al. 1990; Brown et al. 1994; Beck et al. 1999) In 
unstimulated frozen sections of liver EC, IL-8 mRNA was found in sinusoidal and vascular EC while 
MCP-1 mRNA was found only in vascular EC. Our results showed that unstimulated DMVEC, 
HUVEC, LMVEC and Liver EC produced physiologically relevant levels of IL-8. The two 
microvascular cell types and HUVECs also produced MCP-1 constitutively as did the SVEC, 
however, BMEC and Liver EC produced only 1 - 1 . 1  ng/ml which In vivo, would probably not be 
physiologically relevant. MCP-1 mRNA, but not the protein, has been shown to be present in 
transformed BMEC cell lines without stimulation (Vanderkerken et al. 2002). Particularly worth 
noting are the very high levels of MCP-1 and IL-8 (24 ng/ml and 30 ng/ml respectively at 48 hours) 
produced by the HUVECs in comparison to the other endothelial cell types. This begins to suggest 
that although HUVECs are often used as a model for endothelial cell systems, their chemokine 
production is atypical. It is not certain whether the high constitutive secretion of MCP-1 and IL-8 is 
related to its tissue of origin, or its age. SVEC, the other macrovascular endothelial cell type, differs 
from HUVECs in both the location and age of the tissue and produced very little in the way of 
inflammatory chemokines. Also notable, were the high levels of constitutive production of IL-8 by 
DMVEC and LMVEC. IL-8 is particularly important in controlling migration of neutrophils into 
tissues (Larsen et al. 1990; Leonard et al. 1990).
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We demonstrated slight constitutive production of RANTES by DMVEC, though at only 1.5 ng/ml 
after 48 hours in a static culture, this is would probably not be relevant in vivo. In agreement with 
our study Goebeler et al. (1997) found no RANTES mRNA in cultured DMVEC without stimulation, 
this has also been shown in HUVECs - no RANTES was present in supernatants, nor was any 
mRNA found under unstimulated conditions (Marfaing Koka et al. 1995).
In all of our experiments, we did not find any detectable levels of MIP-1a under any stimulatory 
conditions. This is in agreement with previous results (Goebeler et al. 1997; Sundstrom et al. 
2001). When endothelial cells are stimulated with different inflammatory cytokines, it becomes clear 
that TNF-a has an important role in chemokine production during an inflammatory response. We 
have shown that this cytokine induces production of IL-8, RANTES, MCP-1 and to a lesser extent 
IP-10.
3.4.2 Chemokine production by endotheiiai ceiis after cytokine stimulation
The increases in levels of MCP-1 and IL-8 in response to the inflammatory cytokines TNF-a and IL- 
1 have been well documented, both on HUVECs (Gimbrone et a i 1989; Rollins et al. 1990; Sica et 
al. 1990a; Sica et al. 1990b; Randolph and Furie 1995; Parks et al. 1998) and on other endothelial 
cell types (Brown et al. 1994; Goebeler et al. 1997; Beck et al. 1999; Anderegg et a i 2000; Briones 
et al. 2001). However, the effects of TNF-a on RANTES and IP-10 production are less clear.
When investigating IL-8, very few mRNA transcripts were detectable in unstimulated DMVEC, 
however upon stimulation with TNF-a, the number of positive cells and the signal density increased 
(Goebeler et al. 1997). At 1 -  10 ng/ml of TNF-a, maximal IL-8 protein secretion was detectable 
after anything more than 8 hours in culture.
BMEC expressed MCP-1 as their major pro-inflammatory chemokine after TNF-a stimulation with 
IL-8 of secondary importance, while all other endothelia tested expressed IL-8 the highest. The 
reduction in MCP-1 levels between 24 and 48 hours detected for DMVEC could be due to 
internalisation by specific receptors on the surface (e.g. CCR5 see chapter 5). It is suggested that 
in fact, CCR2 expression is reduced on the cell surface of some cell types after stimulation with 
TNF-a or LPS. This has not yet been shown on endothelium.
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We showed that DMVEC and BMEC both secreted high levels of RANTES after 48 hours 
stimulation by TNF-a (62 and 51 ng/ml respectively), all other cell types secreted 11 ng/ml or less 
of RANTES after this stimulation. RANTES is specifically chemotactic for memory T cells, 
monocytes and eosinophils (Schall et al. 1988; Alam et al. 1993). RANTES mRNA and protein 
have both been shown by In situ hybridisation to be increased in DMVEC at 8 hours after 1 ng/ml 
TNF-a stimulation with a further increase demonstrated up to 24, then 48 hours (Goebeler et al. 
1997). The maximum amount of RANTES demonstrated was approximately 100 pg/ml at 48 hours, 
which was much less than we have found, however, this is likely to be due to the lower amount of 
TNF-a used in the stimulation protocol (we used 25 ng/ml compared to their 1 ng/ml). Marfaing 
Koka et al. (1995) showed very little induction of RANTES protein (<0.5 ng/ml) after TNF-a (100 
U/ml) stimulation of HUVEC for 20 hours but low levels of RANTES mRNA were found by In situ. In 
our experiment, we have detected a low, but probably physiologically relevant level of only 3 ng/ml 
after 24 hours. In a comparison of HUVEC with coronary artery endothelial cells (CAEC) (Briones 
et al. 2001), HUVEC did not produce a significant amount of RANTES protein upon stimulation, 
whereas CAEC produced significant amounts (approx. 5 ng/ml after 48 hours TNF-a stimulation 
and 25 ng/ml after IL-1 stimulation). Similar results were also shown using an RNA protection 
assay, demonstrating that the RANTES production is due to protein synthesis, and is not released 
from intracellular stores. The major discernible difference between our experimental protocol and 
that of Briones et al. is that their cells were continually grown with growth supplements. They used 
a medium similar to that used for growth of our lung and dermal endothelia, whereas, we put our 
cells into a maintenance medium containing only 10% FCS and antibiotics. We have detected more 
RANTES than MCP-1 secreted by DMVEC, which has also been shown at the transcription level 
when higher levels of RANTES mRNA than MCP-1 mRNA were found to be present in TNF-a 
stimulated DMVEC (Anderegg et al. 2000).
We showed some IP-10 production was induced in all cell types upon stimulation with TNF-a, 
however, levels were only physiologically significant for BMEC, SVEC, DMVEC and LMVEC. It was 
shown by Rollins et al. (1990) that there was no induction of IP-10 mRNA after TNF-a stimulation 
of HUVECs for either 3 or 24 hours. Briones et al. (2001) showed induction of IP-10 protein and 
mRNA in HUVECs, but in CAEC although the mRNA levels were increased after TNF-a 
stimulation for 24 hours, the levels were reduced by 48 hours, which suggests some sort of 
feedback mechanism.
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In contrast, IFN-y stimulation appears to block the production of IL-8, had little effect on RANTES 
production, but increased the production of MCP-1 from constitutive levels in some cell types and 
induced all endothelial cell types to produce IP-10 as expected from an IFN^ -  inducible protein 
(Luster and Ravetch 1987a). This induction of IP-10 protein and mRNA has also been shown in 
studies of various other endothelial cell types including HUVEC (Rollins et al. 1990), DMVEC 
(Goebeler et al. 1997), LMVEC (Sundstrom et al. 2001) and sinusoidal Liver EC, but not in Liver 
portal vein EC (Shields et at. 1999).
Other groups have also shown no increase of IL-8 after stimulation with IFN-y, but as many of them 
have shown lower constitutive levels of production than we have seen, they would not have 
observed any noticeable reduction in expression. For example: Rollins et at. (1990) showed 
induction of MCP-1 but not IL-8 mRNA after IFN-y treatment of HUVECs. Similar results have been 
shown in DMVEC (Goebeler et al. 1997) and LMVEC (Brown et al. 1994). We have shown that 
SVEC, BMEC and LMVEC show significant increases in MCP-1 production after 48 hours. DMVEC 
and Liver EC show little change, while HUVEC show a slight increase at 24 hours, which is lost by 
48 hours. Goebeler et al. showed no change in MCP-1 protein secretion or mRNA expression by In 
situ hybridisation after IFN-y stimulation of DMVECs, but a slight induction of mRNA and protein - 
up to 1.5 ng/ml above control levels at 24 hours in HUVECs. In our experimental system this would 
not be a physiologically significant induction, but they used a different system and have stimulated 
with lower amounts of TNF-a. Two other groups have also shown an induction of MCP-1 after 
LMVEC stimulation, but the investigation of BMEC and SVEC in this situation is novel. Beck et al. 
(1999) showed an increase in MCP-1 protein in LMVEC with an approximate doubling after 48 
hours, (but not significant) while HUVEC did not respond. MCP-1 mRNA and protein have also 
been shown to increase slightly on LMVEC upon IFN-y stimulation (Brown et al. 1994). There was 
no expression of IL-8 mRNA in unstimulated LMVEC, and also no increase of IL-8 after stimulation 
with up to 500 U/ml of IFN-y, however there was about a six fold increase in the levels of MCP-1 
found after IFN-y stimulation. We have shown an approximate doubling in MCP-1 production at 
both 24 and 48 hours compared to unstimulated LMVECat the same time point..
IFN-y and TNF-a act in synergy to produce high levels of MCP-1 from SVEC and high levels of IP- 
10 and RANTES from all endothelial cell types that we have examined. This synergy between TNF- 
a and IFN-y has been observed in several different cellular events including adhesion molecule
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expression (Detmar et al. 1990; Doukas and Pober 1990) and production of oxygen radicals as well 
as in chemokine expression (Piali et al. 1998).
Goebeler et al. (1997) found that TNF-a, but not IFN-y, induced DMVECs to express MCP-1 mRNA 
after 8 hours of incubation and that at this time, protein was also detectable. RANTES was also 
produced; however, protein was not detectable until 24 hours after stimulation with TNF-a. 
Treatment of DMVECs with both TNF-a and IFN-y together revealed no effect on MCP-1 levels, but 
a synergistic effect resulting in increased levels of RANTES was demonstrated.
Brown et al. (1994) also showed synergy in the production of MCP-1, but not IL-8 by LMVEC, 
however, they were using 20 U/ml of TNF-a and 50 U/ml of IFN-y, whereas we have been using 
higher levels 25 ng/ml of TNF-a and 200 U/ml of IFN-y.
Sundstrom et al. (2001) showed synergy only in the production of RANTES -  not in the case of 
either IL-8 or MCP-1 on LMVEC. Terada et al. (1996), looking at cultured endothelial and epithelial 
cells from the nasal mucosa found that RANTES was again enhanced from the level of either TNF- 
a or IFN-y to a much increased level when both were used together. Marfaing Koka et al. (1995) 
showed that production of RANTES by HUVEC was optimally induced by a combination of IFN-y 
and TNF-a. Approx. 5 ng/ml of RANTES was observed after 20 hours in culture in 48 well plates 
with 100 U/ml of TNF-a and 100 U/ml of IFN-y. IL-1 (3 was shown to have little additive effect when 
TNF-a and IFN-y were used simultaneously. They showed this by both ELISA of supernatants and 
by In situ hybridisation of mRNA. The mechanism of such a synergy appears to involve post 
receptor events perhaps such as activation of activator protein 1 or NF-KB acting on the 5’ 
promoter region of the gene
On certain endothelia TGF-p significantly reduced high constitutive levels of IL-8 and MCP-1, but 
had no effect on levels of IP-10 or RANTES. It was found to have very little effect on IL-8 
production by HUVEC, but reduced MCP-1 levels. We have shown that it reduced the TNF-a 
stimulated secretion of IL-8 and MCP-1 when both cytokines were applied together across several 
EC types. Similar results have been shown in other studies, but all on HUVEC (Chen and Manning 
1996; Weiss et al. 1999). Weiss et al. also show that the p75 TNFR is downregulated by TGF-p, 
although this helps explain reductions in chemokine levels from those shown after the addition of 
TNF-a alone, this mechanism cannot explain the lower production in TGF-p stimulated cells
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compared to unstimulated. We have shown that adding TGF-p to TNF-a has little effect on 
RANTES production an effect also shown by Crane et al. (2000)
3.4.3 Summary and future work
We have tested the production of chemokines by six different endothelial cell types; BMEC, SVEC, 
DMVEC, LMVEC, HUVEC and Liver EC. These cell types do not produce MIP-1a under any of the 
stimulation protocols tested. We have shown constitutive production of physiologically relevant 
levels of IL-8 by HUVEC, Liver EC and microvascular EC and MCP-1 by SVEC, HUVEC and the 
microvascular EC.
When cytokines were applied, most cell types reacted in a similar way, but to differing degrees. We 
have shown that TNF-a increases production of IL-8, RANTES and MCP-1 in all six cell types while 
IFN-y increases production of IP-10 in all cell types except HUVEC and Liver EC. The addition of 
TGF-p reduces production of IL-8 and MCP-1 from constitutive levels and TNF-a and IFN-y used in 
combination induce synergistic production of IP-10 and RANTES by all cell types tested.
HUVEC were found to produce high levels of IL-8 under all stimulation protocols. Liver EC also 
produced high levels of IL-8 in response to TNF-a.
To improve this study, it would have been ideal to have more donors of microvascular endothelium 
and Liver EC. Due to monetary and time constraints this was not possible. We have however, been 
able to give a good overview of chemokine production by endothelial cells from different tissues 
after stimulation by different cytokines.
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4. Binding of chemokines to endothelial monolayers
4.1 Introduction
In the previous chapter, we have shown that chemokines are produced by endothelium in vitro, we 
also know that many other cell types produce them both constitutively and during inflammation. To 
enable firm adhesion of leukocytes to take place, the leukocytes must sense chemokine signals 
during the rolling stage of recruitment. As soluble gradients cannot persist at the endothelial cell 
surface due to their removal by the force of the blood flow, chemokines are presented on the 
glycocalyx. Endothelial cells contain a thick glycocalyx rich in proteoglycans, which serve as the 
anchoring structures for chemokines. By this mechanism, chemokines are immobilised and 
presentation to leukocytes can be achieved (Rot 1992b; Tanaka etal. 1993b)
Proteoglycans are proteins, which have been modified post-translationally by the addition of 
glycosaminoglycan (GAG) side chains at serine residues. The most abundant GAG species (50 -  
90% of total endothelial proteoglycans) is the polyanionic species heparan sulphate, which is 
structurally and biosynthetically related to heparin. Chemokines contain a heparin binding site and 
have been shown to bind with high affinity to heparan sulphate in vitro (Huber et al. 1991).
It has been demonstrated that IL-8 binds to the lumenal surface of post-capillary venules and small 
vein endothelium in the dermis In vivo (Rot 1992a). This is the normal site of leukocyte 
transmigration in most tissues. Studies of cross sections of veins have shown that binding was to 
the EC on the lumen of the veins. There was no accumulation of IL-8 within the endothelial cells -  
suggesting that it was not taken up by the cells and remained bound to the surface. Whether this 
binding was specifically via GAGs was not studied, although the kinetics and affinities suggested 
retention on the glycocalyx. Binding sites for IL-8 have more recently been viewed using electron 
microscopy and it was also found that heparinase digestion reduced IL-8 binding, which suggests 
HSPG to be a ligand for this chemokine (Middleton et al. 1997). In vitro studies have shown that 
MIP-lp or RANTES immobilised on various different proteoglycans are as effective as in their 
soluble form at activating integrin dependent adhesion of T cells (Tanaka et al. 1993a; Tanaka et 
al. 1993b; Gilat et a i 1994). MIP-lp has also been localised to the high endothelial venules (HEV) 
of lymph nodes where lymphocyte migration occurs (Tanaka et al. 1993a). Immobilisation of MIP- 
1a and p on rheumatoid arthritis endothelial cells via HSPG actually enabled more efficient integrin
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mediated adhesion of T cells as compared to the chemokines in their soluble form (Tanaka et al.
1998).
GAG structures can vary considerably between and even within tissues (Gallagher et al. 1992; 
Gallagher 1997), so it is thought that differences in the binding of chemokines to GAGs may act as 
a further molecular method of recruiting leukocytes to specific anatomical sites. For example, the 
heparin binding site has on several chemokines been found to be in proximity to the carboxyl 
terminus and consists of several residues of lysine, surrounded by other basic residues. IL-8 and 
Gro-a exhibit single acidic residues within this area, which are thought to allow them to bind to 
specific types of heparin, specifically those with low sulphation levels. IL-8 binds heparan sulphate 
better than heparin, perhaps because HS is less highly modified than heparin and shows a domain 
type structure with regions of high sulphation, alternating with regions of low sulphation (Witt and 
Lander 1994).
It has been suggested that the binding of chemokines to HSPG has several advantages -  high 
chemokine concentrations can be maintained in the correct location, HSPG can activate some 
chemokines, aid presentation to specific receptors and the soluble molecule is afforded some 
protection from damage by enzymes because of its changed conformation. By binding the GAGs 
on the cell surface, a chemokine can polymerise them and is thought by this method to enhance 
cellular responses to chemokines (Tanaka et al. 1993a; Hoogewerf et al. 1997).
Each tissue of the body has a different function, so the needs of a particular tissue will determine 
what is required of the endothelial cells in its blood vessels. Because chemokines are fundamental 
to leukocyte recruitment, their varied presentation on different endothelial cells helps determine 
which particular cell types will be recruited into which tissues. Different chemokines are produced 
at different sites and under different conditions, but it appears that their presentation to circulating 
leukocytes could also depend on which proteoglycans are present on the surface of the endothelial 
cell.
Chemokine binding to extracellular matrix components is also important during the later stages of 
leukocyte recruitment once the leukocyte is in the interstitium and is migrating to the specific site of 
damage or injury. At this stage, chemokines form a gradient from high (near the injury) to low along 
which the leukocyte can migrate towards the higher concentrations.
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The aim of this study is to determine the levels of binding of our five inflammatory chemokines to 
different endothelia in vitro and to then further investigate using enzyme digestions whether binding 
is via particular components of the proteoglycan layer or by a different mechanism.
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4.2 Methods
4.2.1 Chemokine binding assay
The cells were set up and rested as described in section 2.2 then washed four times in HBSS. 
65 pi of recombinant human chemokine (IL-8, MIP-1a, RANTES, MCP-1 or IP-10, all R & D 
systems) was added in triplicate at 0, 250 and 500 ng/ml diluted in HBSS and incubated at 37°C for 
1 hour. The plate was washed, fixed and chemokines remaining bound to the monolayer were 
detected using the cell based ELISA assay as described in section 2.2.3.
100 pi per well of blotin conjugated anti human chemokine antibody (IL-8, MIP-1 a, RANTES, MCP- 
1 or IP-10, all R & D systems) at a 1:500 dilution in ELISA diluent (see section 2.2.1) was used to 
detect bound chemokine. The chemokine antibodies were directly conjugated antibodies to biotin, 
so no second layer was necessary and the wells were filled with ELISA diluent alone while the 
secondary antibody layer required to detect MHC class I was incubated.
4.2.2 Chemokine binding assay on extracellular matrix components
This experiment was also performed on extracellular matrix components to investigate which ones 
can hold chemokines. 10 pg/ml of laminin (Sigma), type I collagen (Sigma), heparan sulphate 
proteoglycan (HSPG, Sigma) or superfibronectin (Sigma) was used in place of the confluent 
monolayer, incubated overnight at 4°C, then blocked using 100 pl/well of 5 mg/ml BSA for 30 mins. 
The layer was washed four times in HBSS and then chemokines added for 1 hour, fixed and 
assayed as described previously (section 4.2.1).
4.2.3 Enzyme digestion
Enzyme digestions of the proteoglycan layer were performed to investigate its composition. In this 
experiment, a confluent monolayer of BMEC was washed three times in HBSS. Then enzymes 
were added as described in section 2.3 prior to commencing the chemokine binding assay. Briefly 
65 pi of 10 U/ml heparinase III, 1 U/ml chondroitlnase ABC or 1 U/ml neuraminidase (diluted in 
HBSS,) was added to triplicate wells for 1 hour at 37°C before being washed off for the chemokine 
binding assay as described in section 4.2.1.
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4.2.4 Competition binding of RANTES and MIP-ato endothelium
This was performed as described in 4.2.1, except that mixtures of different concentrations of 
chemokines were used in triplicate wells. Mixtures of chemokines were made up which had 
increasing amounts of RANTES from 0 to 1000 ng/ml mixed with 500 ng/ml of MIP-1a and added 
to BMEC for 1 hour as in the previous binding assays. This assay was also repeated with 
increasing concentrations of MIP-1a competing against 500 ng/ml RANTES.
4.2.5 Chemokine binding at different temperatures
To check whether any of the chemokines were being internalised during the time of the experiment, 
we tested chemokine binding at different temperatures. The assay was performed exactly as 
described in section 4.2.1 except each plate was incubated at 4°C, 25°C or 37°C after the addition 
of chemokine until fixation of the cells.
4.2.6 Statistics
To analyse assays in this chapter a one way or two way ANOVA was performed followed by tu keys 
post hoc t-test comparing all pairs of values where necessary.
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4.3 Results
4.3.1 Chemokine binding to different endothelial monolayers
We determined the levels of chemokine binding to different endothelia by means of a chemokine 
binding assay (described in 4.2.1). Figure 4.1 shows the binding of five different chemokines (IL-8, 
MIP-1a, RANTES, MCP-1 and IP-10) to our five different endothelial cell types. For each cell type, 
we compared chemokine binding to the amount of MHC class I expressed. This was to help 
standardise between cell types. We have shown that MIP-1a and RANTES bound at significant 
levels to all five different types of endothelium, whereas IL-8, and MCP-1 did not bind under static 
conditions. Each of the five endothelial cell types bound MIP-1a and RANTES at differing levels 
while microvascular endothelia also bound a significant amount of IP-10 above controls when 500 
ng/ml of chemokine was added.
When 500 ng/ml of chemokine was added to the BMEC monolayer (fig. 4.1a), the endothelium 
bound slightly more RANTES than MIP-1 a after a 1 hour incubation with means of 63% and 54% of 
the MHC class I levels respectively. However when 250 ng/ml of chemokine was added, there was 
a marked difference in binding as MIP-1a bound 3% (approx. one fifteenth of that bound at 500 
ng/ml) while RANTES bound 31% of MHC class I levels (approximately half of the amount bound at 
500 ng/ml).
SVEC bound much higher amounts of RANTES than MIP-1a at both concentrations (fig. 4.1b), 
while DMVEC, LMVEC and HUVEC all bind much more MIP-1a than RANTES with HUVEC 
showing the highest levels of chemokine binding and LMVEC the lowest (figs 4.1 c-e).
We have shown two distinct profiles of binding of chemokine to endothelium. The first type of 
binding is represented by RANTES binding to BMEC and SVEC and showed a proportional 
increase in binding in relation to increased concentration. The second binding pattern, shown by 
the binding of MIP-1a to all five different endothelial cell types, is where the bound chemokine 
increases out of proportion with concentration increases. The binding at 500 ng/ml was typically 5 
to 20 times that at 250 ng/ml. This suggests that MIP-1a uses a co-operative binding mechanism to 
bind to endothelium.
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RANTES binding to LMVEC, DMVEC and HUVEC appeared to be part way between the two with 
approximately 4 to 7 times increase in binding from 250 ng/ml to 500 ng/ml.
This suggests that MIP-1a and RANTES could bind to endothelium by two different mechanisms. It 
is possible that the higher binding, could be mediated by a specific receptor for chemokines as 
opposed to binding to various residues of the proteoglycan layer, or it could indicate different 
affinities of binding to different components of the proteoglycan layer.
MIP-1a and RANTES both bind to similar specific receptors, both bind to CCR1 and CCR5, and 
RANTES also binds to CCR3. So both chemokines will have effects on similar subsets of 
leukocytes.
Having determined that all five cell types bound both MIP-1a and RANTES and that the means by 
which these two chemokines bind could be different, we then wanted to investigate further the 
methods by which these two chemokines were binding.
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Figure 4.1 Chemokine binding to endothelial monolayers
Endothelial cells were grown to confluence in 96 well plates, rested for 24 hours. Then different concentrations 
of chemokines were added (0, 250 or 500 ng/ml of IL-8, MIP-lcx, RANTES, MCP-1 or IP-10) for 1 hour at 
37°C. The cells were then washed, fixed and bound chemokine was detected using biotin labelled specific anti 
human chemokine antibodies. A. BMEC, B. SVEC, C. DMVEC, D. LMVEC, E. HUVEC. The results are of 
triplicate wells from at least two experiments. Significance was tested by ANOVA with a post hoc t-test 
(*=P<0.05)
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4.3.2 Chemokine binding to endotheiiai monoiayers after enzyme digestion
To determine how chemokines might be binding to the endothelial cell, we chose to investigate 
BMEC further as these cells had shown similar binding levels of the two chemokines and clearly 
demonstrated the different types of binding as well as being particularly simple to culture.
We investigated whether the chemokines were binding to the proteoglycan layer by digestion of 
various components of the layer (figs. 4.2 and 4.3). We used the enzymes heparinase III which 
cleaves heparan sulphate proteoglycan, chondroitlnase ABC lyase, which cleaves chondroitin 
sulphate proteoglycan and dermatan sulphate and neuraminidase which splits off sialic acid from 
other glycoproteins (for further details see section 2.3)
We found that the digestion of HSPG by heparinase significantly reduced the binding of RANTES 
at 500 ng/ml, but not at 250 ng/ml (fig 4.2). Heparinase had no effect on MIP-1a binding (fig 4.3), 
while chondroitlnase and neuraminidase had no effect on the binding of either chemokine. 
Although Heparinase significantly reduced the binding of RANTES, it did not abolish binding 
completely, so this suggests that there is more than one method by which RANTES binds.
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Figure 4.2 RANTES binding to BMEC monolayers after enzyme digestion of the proteoglycan layer
Endothelial monolayers were digested with 10 U/ml heparinase, 1 U/ml chondroitlnase, 1 U/ml neuraminidase 
or no enzyme for exactly 1 hour at 37°C. Different concentrations of RANTES were added (0, 250 or 500 
ng/ml) for 1 hour at 37°C. The cells were then fixed and bound chemokine was detected using biotin labelled 
specific anti human chemokine antibodies. A. and B. show duplicate experiments. Significance was tested by 
two way ANOVA with a post hoc t-test (*=P<0.05).
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Figure 4.3 MIP-1a binding to BMEC monolayers after enzyme digestion of the proteoglycan layer
Endothelial monolayers were digested with 10 U/ml heparinase, 1 U/ml chondroitlnase, 1 U/ml neuraminidase 
or no enzyme for exactly 1 hour at 37°C. Different concentrations of MIP-1a were added (0, 250 or 500 ng/ml) 
for 1 hour at 37°C. The cells were then fixed and bound chemokine was detected using biotin labelled specific 
anti human chemokine antibodies. A. and B. show duplicate experiments. No significant differences were 
detected using ANOVA
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4.3.3 Chemokine binding to extracellular matrix components
During leukocyte migration through the tissues, chemokines are bound to ECM components 
allowing leukocytes to migrate via haptotaxis and become activated. To further investigate what 
substrates different chemokines could bind to, we coated 96 well tissue culture plates with different 
ECM components (10 pg/ml of HSPG, laminin, fibronectin or collagen) and then performed the 
binding assay directly onto these components (table 4.1). We found that IL-8 and MCP-1 did not 
bind to any of the ECM components tested, while RANTES bound all those tested to varying 
degrees. MIP-1 a showed binding only to collagen, while IP-10 bound to all substrates tested.
Table 4.1 Chemokine binding to extraceiiuiar matrix components
Assayed by ELISA of bound chemokine to 10 pg/ml of HSPG, laminin, fibronectin or collagen. No significant 
binding (-), Low binding (+) approx. equivalent to 10 -  30% binding to MHC I on BMEC, High binding (++) 
approx. equivalent to >30% binding to MHC I on BMEC.
CHEMOKINE EXTRACELULLAR MATRIX COMPONENT
HSPG Laminin Fibronectin Collagen
IL-8 - - - -
MIP-1a - - ++
RANTES ++ + + ++
MCP-1 - - - -
IP-10 ++ ++ ++ ++
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4.3.4 Effects of temperature on chemokine binding
Our binding experiments were carried out at 37°C during the one hour incubation of chemokines 
with cells before fixation. We lowered the temperature at which this was carried out to slow the 
cells metabolism and turnover of molecules. We tested the binding of MIP-1a, RANTES and IP-10 
to BMEC and SVEC at different temperatures. Using a two way ANOVA with post hoc t-test, we 
tested whether there were significant differences between our binding assays that were normally 
performed at 37°C and those where the cell metabolism was slowed by reducing the temperature 
to 25 or 4®C. The results have some implications for the kinetics of chemokine binding to 
endothelial cells. We have shown that at 500 ng/ml RANTES, the binding was reduced at 25 and 
37°C as compared to 4°C (fig. 4.3a). When 250 ng/ml of MIP-1a was added to BMEC, the binding 
was reduced at 37®C compared to that at 4®C (fig. 4.3b). No significant differences were observed 
in IP-10 binding to BMEC at different temperatures (fig. 4.3c). On SVEC, RANTES binding was 
increased at 500 ng/ml, but reduced at 250 ng/ml when 37°C was compared to 4 or 37°C and no 
significant differences were detected in MIP-1a binding to SVEC (figs. 4.3 d, e). However the 
binding of IP-10 to SVEC was much increased at 37°C as compared to the lower temperatures (fig. 
4.3f).
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Figure 4.4 Binding of RANTES and MIP-1ato BMEC and SVEC at different temperatures
There is little difference observed in the binding of RANTES or MIP-1a to SVEC at different temperatures 
which indicates that the receptors that these chemokines bind to are not being internalised. The chemokine 
binding step and the subsequent reaction was done at 4, 25 and 37 ° 0. A. RANTES binding to BMEC, B.
MIP-1a binding to BMEC, C. IP-10 binding to BMEC, D. RANTES binding to SVEC, E. MIP-1a binding to
SVEC, F. IP-10 binding to SVEC. The experiments shown are one representative of at least 3 performed.
Significance was tested by ANOVA with a post hoc t-test (*=P<0.05).
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4.3.5 Competition binding of RANTES and MIP-a to endothelium
Both MIP-1a and RANTES bind to BMEC at similar levels at 500 ng/ml and both are known to bind 
similar chemokine receptors. To test whether these two chemokines were competing for binding 
sites we used a competition-type binding assay. We have shown that there is no change in the 
binding of RANTES when different concentrations of MIP-1a are added, however, when increasing 
concentrations of RANTES are added, there is a slight but significant reduction in MIP-1a binding 
(fig 4.5a). When Ipg/m l of RANTES is added, the reduction in MIP-1a binding is approximately 
10%. This shows that while MIP-1a cannot compete with RANTES binding to BMEC, RANTES is 
capable of displacing MIP-1a, suggesting that these two chemokines share a binding site.
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Figure 4.5 Competition assays between MIP-1a and RANTES on BMEC
We have found that there Is no competition between RANTES and MIP-1a for binding sites in the assay 
system we are using. A. increasing concentrations of RANTES competing with 500 ng/ml of MIP-1a. Results 
expressed as a percentage of MIP-1a bound as compared to no addition of RANTES. B. increasing 
concentrations of MIP-1a competing with 500 ng/ml of RANTES. Results expressed as a percentage of 
RANTES bound as compared to no addition of MIP-1a. The results show the mean and standard error of 
three experiments. Significance was tested by ANOVA, no significant differences were detected.
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4.4 Discussion
To investigate whether there are differences in the chemokine binding properties of different 
endothelia, we have measured the levels of chemokine binding to different endothelial monolayers 
using a cell based ELISA method. We have shown that MIP-1a and RANTES both bound to all five 
endothelia tested and that IP-10 bound at low, but significant levels to LMVEC and DMVEC. The 
binding profile of RANTES is also quite different to that of MIP-1a on all cell types. Since the 
system used is static we do have to bear in mind that in vivo, the chemokine would be subjected to 
removal by the flow of the blood around the body.
It has now been clearly shown that chemokines can bind to endothelium via GAGs present in the 
proteoglycan layer and it is also known that endothelial cells from different tissues / compartments 
have differences in proteoglycans present and the levels of sulphation of those proteoglycans. 
However, this is the first time that a comprehensive study has directly compared several different 
endothelial cell types for their chemokine binding properties. Several groups have investigated 
chemokine binding under both static and shear flow conditions, though once again mostly using 
HUVECs.
We chose to investigate BMEC further as they demonstrate high levels of binding of both RANTES 
and MIP-1 a and clearly demonstrate the 2 distinct binding profiles. We have shown that some of 
the binding to RANTES is via HSPG, but no significant binding of MIP-1a to heparan sulphate was 
shown. However when we test the chemokine binding at different temperatures, there is reduced 
binding at certain concentrations. It appears that MIP-1a and RANTES may share a binding site, 
and that RANTES has a stronger affinity for this particular ligand. Possible candidates molecules 
include CCR1 or CCR5.
4.4.1 MIP-1a
We have shown significant binding of MIP-1a at 500 ng/ml to all endothelia tested, but have shown 
no binding to purified HSPG and no differences in chemokine binding after digestion of heparan 
sulphate, chondroitin sulphate and dermatan sulphate or sialic acid residues from the proteoglycan 
layer. At a concentration of 250 ng/ml there is higher binding at lower temperatures but this is not 
shown significantly at 500 ng/ml. In our original chemokine binding assay, the pattern of binding
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suggests co-operation, which could mean that I MIP-1a is binding via its specific chemokine 
receptors, CCR1 and CCR5 as it is one of the few chemokines that does not bind to DARC (Szabo 
et al. 1995). We showed that MIP-1 a did bind to collagen, though not to either fibronectin or 
laminin. In vivo studies have also shown no MIP-1a binding to human dermal EC (Middleton et al. 
1997). However, this does not exclude MIP-1a from a role in leukocyte migration at other sites and 
they suggest that it may be more useful at anatomical sites where immobilisation is not necessarily 
required -  for instance in the capillaries of the lung and kidney. It has also been suggested that 
perhaps MIP-1a has more important effects as a stimulatory chemokine acting on endothelial cells 
and leukocytes to produce other inflammatory mediators or other effects of the leukocytes. We 
have also demonstrated that at the concentrations used in these assays, there is no competition 
between MIP-1a and RANTES for binding sites.
Ali et al. (2000) showed on CHO cells that MIP-1a binding to CCR1 & 5 is independent of the 
presence or absence of GAGs, but at low concentrations (pM level), the presence of GAGs 
increased the affinity of MIP-1a for the specific receptors, possibly by some sort of conformational 
change brought on by binding to the GAGs.
IL-8 and RANTES were shown to bind at higher levels to dermal EC than MCP-1, 3 or MIP-1a did 
(Hub and Rot 1998). These results are contradictory to what I have observed - 1 have shown strong 
binding of MIP-1a to dermal endothelia and lower binding of RANTES. It must be noted though, 
that my experiments were performed In vitro on microvascular EC and used much higher 
concentrations of chemokines than these which were actually performed on pieces of skin via an In 
situ immunoassay. In vivo, the conditions will be different and there will be many additional 
components present (e.g. other cells or ECM components) that could change the affinity of a 
chemokine for a particular cell type. In particular it was noted that MIP-1a binds strongly to 
infiltrating macrophages. It is also likely that because I am using a higher concentration, that the 
MIP-1a is more likely to be oligomerised.
4.4.2 RANTES
We have shown that SVEC and BMEC bind significant amounts of RANTES when either 250 or 
500 ng/ml is added to the culture. All other endothelia tested only show significant levels of binding 
at 500 ng/ml and show less overall binding than to MIP-1a. After the proteoglycans present on the
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endothelial cell surface are digested with heparinase, there is decreased binding of RANTES at 
500 ng/ml and although there is a reduction at 250 ng/ml, this result is not statistically significant. 
This shows that heparan sulphate is important in RANTES binding to endothelium, however, there 
could be more than one method by which RANTES binds, as heparinase does not totally abolish all 
RANTES binding to BMEC, it reduces it by approximately 50%. We also showed that RANTES 
could compete with MIP-1a for binding sites, which suggested that HSPG was not its only binding 
site as MIP-1a was not found to bind HSPG (the other RANTES ligand) significantly.
We have shown a slight but significant reduction in RANTES binding at 37°C as compared to 4°C 
on BMEC when 500 ng/ml of the chemokine is added. The results on SVEC are somewhat 
different, with increased binding noticeable at 500 ng/ml at 37°C, while slightly decreased binding is 
seen at 250 ng/ml at 37°C as compared to 4°C. Looking at these results overall suggest that 
RANTES may be binding by more than one method perhaps both to CCR1, 3 or 5 and to the 
proteoglycan layer and it could be dependent on the concentration of chemokine present.
RANTES has been shown to bind selectively to dermal venular ECs (not capillaries or arteries^ in 
vivo and the binding sites were specific and saturable (Hub and Rot 1998). Since we are using 
cultured microvascular EC, this could explain the difference. Also, the dermal endothelial cells that 
we have used were at passage 5 - 7  and could possibly have lost some of their specific phenotype 
by this stage. Hub and Rot showed that unlabelled IL-8 competing with labelled RANTES was able 
to entirely block RANTES binding, while IL-8 binding was strongly reduced by competition with 
unlabelled RANTES but not abolished completely. Our data shows a slight reduction in MIP-1a 
binding when in the presence of high concentrations of RANTES.
RANTES binding on cultured microvascular EC has been shown to be in similar patterns to those 
on HUVEC, this concurs with my results, which show little difference between HUVEC and 
microvascular EC (Hoogewerf ef a/. 1997).
Using heparinase on HUVEC, the binding of RANTES was reduced by 10 -  40% (Kuschert et al.
1999). Although we have not tested this on HUVEC in this study, this is similar to what we have 
found for BMEC (approximately 50% reduction).
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4.4.3 IP-10
We have shown that IP-10 bound significantly only to lung and dermal EC and then at a very low 
level. In some experiments, we showed IP-10 binding to SVEC, however this was inconsistent. In 
investigating the effects of different temperatures on SVEC, we found that IP-10 binding was 
significantly higher at 37°C than at 25 or 4°C.
Using a fusion protein of IP-10 and alkaline phosphatase. Luster et al. (1995) have demonstrated 
that the binding site for IP-10 is the same as that for PF-4 and that both of them are able to inhibit 
proliferation/angiogenesis. The binding of IP-10 to EC is specific, saturable, and PF-4, heparin and 
heparan sulphate all reduce its binding. They found that IL-8, MIP-1a, MIP-ip, MCP-1 and 
RANTES had no effect on IP-10 binding suggesting differences in the binding sites for GAGs.
4.4.4 IL-8
In these studies, we have used high (higher than physiological levels) of chemokines. The system 
we have used for detection requires many washing stages, which tend to loosen the endothelial 
cell from the gelatin and from the monolayer. If during the experiment, the endothelial cells become 
activated, then the cells lift off yhe plate. It appears that this might be happening on addition of IL-8. 
This is interesting to note as it is possible, that although in this assay, we cannot definitively 
demonstrate binding to the endothelium, activation by IL-8 could be important in the migration of 
endothelial cells. To improve the assay, it would perhaps be better to use a radiolabelled 
chemokine at a lower concentration as this would be more sensitive.
In the results presented for IL-8, some binding appears to be occurring, particularly to HUVEC, but 
due to the loss of up to 70% of the cells, we cannot draw any conclusions. Previous publications 
have found no binding of IL-8 to cultured HUVECs (Hechtman et at. 1991; Rot 1992a),
In other studies by Middleton et al. (1997) on the dermis In vivo, IL-8 was observed under the 
electron microscope on the lumenal EC surface particularly concentrated on the microvillus 
processes in close proximity to adhesion molecules. When radiolabelled IL-8 was injected 
intradermally, they showed that it rapidly crossed to the lumen via a form of transcytotic vesicular 
transport and was presented on the cell surface. The digestion of HSPG using heparinase reduced 
the IL-8 found in relation to EC and also if the C-terminus (GAG binding domain) is truncated they
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found that the IL-8 did not trancytose so well. Hence the C-terminus GAG binding domain is 
thought to be required for transcytosis.
4.4.5 MCP-1
In these experiments, we have shown no binding of MCP-1 to any of the five endothelial cells 
tested. It has previously been described that MCP-1 did not associate with the HUVEC cell surface, 
whereas Gro-a did via HSPG -  to detect this, FACS, cell surface ELISA and immunofluorescent 
staining were used (Weber et al. 1999b). This differs from published results In vivo, where MCP-1 
and MCP-3 have been shown to bind selectively to venular ECs of the dermis (not capillaries or 
arteries) and it was found that the binding sites were specific and saturable (Hub and Rot 1998). 
These variations in results could be due to the heterogeneity of endothelium or due to the different 
methods employed.
4.4.6 General discussion
We have shown that heparinase significantly reduced RANTES binding to BMEC, suggesting that 
HSPG is important in RANTES binding. However it appears that MIP-1a binds by a different 
method. Figure 4.1 shows the binding of MIP-1a to the different endothelia. It is possible that it 
could be more specific than the RANTES binding as doubling the concentration more than doubles 
the amount of MIP-1a detected, it is possible that at 500 ng/ml, MIP-1a was in the form of a dimer, 
hence high levels of binding were detected. The binding could be via a chemokine receptor or via 
another molecule on the cell surface (another proteoglycan or a different type of receptor). MIP-1a 
has been previously shown to bind HSPG as a dimer, but heparin as a monomer (Hoogewerf et al. 
1997; Koopmann and Krangel 1997; Stringer et al. 2002), but as digestion with heparinase had no 
effect in this model, we must discount this possibility.
We have shown that some of the binding of RANTES is via HSPG, but not all of it, and we have 
shown that there is potentially a different specific receptor method of binding of MIP-1a to 
endothelium. DARC has been found on post-capillary venules (Hadley et al. 1994; Peiper et al. 
1995) and is known to bind several CC and CXC chemokines with the notable exception of MIP-1a 
(Neote et al. 1993a; Szabo et al. 1995). The other potential method for chemokine binding is via 
specific receptors -  which we will investigate in more detail in the next chapter. There is the
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potential for the involvement of DARC in RANTES binding -  either alone or in co-operation with 
HSPG or CCR1,3 or 5.
Hoogewerf et al. (1997) found that RANTES, MCP-1, MIP-1a and IL-8 bound to HUVECs and that 
IL-8, MCP-1 and RANTES form oligomers when binding to the cell surface or to immobilised 
heparin, but that MIP-1a remains as a monomer under the same conditions. However later studies 
(Stringer et al. 2002) show that the dimer of MIP-1a binds strongly to HSPG, but not heparin. 
Mutation of the heparin binding site did not affect the binding or signalling by MIP-1 a (Koopmann 
and Krangel 1997), therefore HS does not appear to be required for binding of MIP-1 a. When the 
proteoglycan layer was digested using a combination of heparinases and chondroitinases 
(Hoogewerf et al. 1997) the binding of RANTES, MCP-1, MIP-1 a and IL-8 was reduced but by 
different amounts (40 -  80%). In their study a 4 hour digest at 37°C was used, but with much lower 
enzyme concentrations. Since the primary binding site of MIP-1 a to HUVEC is not via GAG 
binding, it might be via a specific high affinity chemokine receptor, but by RT PCR they could not 
detect any CXCR1-2, CCR1-5 or DARC mRNA.
RANTES, MIP-1 a, MCP-1 and IL-8 bound to HUVEC could be selectively competed for by soluble 
GAGs (Kuschert et al. 1999). RANTES was the most selective -  remaining bound to EC under very 
high concentrations of competing GAGs, while MIP-1 a was the least selective -  easily being 
competed for by heparin while IL-8 and MCP-1 were intermediate. Similar results were obtained 
when the chemokines were immobilised on heparin. By using a species of heparin with reduced 
sulphation levels, they found that binding required the N and O sulphated groups, however despite 
chondroitin and dermatan sulphate having similar sulphation levels they showed very different 
binding patterns.
Witt and Lander (1994) have demonstrated that IL-8 and Gro bind to the same fractions of HSPG, 
whereas PF-4 and NAP-2 bind to different specific moieties. They also showed that the specificity 
of binding is determined by the glutamate residues present in the GAG binding portion of the 
chemokine. This means that the sulphation patterns on the GAGs in the proteoglycan layer 
determine which particular chemokines will bind at which particular sites.
BMEC express more HSPG per cell than HUVEC and the sulphation patterns are different -  BMEC 
show higher levels of sulphation as well as more N-sulphated domains although the proportions of 
heparan sulphate, chondroitin sulphate and dermatan sulphate did not change (Netelenbos et al.
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2001). This could begin to explain some of the differences observed in chemokine binding between 
cell types.
Chemokine interactions with the glycocalyx of endothelium have an important role in modulating 
the presentation of chemokines to circulating leukocytes. Chemokines bound to the proteoglycan 
layer are not susceptible to being washed away under flow conditions and more efficiently recruit 
leukocytes. The binding of chemokines to HSPG promotes the accumulation at appropriate sites, 
and since GAGs have been found to display differential specificity for structural motifs, they have 
the potential to provide specificity to the process of presentation of chemokines at the vessel wall. 
GAG expression has been observed to be altered in certain disease states such as atherosclerosis 
and rheumatoid arthritis, so presentation of different chemokines may explain why certain cell types 
are recruited more during these disease states. So chemokine presentation on the vessel wall 
provides a mechanism for site and stimulus specific selective location of chemokines and hence 
leukocytes.
In this study we have shown MIP-1 a and RANTES binding to all five endothelial cells and IP-10 
binding to LMVEC and DMVEC at a low level and inconsistently on SVEC. We have shown by 
digesting HSPG that this is the mechanism by which RANTES binds, however, there is a possibility 
that there is another mechanism too as heparinase digestion did not reduce RANTES binding 
completely to zero. MIP-1 a does not bind HSPG under these conditions, however it must bind via a 
different mechanism, possibly through specific CC receptors.
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5. Chemokine receptor expression
5.1 Introduction
In 1991 the first specific chemokine receptors were discovered, they were two receptors for IL-8, 
now named CXCR1 and CXCR2, (Holmes etal. 1991; Moser etal. 1991; Murphy and Tiffany 1991; 
Schumacher et al. 1992). However until relatively recently, the actions of chemokines and the 
expression of their specific receptors had only been described for leukocytes. Now, there are 
several studies, which show that other cell types including endothelium are able to bind to and 
respond to chemokines (Rot 1992a; Rot 1992b; Horuk et al. 1997; Tanabe et al. 1997 and see 
table 5.1).
Chemokine receptors comprise a family of seven -  transmembrane-spanning G protein receptors 
that signal mainly through Gj - type proteins. The receptors have a single polypeptide chain 
approximately 350 amino acids in length and consist of a short extracellular N-terminus and an 
intracellular C-terminus, with three intracellular and three extracellular loops in between. A 
disulphide bond links highly conserved cysteines in extracellular loops 1 and 2. The N-terminus and 
the third intracellular loop are thought to be essential for the specific binding of chemokines. These 
chemokine receptors exhibit 25 -  80 % sequence homology and are part of a much larger family 
that include receptors for neurotransmitters, inflammatory mediators, hormones, paracrine 
substances and many other molecules.
DARC was the first chemokine receptor to be identified on endothelial cells (Hadley et al. 1994). 
Since then, chemokine receptors have been found to be present on vascular endothelium by 
several different groups (reviewed in Murdoch and Finn 2000). Unfortunately most of these studies 
concentrate on one or maybe two different types of endothelium, almost always HUVEC. In this 
study, we examine how chemokine-receptor expression varies between endothelia from several 
different vascular beds. Evidence concerning the presence of endothelial expressed chemokine 
receptors has been conflicting (see table 5.1). Published results so far vary widely from no 
chemokine receptors present (Petzelbauer et al. 1995) to several receptors present (Gupta et al. 
1998; Murdoch et al. 1999). Many of the studies have focused on HUVECs, however, brain 
microvascular, dermal microvascular and human coronary artery endothelial cells are also used as
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comparisons in some studies. There do not seem to have been any studies done specifically on 
SVECs. In this study, we have examined five different endothelial cell types.
Table 5.1 Summary of chemokine receptors detected on endothelium
REFERENCE ENDOTHELIUM RECEPTORS
EXAMINED
RECEPTORS FOUND
Schonbeck et al. 
(1995)
SVEC & HUVEC 
(no distinction)
CXCR1 & 2 CXCR1
Petzelbauer et al. 
(1995)
HUVEC
DMVEC
CXCR1 & 2 none
Murdoch et al. (1997) 
(poster abstract)
HUVEC CXCR1 & 2 
CCR1 - 5
CXCR1 & 2 
CCR1,2B, 3,4, 5
Fell and Augustin 
(1998)
HUVEC
DMVEC
CXCR1 -  4 
CCR1 -  6 
DARC 
CXCR1 - 4  
CCR1 -  6 
DARC
CXCR3, 4 > CXCR2 > CXCR1
Weak CCR5
DARC
CXCR3,4>CXCR1,2
none
DARC
Gupta etal. (1998) HUVEC CXCR1 - 4  
CCR1 - 3
CXCR4 > CCR3 > 
CXCR1,CCR1,2
Volin etal. (1998) HUVEC & bovine CXCR4 CXCR4 on all cell types
Berger etal. (1999) CAEC 
Brain EC
CXCR1 - 4  
CCR1 - 5
CXCR4, CCR3, CCR5 on all. 
CCR2A on CAEC only. 
CXCR1 & 3 on Brain EC only.
Murdoch etal. (1999) HUVEC CXCR1 - 4 CXCR4 > CXCR1 > CXCR2
Weber etal. (1999a) HUVEC CCR1 & 2 Low CCR2 > CCR1
Molino et al. (2000) CAEC
lAEC
HUVEC
CXCR4 CXCR4
Salcedo et al. (2000a) HUVEC
DMVEC
CCR2 CCR2 more abundant on DMVEC 
than HUVEC
Salcedo et al. (2000b) DMVEC
HUVEC
CXCR1 - 4  
CXCR1 -4
CXCR4 > CXCR1 > CXCR3 > 
CXCR2
CXCR4 > CXCR3 > CXCR1 > 
CXCR2
Garcia Lopez et al. 
(2001)
Many tissues 
HUVEC
CXCR3
CXCR3
Found CXCR3 on larger vessels in 
many tissues including lung. Not 
found on skin EC.
Not detected on HUVEC
Romagnani et al. 
(2001)
HMVEC from 
different sources
CXCR3 CXCR3 is cell cycle dependent
Salcedo et al. (2001 ) DMVEC CCR1 - 4 Low CCR1 - 4
The specific role of chemokine receptors on endothelial cells has yet to be fully determined, 
however it is already known that endothelial cells respond to chemokines via the chemokine 
receptors; for example during chemotaxis or proliferation. In this study, we have compared the 
expression of chemokine receptors CCR1-6 and CXCR1-5 by the same five endothelial cell types 
used in the previous chapter.
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5.2 Methods
5.2.1 Detection of chemokine receptors by Fiow cytometry
Endothelial cells were detached from 150 cm^ culture flasks by enzyme digestion with 
trypsin 0.025% / EDTA 0.01%. After neutralisation of the trypsin using culture medium, the cells 
were spun at 1500 rpm for 5 mins. The pellet was resuspended in 1 ml of 4% formaldehyde diluted 
in PBS and incubated for 10 mins on ice. After another centrifugation, the pellet was resuspended 
in 1 ml of 0.1% Triton X-100 in PBS for 1 min. At the end of 1 min, 5 ml of PBS was added to the 
suspension and the cells were centrifuged again. The cells were blocked by resuspending the 
pellet in 0.1 mg/ml of rabbit IgG and 10% normal goat serum, in PBS for 30 mins on ice. The cells 
were transferred into microfuge tubes, allowing 1x10® cells per tube (25 pi of 4 x 10® cells/ml). An 
anti-chemokine receptor antibody directly conjugated to either PE or FITC was added to each tube 
and incubated at 4°C for 1 hour. Antibodies to CXCR1-5, CCR1-3, 5 & 6 and matching isotype 
control antibodies were purchased from R & D systems, 10 pi of each of these were used without 
dilution. The antibody to CCR4 from Santa Cruz Biotechnologies (Santa Cruz, CA. USA) was 
diluted 1:100 as was the anti-vWF from Sigma These two antibodies were not conjugated to 
fluorescent markers, hence required a secondary antibody to be added.. 500 pi of PBS was added 
to each tube and then the tubes were centrifuged at 2000 rpm in a microfuge for 1 min. For 
detection of CCR4 and vWF, a secondary FITC conjugated goat anti rabbit antibody (used at 
1:400, Chemicon, Harrow, UK) was added to the washed cells and incubated at 4°C for a further 
45 mins. 500 pi of PBS was also added to this, then these tubes were centrifuged for one final time 
before being resuspended in 300 pi of PBS in FACS tubes. The cells were analysed using a 
Becton Dickinson FACSCalibur. 10,000 events were analysed per sample tube, the medians were 
determined and the medians of the isotype controls or secondary antibody alone were subtracted. 
The results shown are one representative of at least three experiments.
5.2.2 Detection of chemokine receptors by Immunocytochemistry
EC were grown to 70 -  80% confluence on 0.2% gelatin coated glass coverslips in 12 well tissue 
culture plates. They were fixed for 10 mins at room temperature using 4% formaldehyde in PBS, 
then permeabilised for 5 mins at room temperature using 0.1 % Triton X-100 diluted in PBS and
111
blocked with 10% normal goat serum for 30 mins at room temperature. The cells were stained for 
one hour at 4°C using chemokine-receptor specific fluorescent antibodies (same as described for 
FACS experiments except the anti CCR4 was used at a 1:60 dilution in this experiment). The 
coverslips were washed three times in PBS. For CCR4 and vWF staining, goat anti rabbit cy3 
conjugated antibody (1:400, Chemicon) was added for 1 hour at 4°C. The coverslips were then 
mounted onto slides using fluoromount, left overnight to dry and viewed using a confocal 
microscope. Images were taken in the horizontal plane at 1 pm intervals through the specimen. 
The images were then overlaid to produce a composite.
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5.3 Results
We determined the expression of chemokine (CXC and CC) receptors by permeabilised resting 
endothelial cells both by flow cytometry and by immunocytochemistry using receptor specific 
antibodies. Figure 5.1 summarises the expression of chemokine receptors CCR1-6 and CXCR1-5. 
It shows one representative experiment with duplicate samples. We showed similar patterns across 
several experiments, although the actual values of mean fluorescence varied considerably from 
experiment to experiment. Figures 5.2 - 5.11 show FACS histograms from which the data in Figure
5.1 is derived, while Figures 5.12 - 5.21 show immunocytochemistry staining of these same 
receptors on the different endothelial cell types. In all five endothelial cell types examined, we have 
shown high levels of CXCR1 and CXCR3. CCR3 was also present at lower levels in endothelia 
from all tissues except the lung (which showed virtually no expression), CCR4 expression varied 
widely between cell types and from experiment to experiment. CXCR4 and 5 were expressed by 
SVEC and HUVEC only.
5.3.1 Flow cytometry
HUVECs ‘the standard EC expressed CXCR1 highly with similar amounts of CXCR3 and low 
levels of CCR3 and CCR4. CXCR4 was also shown to be present in small amounts on resting 
HUVECs.
The level of CXCR1 (Fig. 5.1a) a receptor for IL-8, on the transformed bone marrow EC line is 
comparable to that on HUVEC, whereas SVEC showed slightly more CXCR1 than HUVEC and 
microvascular endothelia showed less than half of the amount found on HUVECs. CXCR2, the 
second receptor for IL-8, was found only at extremely low levels and not at all on microvascular 
endothelial cells.
CXCR3, the receptor for IP-10, l-TAC and Mig, was present on HUVECs at levels very slightly 
below that for CXCR1. SVEC, BMEC and LMVEC showed a higher level of expression of CXCR3 
compared to that on HUVEC, with BMEC and LMVEC also showing CXCR3 at a higher level than 
they expressed CXCR1. However DMVEC again showed a lower level of this receptor than all 
other cell types.
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CXCR4 and CXCR5 were expressed only on SVEC and HUVEC, with higher levels seen on the 
SVEC. This suggests a difference between macrovascular and microvascular endothelium.
CCR3 is a receptor for many different chemokines including some of the monocyte 
chemoattractant proteins (MCPs) and eotaxin. It was found to be highly expressed (Fig. 5.2b) on 
SVEC, with lower expression on BMEC, DMVEC and HUVEC, but virtually no expression on 
LMVEC. CCR4 was expressed on all 5 cell types -  low, but consistent between experiments on 
BMEC and HUVEC, but with very variable expression on SVEC, DMVEC and LMVEC. The fact 
that the expression is consistent on BMEC is likely to be due to the fact that it is a cell line, hence 
there is no heterogeneity between different cultures. The variation observed in primary cultures of 
SVEC, DMVEC and LMVEC could be due in part to differences between individual donors. The 
values shown in fig. 5.1b are the highest observed values of CCR4 (sometimes no expression was 
detected).
There was virtually no CCR1, CCR2 or CCR5 expression detected, and only low amounts of CCR6 
were detected on SVEC and both types of microvascular endothelium.
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Figure 5.1 Summary of chemokine receptor expression on different resting endothelia
Resting endothelial cells were harvested by trypsinisation, then the levels of chemokine receptors were 
detected using receptor specific antibodies and analysed by flow cytometry. A. expression of CXCR1-5, B. 
expression of CCR1-6. Results are expressed as the median fluorescence for each receptor of a 
representative experiment of three performed.
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Figure 5.2 Flow cytometry histograms of CXCR1-5 immunofluorescence on resting BMEC
Resting endothelial cells were harvested by trypsinisation, then the levels of chemokine receptors were
detected using anti human chemokine receptor specific antibodies (filled peak). Isotype matched controls
(unfilled peaks) were used and 10,000 events analysed by flow cytometry.
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Figure 5.3 Flow cytometry histograms of CCR1-6 immunofluorescence on resting BMEC
Resting endothelial cells were harvested by trypsinisation, then the levels of chemokine receptors were 
detected using anti human chemokine receptor specific antibodies (filled peak). Isotype matched controls 
(CCR1-3, 5 and 6) or secondary antibody alone (CCR4) were used as controls (unfilled peaks) and 10,000 
events analysed by flow cytometry.
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Figure 5.4 Flow cytometry histograms of CXCR1-5 immunofluorescence on resting SVEC
Resting endothelial cells were harvested by trypsinisation, then the levels of chemokine receptors were
detected using anti human chemokine receptor specific antibodies (filled peak). Isotype matched controls
(unfilled peaks) were used and 10,000 events analysed by flow cytometry.
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Figure 5.5 Flow cytometry histograms of CCR1-6 immunofluorescence on resting SVEC
Resting endothelial cells were harvested by trypsinisation, then the levels of chemokine receptors were 
detected using anti human chemokine receptor specific antibodies (filled peak). Isotype matched controls 
(CCR1-3, 5 and 6) or secondary antibody alone (CCR4) were used as controls (unfilled peaks) and 10,000 
events analysed by flow cytometry.
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Figure 5.6 Flow cytometry histograms of CXCR1-5 immunofluorescence on resting DMVEC
Resting endothelial cells were harvested by trypsinisation, then the levels of chemokine receptors were
detected using anti human chemokine receptor specific antibodies (filled peak). Isotype matched controls
(unfilled peaks) were used and 10,000 events analysed by flow cytometry.
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Figure 5.7 Flow cytometry histograms of CCR1-6 immunofluorescence on resting DMVEC
Resting endothelial cells were harvested by trypsinisation, then the levels of chemokine receptors were 
detected using anti human chemokine receptor specific antibodies (filled peak). Isotype matched controls 
(CCR1-3, 5 and 6) or secondary antibody alone (CCR4) were used as controls (unfilled peaks) and 10,000 
events analysed by flow cytometry.
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Figure 5.8 Flow cytometry histograms of CXCR1-5 immunofluorescence on resting LMVEC
Resting endothelial cells were harvested by trypsinisation, then the levels of chemokine receptors were
detected using anti human chemokine receptor specific antibodies (filled peak). Isotype matched controls
(unfilled peaks) were used and 10,000 events analysed by flow cytometry.
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Figure 5.9 Flow cytometry histograms of CCR1-6 immunofluorescence on resting LMVEC
Resting endothelial cells were harvested by trypsinisation, then the levels of chemokine receptors were 
detected using anti human chemokine receptor specific antibodies (filled peak). Isotype matched controls 
(CCR1-3, 5 and 6) or secondary antibody alone (CCR4) were used as controls (unfilled peaks) and 10,000 
events analysed by flow cytometry.
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Figure 5.10 Flow cytometry histograms of CXCR1-5 immunofluorescence on resting HUVEC
Resting endothelial cells were harvested by trypsinisation, then the levels of chemokine receptors were
detected using anti human chemokine receptor specific antibodies (filled peak). Isotype matched controls
(unfilled peaks) were used and 10,000 events analysed by flow cytometry.
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Figure 5.11 Flow cytometry histograms of CCR1-6 immunofluorescence on resting HUVEC
Resting endothelial cells were harvested by trypsinisation, then the levels of chemokine receptors were 
detected using anti human chemokine receptor specific antibodies (filled peak). Isotype matched controls 
(CCR1-3, 5 and 6) or secondary antibody alone (CCR4) were used as controls (unfilled peaks) and 10,000 
events analysed by flow cytometry.
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5.3.2 immunocytochemistry
The confocal images from immunocytochemistry staining of subconfluent cells enabled us to 
localise chemokine receptors within the cell. Similar expression profiles to those found with flow 
cytometry were found (Figs 5.12 -  5.21). Ail receptors were localised throughout the cytoplasm, 
particularly In the area close to the nucleus. Staining was also localised to the cell surface. With the 
exception of CCR4, the chemokine receptors tested stained all cells uniformly. The CCR4 
expression was very variable, appearing to be localised In vesicles of some cell types. It Is 
uncertain whether this distribution could affect the flow cytometry data. With Immunocytochemistry, 
It Is possible to visualise the low levels of chemokine binding seen with several chemoklnes (e.g. 
CCR2). The receptors that bind at a low level appear to be sparsely distributed across the cell 
surface, with less obvious binding around the nucleus.
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Figure 5.12 CXC chemokine receptor staining of permeabilised BMEC
Endothelial cells were grown on gelatin coated coverslips then chemokine receptors were detected using
specific chemokine receptor antibodies (left column). Isotype matched controls were used as negative controls
(right column). Images were taken with a confocal microscope at x40. Scale bar = 40pm
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Figure 5.13 CC chemokine receptor staining of permeabilised BMEC
Endothelial cells were grown on gelatin coated coverslips then chemokine receptors were detected using 
specific chemokine receptor antibodies (left column). Isotype matched controls (CCR1-3,5 and 6) or 
secondary antibody alone (CCR4) were used as controls (right column). Images were taken with a confocal 
microscope at x40. Scale bar = 40pm
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Figure 5.14 CXC chemokine receptor staining of permeabilised SVEC
Endothelial cells were grown on gelatin coated coverslips then chemokine receptors were detected using
specific chemokine receptor antibodies (left column). Isotype matched controls were used as negative controls
(right column). Images were taken with a confocal microscope at x40. Scale bar = 40pm
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Figure 5.15 CC chemokine receptor staining of permeabilised SVEC
Endothelial cells were grown on gelatin coated coverslips then chemokine receptors were detected using 
specific chemokine receptor antibodies (left column). Isotype matched controls (CCR1-3,5 and 6) or 
secondary antibody alone (CCR4) were used as controls (right column). Images were taken with a confocal 
microscope at x40. Scale bar = 40pm
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Figure 5.16 CXC chemokine receptor staining of permeabilised DMVEC
Endothelial cells were grown on gelatin coated coverslips then chemokine receptors were detected using
specific chemokine receptor antibodies (left column). Isotype matched controls were used as negative controls
(right column). Images were taken with a confocal microscope at x40. Scale bar = 40pm
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Figure 5.17 CC chemokine receptor staining of permeabilised DMVEC
Endothelial cells were grown on gelatin coated coverslips then chemokine receptors were detected using 
specific chemokine receptor antibodies (left column). Isotype matched controls (CCR1-3,5 and 6) or 
secondary antibody alone (CCR4) were used as controls (right column). Images were taken with a confocal 
microscope at x40. Scale bar = 40pm
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Figure 5.18 CXC chemokine receptor staining of permeabilised LMVEC
Endothelial cells were grown on gelatin coated coverslips then chemokine receptors were detected using
specific chemokine receptor antibodies (left column). Isotype matched controls were used as negative controls
(right column). Images were taken with a confocal microscope at x40. Scale bar = 40pm
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Figure 5.19 CC chemokine receptor staining of permeabilised LMVEC
Endothelial cells were grown on gelatin coated coverslips then chemokine receptors were detected using 
specific chemokine receptor antibodies (left column). Isotype matched controls (CCR1-3,5 and 6) or 
secondary antibody alone (CCR4) were used as controls (right column). Images were taken with a confocal 
microscope at x40. Scale bar = 40pm
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Figure 5.20 CXC Chemokine receptor staining of permeabilised HUVEC
Endothelial cells were grown on gelatin coated coverslips then chemokine receptors were detected using
specific chemokine receptor antibodies (left column). Isotype matched controls were used as negative controls
(right column). Images were taken with a confocal microscope at x40. Scale bar = 40pm
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Figure 5.21 CC chemokine receptor staining of permeabilised HUVEC
Endothelial cells were grown on gelatin coated coverslips then chemokine receptors were detected using 
specific chemokine receptor antibodies (left column). Isotype matched controls (CCR1-3,5 and 6) or 
secondary antibody alone (CCR4) were used as controls (right column). Images were taken with a confocal 
microscope at x40. Scale bar = 40pm
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5.4 Discussion
Expression of chemokine receptors by endothelial cells is still under much discussion. While it is 
now accepted that endothelial cells do express chemokine receptors, it is still much debated as to 
which receptors are expressed and why.
The results from research on CXC receptors is still conflicting, but seem to suggest that CXCR1 
and CXCR4 are present in HUVECs (Schonbeck et al. 1995; Gupta et al. 1998), with CXCR2 
mRNA being found by some researchers as well (Murdoch et al. 1999). In their results, both Gupta 
et al. and Murdoch et al. suggested that CXCR4 is the most abundant chemokine receptor on 
human EC. A more comprehensive study of all CCR1-6 and CXCR1-4 on HUVECs and DMVECs 
by RT-PCR has shown no CC receptors except for variable expression of CCR5 on subconfluent 
monolayers of HUVEC. They did however show the presence of all four CXC receptors with lower 
levels of CXCR1 and 2 (Fell and Augustin 1998).
In this study, we have used flow cytometry to determine the amounts of chemokine receptor 
present on our five different types of endothelial cell, we then used immunocytochemistry to 
determine the distribution of these receptors within the cell. We have shown distinct differences in 
chemokine receptor expression between endothelia from different vascular beds.
The subconfluent cultures of cells allow us to see each individual cell more clearly and determine 
where in the cell the receptors are, however at confluence, cells will be contact inhibited and will 
have stopped growing, so there could be slight differences in receptor levels between FACS results 
and immunocytochemical staining. The trypsinisation step could also have a potentially damaging 
effect on surface receptors hence the need for the two different methods.
5.4.1 CXCR1 and 2
CXCR1 and 2 are the only known mammalian receptors for ELR+ CXC chemokines (Belperio et al. 
2000). This includes IL-8, which has a similar affinity for both receptors, however, CXCR1 is highly 
selective for IL-8 whereas CXCR2 is somewhat less selective for IL-8 compared to all the other 
ELR+ CXCR chemokines. The only other ligand which competes for CXCR1 is GCP-2, and this is 
an equipotent agonist at CXCR1 and 2 (Wolf et al. 1998). Following this, CXCR1 has been found to 
be the dominant receptor for IL-8 chemotaxis, whereas CXCR2 mediates neutrophil chemotaxis to
137
NAP-2 and Gro-a at relatively low concentrations (Wuyts et al. 1998; Feniger-Barish et al. 1999; 
Feniger-Barish et al. 2000).
One of the earliest papers investigating the specific receptors for IL-8 on HUVEC and DMVEC 
derived from human breast could not detect either CXCR1 or CXCR2 (Petzelbauer et al. 1995). 
However another paper published around the same time showed that endothelial cells (SVEC and 
HUVEC used indiscriminately) specifically bound IL-8 and that CXCR1, but not CXCR2 mRNA was 
present (Schonbeck et a i 1995).
Using DMVEC, Salcedo et al. (2000b) showed virtually no CXCR2 on the cell surface or in 
permeabilised cells, but they showed relatively high levels of CXCR1. HUVEC were shown to 
express both CXCR1 and 2, but at much lower levels than DMVEC. This group also demonstrated 
that after IL-8 stimulation, CXCR1 and 2 get internalised. Using blocking antibodies, they showed 
that by blocking CXCR2, migration was reduced by approx. 30% and blocking CXCR1 reduced 
migration by 70%. When both antibodies were used in combination, over 90% of migration was 
blocked. So although CXCR2 was shown to be less abundant on the cells, it still made a 
considerable contribution to migration. Murdoch et a i (1999) showed the presence of CXCR1 
and 2 mRNA, however with flow cytometry, they showed no CXCR2 protein. Whether this is due to 
only the mRNA and not the protein of CXCR2 being present or whether this is due to incorrect 
primers (as there is 78% homology in CXCR1 and CXCR2 sequences) is stiil unclear.
5.4.2 CXCR3
CXCR3 is the receptor to three known ligands, IP-10, ITAC and Mig. These are all ELR- and hence 
angiostatic. IP-10 and Mig bind to CXCR3 with approximately the same affinity, whereas l-TAC has 
higher binding affinity. Murdoch et a/, showed low levels of CXCR3 mRNA in HUVECs, however 
they did not investigate the ievels of protein expressed. Protein expression has been shown in 
larger vessels, but not in cultured HUVECs (Garcia Lopez et a i 2001). Other groups have shown 
CXCR3 to be present on brain microvascular endothelia (Berger et al. 1999) and at low levels on 
DMVEC (Salcedo et al. 2000b) and expression has been found to be cell cycle dependent 
(Romagnani et a i 2001). My experiments show relatively high levels of CXCR3 In SVEC and 
HUVEC, and low in DMVEC, similar to those found by Salcedo et a i and Murdoch et a i
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5.4.3 CXCR4
CXCR4 is very widely expressed on most haematopoietic cell types and is expressed by vascular 
endothelial cells. The ligand for CXCR4 is SDF-1, which is alternately spliced to form SDF-1a or 
SDF-ip. These two variants only vary by a four amino acid extension at the C-terminus. Being such 
an important receptor in development as well as a co-factor in HIV (Feng et al. 1996; Locati and 
Murphy 1999; Murdoch 2000), CXCR4 has been studied much more than any other chemokine 
receptor.
In this study, I have shown moderate levels of CXCR4 in SVEC and HUVEC, with virtually none 
present on the three other EC types. Many groups have shown substantial levels of CXCR4 both 
by mRNA and FACS on several different endothelial cell types. In HUVEC, Murdoch et al. (1999) 
showed high levels of CXCR4 mRNA and levels of protein present equivalent to that shown in my 
experiments. Gupta et al. showed by RT-PCR that CXCR4 was present on HUVEC as well as on 
coronary artery endothelium. Using flow cytometry, CXCR4 has been shown to be present at high 
levels on DMVEC (Salcedo et a i 2000b) and HUVEC (Berger et a i 1999; Salcedo et a i 1999). The 
presence of CXCR4 mRNA has been shown in many different arterial endothelial tissues by In situ 
hybridisation and by PCR on cultured HUVEC as well as immunocytochemistry (Volin et a i 1998).
5.4.4 CXCR5
This chemokine receptor is important in the development of normal lymphoid tissue and is found on 
most B cells as well as some subsets of T cells where it is dynamically regulated. Its only known 
ligand is BCA-1. CXCR5 has been found in my experiments to be present at a low level only on 
SVEC. As far as I can tell from the literature, this is the first examination of CXCR5 expression in 
endotheiium.
5.4.5 CC receptors
Until now, there has been little evidence to suggest that any CC receptors are found at high levels 
on endothelium -  however low levels of certain receptors (CCR1, CCR3, CCR4 and CCR5) have 
been found in some studies (Gupta et a i 1998; Murdoch et a i 1999). One group has found that 
CCR3 is present on coronary artery endothelial cells (CAEC) and that CCR5 is expressed at low 
levels in both brain microvascular endothelial cells (BMVEC) and CAEC (Berger et a i 1999).
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In this study I have shown, on all except lung endothelium, high levels of CCR3, a chemokine 
receptor which is found on eosinophils and is important in their homing via eotaxin especially 
during allergic inflammation such as asthma.
CCR4 is a selective marker for T cells, in particular Th2 cells. It binds to TARC and MDC (Imai et 
al. 1997; Imai et al. 1998). It is involved in several different processes including dendritic cell 
trafficking, T cell recirculation and several other processes, but it has been found to be vital in the 
homing of T cells to human skin, though not to the gut (Campbell et al. 1999). CCR4 has not 
previously been found on endothelial cells, and in our experiments, we found that it is present at 
extremely variable levels on our primary cells. This chemokine receptor was the only one where a 
directly conjugated antibody was not available from R & D systems. Hence we used a non­
conjugated antibody from Santa Cruz. This had problems associated with it as during the second 
centrifugation step, many cells appeared to break up, leaving us with more debris in the tube than 
the other receptors. This could partially explain the variable results found, however when we look at 
the immunocytochemistry data, we find that there appear in certain cell types to be large vesicles 
which stain very brightly for CCR4.
One of the problems that we encountered was that the dermal and lung microvascular endothelial 
cells were very much larger and more fragile that the SVEC, HUVEC and BMEC. Consequently 
some of the variability in CCR4 expression could be due to these physical differences affecting 
recovery of cells in the FACS.
Many of the differences between my results and those discussed here could be due to differences 
in antibodies used. For example; we have tried two different antibodies to CXCR3, the first one we 
tried was not directly conjugated to FITC and gave high, but quite varying results. So when R & D 
introduced the directly conjugated, we switched to that as the results were more consistent. Yet 
Murdoch et al. using several different antibodies to CXCR3 including those with the same 
specificities as our two, were unable to show any expression of CXCR3 on HUVEC (Craig 
Murdoch, personal communication). It is also possible that there could be slight differences due to 
individual patients, however repeats of these experiments with different patients yield similar 
patterns of expression from the flow cytometry (data not shown).
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5.4.6 Summary
In this study we have shown that chemokine receptors are present on endothelium and that there 
are differences between endothelia derived from different parts of the body. Since chemokines 
have been implicated in the process of angiogenesis, we will also address the question of whether 
the variability in chemokine receptor expression on different endothelium contributes to differences 
in endothelial responses to specific chemokines. This will be examined in more detail In chapter 7.
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Chapter 6 
Oligosaccharide expression ( 
dMerent endothelial monolayers
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6. Oligosaccharide expression on different endothelial monolayers
6.1 Introduction
In Chapter 4 we showed that there are differences in the binding of chemokines to endothelial cells 
derived from different vascular beds, and that HSPG in the proteoglycan layer is involved in this 
binding We then wanted to further investigate the differences within the glycocalyx between 
endothelial cells. In this chapter, we investigate in more detail the composition of the proteoglycan 
layer, in particular the sugar residues present. To do this, we have used lectins to determine the 
levels of particular sugar structures on the endothelial cell surface.
Lectins are sugar-binding proteins which have been found in plants, viruses, micro-organisms and 
animals (reviewed in Singh et al. 1999). They all incorporate one or more sites which have highly 
specific, but reversible binding for carbohydrates. Some lectins contain a second type of binding 
site that binds with ligands other than sugars, this gives the lectins more specificity as they can 
bind to acetylaminocarbohydrates, aminocarbohydrates, sialic acid and other ligands.
Table 6.1 illustrates the binding specificities of the lectins used in this study. All those used belong 
to the legume family of lectins and are derived from one part or another of different plants. Several 
of the lectins we used have been shown to bind to the same primary monosaccharide, however 
there are subtle differences between each lectin as they also can recognise certain other moieties 
close to the primary binding sequence and they often show preferential binding to oligosaccharides 
rather than monosaccharides (Chatter]ee and Ahmed 1998). Components of the family of legume 
lectins have shown many useful functions; they were first used in the agglutination of different 
blood cells (Sharon 1983), but they also serve as a useful marker for endothelium. Human 
endothelial cells specifically display certain a-L-fucose residues, which are reactive with UEA-1. 
Hence this lectin is often used as a marker of human endothelial cells and is useful in their isolation 
(Hormia et al. 1983; Jackson et al. 1990). GSL-1 stains endothelial cells in many different species, 
but only approx. 10% of human endothelium by binding terminal a-galactose (Bankston et al.
1991).
There are many studies, which have previously investigated lectin binding to different endothelia. 
Although some studies have used SVEC or HUVEC, the majority have been performed on different
143
species of mammals and there has been a great deal of difference found from one species to 
another.
The aim of this study is to determine whether there are any differences in the basal levels of 
expression of different oligosaccharides on different endothelium and to then investigate the effects 
of digestion of proteoglycans on this expression. We show several differences between endothelial 
cell types.
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6.2 Methods
6.2.1 Lectin binding assay
Cells were set up and rested as described in section 2.2.2. They were washed, fixed and blocked 
as described in section 2.2.3 before washing three times in 0.1% tween 20 in PBS. The binding of 
oligosaccharides to specific lectins was detected by adding 65 pi per well of 10 pg/ml biotinylated 
lectin (Vector laboratories, Peterborough, UK) in ELISA diluent as listed in table 6.1. 10 pg/ml of 
MHO class I antibody and E-selectin antibody (Serotec) and 1:1000 of anti HSPG antibody 
(Chemicon) were also added in ELISA diluent to help standardise between experiments and 
determine the activation state of the endothelium. All treatments were randomised across the plate 
in triplicate, then incubated for 1 hour at 37°C as previously described. At the end of 1 hour, the 
plate was washed and 100 pi of the biotinylated rabbit anti mouse immunogiobulins (Dako) added 
at 1:700 dilution in ELISA diluent for those wells containing MHO class I, E-selectin or HSPG 
primary antibody with just ELISA diluent added to those with lectins. The levels of binding of each 
antibody or lectin were visualised as described in section 2.2.
6.2.2 Enzyme digestion
Enzyme digestions of the proteoglycan layer were performed to investigate its composition, in this 
experiment, a confluent monolayer of BMEC was washed three times in HBSS. Then enzymes 
were added as described in section 2.3 prior to commencing the lectin binding assay as described 
in section 6.2.1.
6.2.3 Statistics
To test significance, two way ANOVAs were performed on each experiment followed by a post hoc 
t-test comparing pairs of results or all results as necessary.
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6.3 Results
6.3.1 Lectin binding to different endotheiiai monoiayers under resting conditions
We determined the levels of binding of various different lectins to their specific oligosaccharide 
ligands found within the proteoglycan layer of different endothelial monolayers. The lectins used 
and their specificities are described in Table 6.1. Figures 6.1 and 6.2 show the levels of binding of 
all the lectins tested to each of the different endothelial cell types tested. We have used the bone 
marrow endothelial cell line as a standard in this comparison. This is because as it is an 
immortalised cell line, it is likely to vary less between experiments than any of the other endothelial 
cell types. We have then standardised the lectin binding against MHC class I binding at 100 % as 
in previous experiments to aid in the comparison of different endothelial cell types. The results in 
figures 6.1 and 6.2 are one representative example out of three experiments performed, however 
as the results are not always consistent between experiments (SVEC were the most consistent 
suggesting less differences between individuals), we can only consider those results that are 
consistently statistically different. The level of significance used is P<0.05. Significant results 
discussed here are those where in a majority of experiments performed, the data showed the same 
trend and was significant. It is these results that we will examine in more detail. If a result is not 
significant in a majority of experiments performed, or is significant, but shows variability (i.e. 
different pattern of expression in different experiments) it is not discussed here.
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Figure 6.1 Lectin binding to monolayers of primary macrovascular endothelium compared to the 
transformed bone marrow cell line.
Biotinylated lectins were used to detect differences in the carbohydrates on the endothelial cell surface of A. 
SVEC and B. HUVEC. The experiments shown are one representative of at least 3 performed. Significance 
was tested by AN OVA with a post hoc t-test.
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Figure 6.2 Lectin binding to monolayers of primary microvascular endothelium compared to the 
transformed bone marrow cell line
Biotinylated lectins were used to detect differences in the carbohydrates on the endothelial cell surface of A. 
DMVEC and B. LMVEC. The experiments shown are one representative of at least 3 performed. Significance 
was tested by AN OVA with a post hoc t-test.
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All of the 22 lectins tested bound to all endothelia with the exception of two galactose binding 
lectins SJA and B4, which did not statistically bind any higher than the baseline to HUVEC and 
LMVEC and showed very low binding on other celi types. The levels of reaction of lectins with the 
different endothelia are similar in most cases, however there are some interesting differences. The 
binding levels are presented as a summary in Tabie 6.2.
Table 6.2 Summary of results of binding of lectins to different endothelial cells
The tabie also shows the variations observed between experiments. The results are classified according to 
amount of binding detected with + being less than 25 % of MHO class I levels, ++ is 25 -  75 % binding, +++ is 
75-125 % binding, ++++ is 125 -  175 % binding and +++++ is over 175 % binding.
LECTIN CELL TYPEBMEC SVEC HUVEC DMVEC LMVEC
Con A +++++ ++++ +++++ ++++ / +++++ +++++
DSL ++++ / +++++ +++ ++++ +++ / ++++ ++++
DBA + + + + +
ECL +++ / ++++ +++ +++ / ++++ +++ +++ / ++++
GSLI ++ ++ + ++ ++
B4 + / ++ ++ - / + + - / +
GSLII ++ ++ +/++ + -7 +
Jacaiin ++ -+++++ ++++ + / ++ ++ +-+++++
LCA +++ /++++ +++ ++++ +++ ++++
LEL ++ + / ++ ++ ++ +++
PNA ++ +++ + ++ ++
PHA-E +++++ ++++ +++++ ++++ / +++++ +++++
PHA-L +++ +++ ++ ++ / +++ ++
PSA ++++ +++ ++++ +++ ++++
RCA-120 +++++ ++++ +++++ ++++ / +++++ +++++
STL +++ ++ / +++ ++ / +++ ++ ++ / +++
SJA + + - /  + + -
SBA ++ ++ ++ ++ + /++
UEAI ++ / +++ + /++ + /++ ++ + / ++
W L ++ +++ ++ ++ ++ / +++
WGA ++++ +++ ++++ +++ ++++
sWGA ++ ++ + + /++ ++
Ail EC presented a strong reaction with Con A, RCA120 and PHA-E. They also all had moderately 
strong reactions with WGA, LCA, PSA, DSL and ECL, but low levels of binding to PNA, SBA, UEA- 
1, GSL-I, sWGA, GSL-II, LEL, STL and VVL. DBA, SJA and B4 bound at extremely low levels and 
in some ceii types were not significantly different from the control.
The binding to BMEC to Con A, RCA120 and PHA-E varied somewhat between experiments, 
however, SVEC showed consistentiy lower binding compared to BMEC, whiie binding to the other 
cell types was statistically no different over several experiments compared to BMEC or to each
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other. This is largely due to the inconsistencies between experiments, which were particulariy 
evident for DMVEC and LMVEC.
A similar pattern of binding was observed for the lectins LCA, PSA, DSL and LEL although at a 
reduced level. SVEC was the only cell type that across three experiments bound at a significantly 
(P<0.05) lower level.
The binding of WGA to BMEC appeared to vary between experiments, and in each experiment, 
there was no statistical difference demonstrated between it and any other cell type. So although 
there were noticeable differences in the binding of WGA to different cell types, it was largely due to 
the variation experienced between cuitures. WGA and succinylated WGA both bind the same 
residue, the modified form (sWGA) binds to a more restricted ligand and showed lower levels of 
binding. This is because WGA can also interact with sialic acid residues. The reduction from WGA 
binding to sWGA binding levels was particularly noticeable on HUVEC and LMVEC -  suggesting 
that these cell types were perhaps more heavily sialylated on N-acetylglucosamine.
In a similar way, Jacaiin bound the same residue as PNA (galactosyl (p-1,3) 
N-acetylgalactosamine), with the exception that Jacaiin can also still bind when the residue is 
sialylated, this is reflected in the lower binding levels of PNA on BMEC and SVEC. Jacaiin binding 
showed considerable variability between experiments, in particular on BMEC and LMVEC. 
However within the same experiment, the differences were little, and the same overall pattern of 
binding was observed, but with levels of binding for Jacaiin.
Likewise, LCA, PSA and Con A share similar receptor sites, but each has very slightly different 
specificities for residues around the specific receptor site. Con A recognises a smaller receptor site 
than LCA and PSA, and hence has a wider range of binding and so binds more.
SBA and PHA-L binding was not statistically different between the celi types tested, with the 
exception of LMVEC, which showed significantly reduced binding in comparison to the other cell 
types.
UEA-1 binds to a linked L-fucosyl residues and is used as a marker for human endothelium. It was 
expressed at a high level by BMEC, with significantly lower levels of expression on SVEC, HUVEC 
and LMVEC and inconsistencies on DMVEC.
DBA bound between 10 and 25% of the level of MHC class 1 and showed no consistent 
differences in binding between cell types.
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GSL-I exhibited higher binding than B4 as it contains all 5 isolectins rather than just the one. SVEC 
and BMEC bound at a simiiar level (approx. 50%) while there was significantly lower binding of B4 
found on HUVEC, DMVEC and LMVEC.
6.3.2 Binding of lectins to endothelium after enzyme digestion
The use of enzymes to digest different components of the proteoglycan layer showed very 
interesting resuits as the digestions with heparinase or chondroitinase had no effect. The removal 
of sialic acid residues from the iayer by using neuraminidase showed massive increases in the 
binding of certain lectins. Of the lectins examined, PNA, VVL and PHA-L showed significant 
increases in binding.
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Figure 6.3 Effects of enzyme digestion on the proteoglycan layer of BMEC
Biotinylated lectins were used to detect differences in the carbohydrates on the endothelial cell surface of 
BMEC after digestion with 10 U/ml heparinase, 1 U/ml chondroitinase, 1 U/ml neuraminidase or no enzyme for 
exactly 1 hour at 37°C. The experiment shown is one representative of at least 3 performed. Significance was 
tested by ANOVA with a post hoc t-test (*=P<0.05).
153
6.4 Discussion
We have tested the binding of 22 different lectins to five different types of human endothelia in 
culture, which provides a comparison of oligosaccharide expression. We have found that there is a 
great deal of heterogeneity in the leveis of specific oligosaccharides present on these different 
endothelial cells. The cells used in this assay were at confluence and were contact inhibited. They 
were seeded at a high density, then grown overnight to confluence and rested for 24 hours to allow 
development of the glycocalyx before performing the assay. The overall results including 
experimental variations are summarised in table 6.2.
6.4.1 Lectin binding to resting endothelium
UEA-1 is used as a marker of human endotheiiai cells. Holthofer et al. (1982) have shown specific 
binding to many endothelial cell types from different organs and different sized vessels. These 
include the kidney, liver (with the exception of the sinusoids), pancreas, lung, skin, brain and 
piacenta as well as cultured HUVEC. This was also shown by another study that investigated UEA- 
I binding to EC in culture -  demonstrating that it specificaliy bound to isolated endothelium. It was 
also shown to be a useful tool in the isolation of pure endothelial cultures (Jackson et al. 1990). 
There are very few studies in the literature investigating the expression of oligosaccharides on 
human endothelium, apart from the binding of UEA-1. Much more literature is available on a wide 
variety of other mammalian species including rats, mice, dogs, cats, cows, horses, sheep, pigs and 
monkeys (Alroy et al. 1987; Abdi et at. 1995; Smolkova et at. 2001).
GSL-I binding to terminal a-galactose is used as a marker for endothelial cells in many different 
species, but it only binds approximately 10% of human endothelium (Alroy et a i 1987). WGA was 
found to bind to endothelial cells from many different species, whereas succinylated WGA, which is 
the modified form, only binds to some human specimens and not those of any other animals. Alroy 
et a/’s study found that RCA120 bound to all the endothelia from all the species tested, but Con A, 
DBA, LCA, PNA and SBA did not stain in any species studied. This is very different to our study 
where we have shown high levels of Con A and LCA binding to endothelia, with lower levels of 
binding of all the other lectins used in their study. Some of the differences could be due to the 
methods used. As all their sections were paraffin processed, it is possible that some of the smaller 
oligosaccharides were destroyed in the processing.
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Another possible source of variation between experiments is changes in physiological conditions or 
stress as variations in glycosyiation of some giycoproteins can then be induced (Spicer and Schulte
1992) e.g. during hypoxic stress (Weinhouse et al. 1993).
In a study investigating the heterogeneity of liver endothelium a simiiar affinity binding of Con A and 
RCA120 was found throughout the different types of endothelium found in the liver (Dini and Carla 
1998). However PHA and WGA binding was found to be higher in the periportal zone and UEA-1 
binding was low, but present consistently on the sinusoidal endothelium.
In pigs, endothelium does not label with UEA-1. Heterogeneity of binding of other lectins has been 
shown aiong the vascular tree -  both microheterogeneity, where there are differences in lectin 
binding to the same EC cell type and macroheterogeneity where there are differences between 
different types of EC and between different organs (Brouland et al. 1999). They showed littie 
binding to liver EC and high binding to umbiiical vein of ail the lectins that they studied (B4, DBA, 
EEA-1, HPA, MAL-1 and PNA) although the binding of PNA was very low to all endothelial cell 
types. They also demonstrated differences in vWF binding to different EC types. It was suggested 
that this shows the plasticity or unstability of endotheiiai cells. In another study using foetal pig 
endothelium from different organs there was much variety in the levels of binding including the very 
strong labelling of the brain with PNA. This suggested that tissue specific heterogeneity in 
oligosaccharide expression is already determined to some extent in the foetus (Plendl et al. 1996). 
Using a rat model Smolkova et al (2001) showed differences in endothelial cell binding of lectins 
between organs. They found that LCA, ConA, LEA, WGA and RCA120 bound to rat vascular EC, 
while PNA and UEA-1 did not. The lectins aii bound to the luminal plasma membrane and 
heterogeneity was observed with HPA and GSL-I reacting with most endothelial cell types with the 
exceptions of kidney glomerular EC, liver sinusoidal EC and adrenal gland EC.
We have shown virtually no binding of DBA to any of our endothelial cell types and there is no 
mention in the literature of it binding to human endothelial cells. Ponder and Wilkinson (1983) have 
however shown heterogeneity in DBA binding between different strains of mice which was not 
found by Alroy et al. (1987). It would appear that DBA staining differs according to species, organ 
and segment of the vascular tree (Ponder and Wilkinson 1983; Spicer and Schulte 1992)
The affinity of binding of 39 different lectins was tested to sheep lung endothelium (Abdi et al. 
1995). It was found that GSL-1, DSA and LEA bound to the pulmonary artery, but that differential 
binding occurred in different vessel types within the lung e.g. there was less binding to the small 
vessels. These results agree with what we have observed in cultured human endothelium, but they
155
also found no binding of DBA, ECL and UEA-1. The binding of DBA is similar to that which we have 
demonstrated, however we have shown binding of ECL and UEA-1 to all our endothelial cell types 
including the lung which suggests a difference between species.
From the results in this study, we showed that there were only small differences in the levels of 
binding of individual lectins to different endotheiiai monolayers. Hence it was not possible to relate 
the levels of particular oligosaccharides to the different leveis of chemokine binding to endotheiiai 
monolayers shown earlier. To determine more clearly whether particular oligosaccharides are 
required for binding of specific chemokines, it would be possible to use lectins to block the 
oligosaccharides and to then test the chemokine binding to see if the lectins have any blocking 
effect.
6.4.2 Effects of enzyme digestion
In this study we also showed that neuraminidase digestion of the giycocalyx allowed increased 
binding of certain lectins including PNA, VVL and PHA-L to their specific sugars. Due to the 
expense of the enzymes, this was only tested on BMEC and only on a select panel of lectins. We 
could expect to see similar results for other lectins in particular RCA120 and SBA, which have 
previousiy been shown to bind more when the siaiic acid is removed and their binding site is 
exposed.
An early experiment treating myoblasts with neuraminidase was found to increase the amount of 
RCA120 detected (Hoiland et al. 1984). This appears to work by cleaving the sialic acid residues 
from the proteoglycan layer, hence exposing more binding sites for the lectin to react with. This has 
since been shown to also apply to binding of lectins to endothelial cell from various different 
species. It is particularly effective on SBA and PNA as was demonstrated on Bovine Aortic EG, 
(Augustin-Voss and Pauli 1992). The removal of sialic acid residues was actually found to reduce 
binding of WGA to rat endothelium (Smolkova et al. 2001), it would appear that the positively 
charged WGA perhaps requires the negative charge provided by the sialic acid to bind with high 
affinity.
In the same study they also showed that HPA and GSL-I binding were increased after treatment 
with the enzyme, but no detectable effects were observed on PNA or LEA which is in contrast to 
the eariier study (Augustin-Voss and Pauli 1992). In investigating most mammalian species (with 
the exception of the rat), Alroy et al. (1987) found that PNA bound after treatment to most species 
with the exception of the cat. The effects of neuraminidase on SBA binding were only striking in 
bovine and murine specimens although there was binding observed to some endothelial cells in
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cats, dogs, goats, horses and humans. The differences demonstrated in sWGA and WGA binding 
as weli as the fact that PNA binds well after neuraminidase digestion of the proteoglycan layer 
suggests that it is heaviiy siaiyiated on all the species that they tested.
Heparinase and chondroitinase, which remove heparan sulphate and dermatan sulphate 
respectively had no effect on the binding of PNA, UEA-1, sWGA, STL-1, W L, GSL-1, PHA-L, DSL 
or B4 to endothelial cells. This showed that the lectins do not show specificity for either of these 
moiecules.
6.4.3 Summary
In the last few chapters, we have shown many differences between endotheiia -  in their chemokine 
production, receptor expression, composition of the proteoglycan layer and binding to it. In the next 
chapter, we will investigate whether chemokines have any functional effects on endothelial cells in 
cuiture.
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Chapter 7
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7. Endothelial cell responses to chemokines
7.1 Introduction
In Chapter 5 we showed that all the endothelial cell types tested expressed chemokine receptors. 
In this chapter, we wiil investigate whether chemokines acting on their receptors are invoived in the 
processes of angiogenesis.
Angiogenesis, the formation of new blood vessels is a basic process in infiammation, reproduction, 
deveiopment, tumour growth and tissue repair. It is a sequence of compiex and tightly controlled 
events which first of ail involves the release of matrix metailoproteinases by endotheiiai celis, these 
can act on the basement membrane to break it down, which then allows the proliferation and 
migration of endotheiiai celis into tissue. The final step in the formation of a new blood vessel is the 
reconstruction of the matrix and formation of a capiiiary tubule from the endothelial cells present.
The process depends on the balance of promotors (angiogenic factors) and inhibitors (angiostatic 
factors). During wound repair, the baiance shifts towards angiogenic factors. Once new blood 
vessels are established, the equiiibrium is re-estabiished. In contrast, lack of regulation of 
angiogenesis favours increased vascularisation and can have pathologicai significance in certain 
diseases such as rheumatoid arthritis, psoriasis and ocular diseases as weil as cancer.
VEGF and FGF (both acidic and basic forms) are weli estabiished angiogenic and endotheiiai 
proliferative factors. CXC chemokines and some CC chemokines have aiso been impiicated in the 
process of angiogenesis. Plateiet factor 4 (PF-4) was the first angiostatic chemokine found and 
was aiso found to attenuate angiogenesis during tumour growth (Maione et al. 1990; Sharpe et al. 
1990). IL-8 was then discovered to be angiogenic in vivo and to promote endothelial proliferation in 
vitro (Koch et al. 1992).
The angiogenic properties of CXC chemokines are dependent on the expression of the highiy 
conserved ELR (Glu-Leu-Arg) motif which immediateiy precedes the first cysteine residue (Stricter 
et al. 1995b; Beiperio et al. 2000). The lack of the ELR motif indicates chemokines that are 
angiostatic; these inciude CXCR3 binding chemokines as weii as PF-4. Table 7.1 shows the CXC 
chemokines that are known to regulate the process of angiogenesis (Moore et al. 1998).
159
Table 7.1 Known angiogenic and angiostatic CXC chemokines
Classified by the presence or absence of the ELR (Glu-Leu-Arg) motif preceding the first cysteine residue.
ANGIOGENIC CXC CHEMOKINES 
CONTAINNG THE ELR+ MOTIF
ANGIOSTATIC CXC CHEMOKINES THAT 
LACK THE ELR MOTIF (ELR-)
IL-8 IP-10
ENA-78 PF-4
Gro-a, -(3, -y Mig
GCP-2
NAP-2
This is an exploratory study and as such has many problems associated with it. The first step in 
this study was to investigate whether chemokines could induce proliferation of endothelial cells and 
to see whether there are any differences in responses between endothelial cells isolated from 
different tissues.
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7.1 Methods
7.1.1 Thymidine incorporation assay
Proliferation assay medium: M l99 with 2 mM glutamine supplemented with 1 % PCS, 100 U/mi 
Penicillin, 100 pg/ml streptomycin.
Celis were piated into 0.2% gelatin coated 24 well plates at a density of 4 x 10"^  ceiis per well in 
600pl of proiiferation assay medium. The plates were grown overnight for 16 hours before 
stimulation this achieves approximately 30% coverage of the area of the plate with EC at the start 
of the assay. Concentrations of 0 -  50 ng/ml of chemokines and cytokines diiuted in assay medium 
were then added to triplicate welis to stimulate the endothelial cells. Standard growth medium 
(M l99 with 10% PCS) was used as a positive control. The endothelial cells were then incubated for 
24 hours before the addition of 2 pCi thymidine per weli for a further 24 hours. The cells were 
then trypsinised and collected on filter paper using an automatic cell harvester (Skatron combi celi 
harvester). The radioactivity of the fiiters was read by liquid scintiliation on a Waliace microbeta 
triiux counter. Experiments were repeated three times.
7.1.2 Optimisation of conditions for the assay
The first experiment was performed on SVEC without the addition of chemokines, but with different 
concentrations of PCS, to determine the optimum concentration of PCS to perform a proliferation 
assay (fig. 7.1). We showed a significant increase in proliferation of SVEC after the addition of 5 or 
10 % PCS to Ml 99, but not after the addition of 1%. We then chose to use 1 % PCS for the majority 
of our assays as this would interfere less with the proliferation of the celis. We chose to use 10% 
PCS as our positive control as this induced proliferation.
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Figure 7.1 SVEC proliferation with differing amounts of FCS
^H-thymldine incorporation was used to measure the proliferation of SVEC in a preliminary experiment to 
determine the optimum concentration of FCS for a proliferation assay. Results are the average of triplicate 
wells. Significance was tested by ANOVA with a post hoc t-test (* = P<0.05).
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7.2 Results
We have investigated the proliferation of endothelial cells after a 48 hour incubation with different 
chemokines, and with thymidine added to the culture for the last 24 hours. Overall, we have 
shown very few significant differences in these assays as compared to the control of assay medium 
with no chemokine added (see figs. 7.2 -  7.5).
However we have shown that Gro-a (a known angiogenic chemokine) does cause endothelial cells 
to proliferate -  at both 5 and 50 ng/ml in SVEC and DMVEC, but only at 5ng/ml in LMVEC. We 
showed no significant effects of Gro-a on HUVEC proliferation. TGF-p showed no significant 
effects on SVEC, DMVEC or LMVEC proliferation and no consistent results on HUVEC -  in some 
experiments, TGF-p increases proliferation, and in others it decreases it (as shown in fig. 7.5b).
We have shown no effect of either IL-8 or MCP-1 on SVEC, DMVEC or HUVEC, however both 
chemokines show a significant decrease in thymidine incorporated (and hence cell number) in 
LMVEC (figs. 7.4c, e). This could be due to fewer cells as they lifted off at higher doses of these 
two chemokines -  an effect that was aiso observed on DMVEC, but to a lesser extent.
IP-10 is a known angiostatic chemokine; however, we have not been able to show this effect on 
SVEC, LMVEC or HUVEC and oniy in some experiments performed on DMVEC (as shown in fig. 
7.3d). The concentration of 50 ng/ml of IP-10 reduced the cell numbers (but reduced them below 
the background level).
We have shown an increase in proliferation of SVEC after the addition of over 5 ng/ml of Eotaxin to 
the culture medium (fig. 7.2f), but no effects on any other cell type. We have also tested the effect 
of these 6 different inflammatory mediators on ceiis in culture with 5% serum. To provide a direct 
comparison, we used the same initial concentration of cells, however this did not appear to be the 
ideal density as when we came to read the plates after 48 hours of stimulation, all the wells on the 
plate were almost confluent. The only difference between wells that we could consistently 
demonstrate was that Eotaxin was causing proliferation of SVEC (fig. 7.6f)
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Figure 7.2 Effects of chemokines on proliferation of SVEC
SVECs were cultured in proliferation assay medium and stimulated with different chemokines at different 
concentrations for 24 hours followed by 24 hours of thymidine incorporation to measure proliferation. 
Chemokines used were A. Gro-a, B. TGF-p, C. IL-8, D. IP-10, E. MCP-1, and F. Eotaxin. Results presented 
are the mean ± S.E. of triplicate wells from one representative experiment. Significance was tested by ANOVA 
with a post hoc t-test (* = P<0.05) where necessary.
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Figure 7.3 Effects of chemokines on proliferation of DMVEC
DMVECs were cultured In proliferation assay medium and stimulated with different chemokines at different 
concentrations for 24 hours followed by 24 hours of thymidine Incorporation to measure proliferation. 
Chemokines used were A. Gro-a, B. TGF-p, C. IL-8, D. IP-10, E. MCP-1, F. Eotaxin. Results presented are 
the mean ± S.E. of triplicate wells from one representative experiment. Significance was tested by ANOVA 
with a post hoc t-test (* = P<0.05) where necessary.
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Figure 7.4 Effects of chemokines on proliferation of LMVEC
LMVECs were cultured in proliferation assay medium and stimulated with different chemokines at different 
concentrations for 24 hours followed by 24 hours of thymidine Incorporation to measure proliferation. 
Chemokines used were A. Gro-a, B. TGF-p, C. IL-8, D. IP-10, E. MCP-1, F. Eotaxin. Results presented are 
the mean ± S.E. of triplicate wells from a representative experiment. Significance was tested by ANOVA with a 
post hoc t-test (* = P<0.05) where necessary.
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Figure 7.5 Effects of chemokines on proliferation of HUVEC
HUVECs were cultured in proliferation assay medium and stimulated with different chemokines at different 
concentrations for 24 hours followed by 24 hours of thymidine incorporation to measure proliferation. 
Chemokines used were A. Gro-a, B. TGF-p, C. IL-8, D. IP-10, E. MCP-1, F, Eotaxin. Results presented are 
the mean ± S.E. of triplicate wells from a representative experiment. Significance was tested by ANOVA with a 
post hoc t-test (* = P<0.05) where necessary.
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Figure 7.6 Effects of chemokines on proliferation of SVEC cultured in 5 % serum
SVECs were cultured In M l99 with 5 % FCS instead of 1 % FCS and stimulated with different chemokines at 
the concentrations shown for 24 hours followed by 24 hours of thymidine incorporation to measure 
proliferation. Chemokines used were A. Gro-a, B. TGF-p, C. IL-8, D. IP-10, E. MCP-1, F. Eotaxin. Results 
presented are the mean ± S.E. of triplicate wells from one representative experiment. Significance was tested 
by ANOVA with a post hoc t-test (* = P<0.05) where necessary.
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7.3 Discussion
In the literature, the concentrations of chemokines, the length and type of the assays, cell densities 
and serum levels used In assessing proliferation vary considerably. The parameters chosen for our 
assays were based on the most common conditions encountered for thymidine incorporation 
assays, however we have not been able to reproduce many of the results found in the literature.
We had problems with optimising the assay, as to compare proliferation between cell types, we 
needed to keep as many conditions as possible the same for all cell types. SVEC and HUVEC 
grow very much faster than LMVEC and DMVEC, which caused difficulties, as these were the cell 
types that the assay was set up with due to their availability at the time. This is also shown in the 
results obtained by Petzelbauer et al. (1995) where no proliferation was demonstrated in response 
to IL-8. One possible solution would be to increase the serum levels as DMVEC and LMVEC 
survive much better in higher serum levels. We tried this, but found that SVEC and HUVEC were 
achieving confluence before the end of the assay. Ideally If there had been more time, we would 
have liked to reduce the cell density and optimise the assay length. The other option, which makes 
it slightly less easy to compare between cell types, would be to optimise the assay for each cell 
type.
In these assays, we once again encountered a problem with a slight reduction in cell numbers at 
high doses of chemokine, which wasn't apparent when the cells were viewed under the microscope 
before trypsinisation. It appears that the cells become loose and are then easily removed when the 
culture medium is aspirated to add trypsin to digest the cells. It would be more beneficial to use a 
different method of harvesting - perhaps as some groups have used, it would be better to freeze 
and thaw the cultures several times rather than remove the medium and hence lose some of the 
cells and some of the radioactivity. This phenomenon was evident in cells cultured with most 
chemokines -  particularly the ELR+ CXC, which are known to have quite potent angiogenic 
properties, but it did significantly affect the results.
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Figure 7.7 Summary of results obtained from thymidine incorporation assays
Showing endothelial cell proliferation (+), no statistical significance (NS), or a reduction in thymidine 
incorporation into endothelial cells in comparison to control samples (-).
SVEC DMVEC LMVEC HUVEC
Gro-a + + + NS
TGFP NS NS NS -
IL-8 NS NS - NS
IP-10 NS - NS NS
MCP-1 NS NS - NS
Eotaxin + NS NS NS
7.3.1 Angiogenic factors
It has been shown that Gro-a is angiogenic for HUVEC, (Fujisawa et al. 1999) however, HUVEC is 
the only cell type in which we have shown no proliferation in response to Gro -a. It is possible that 
this is due to the different methods used. In their study, Fujisawa et al. serum starved their 
endothelial cells, then added chemokines (10 -100  nM) for 24 hours before doing an MTT assay. 
They also showed that proliferation could be inhibited by the addition of antibodies against Gro. 
The mechanisms by which angiogenesis occurs are still being investigated. In these experiments 
we have not serum starved our cells as the microvascular endothelium are particularly sensitive to 
this treatment and also under physiological conditions, endothelium are continually bathed in 
plasma, so we felt that having some serum present would be preferable.
As has already been mentioned, IL-8 is a known mediator of angiogenesis in endothelial cells 
inducing proliferation and promoting chemotaxis in vitro and inducing neovascularisation in vivo 
(Koch et ai. 1992; Norrby 1996). In these experiments, we have shown no significant proliferative 
activity in response to IL-8 at the concentrations tested.
This could be because of different conditions, Koch et ai. used 10% serum to grow their cells 
overnight before washing and using 1% for the assay, whereas we have used 1% serum for the 
plating stage and the whole assay. They also plated their cells at one quarter the density that we 
did before growing them for 72 hours and counting cells. But, their results also show a decrease in 
proliferative activity at higher chemokine doses, with a maximal at lOnM (approx. 4ng/ml). This 
agrees with the reduction in proliferation observed at 50 ng/ml that we see on SVEC with 5%
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serum and on all other cell types with 1% serum, though it is only significant on LMVEC (see table 
7.2).
In another study, it was shown that IL-8 added at high doses (over 0.25 nM or 0.1 ng/ml) did not 
induce proliferation in 5% serum, whereas lower doses induced proliferation and thymidine 
incorporation (Langeggen et al. 2001). Since the concentrations that we have used are 1.25 -  125 
nM, this could explain the lack of proliferation observed. Strieter et al. (1995a) in their first study in 
vivo found that doses of 2 -  40 ng/ml induced angiogenesis when administered intracorneally in 
rabbits, while lower and higher doses had no effect. Similar results were also obtained in rat 
corneas (Koch et ai. 1992).
We and others have shown the presence of CXCR1 and 2 on HUVEC and other cell types 
(Chapter 5 and Murdoch et ai. 1999; Salcedo et ai. 2000b). These two receptors are the binding 
sites for IL-8, but Gro-a binds only to CXCR2, as do all the other ELR+ CXC chemokines. This is 
one of the reasons among many others that Addison et ai. (2000) proposed that CXCR2 is the 
receptor through which angiogenic activity is mediated. Studies on CXCR2 knockout mice 
demonstrated a delayed wound healing response including reduced neovascularisation in 
comparison to the wild type mouse, this was postulated to be due to a reduced angiogenic 
response to MIP-2, the murine homologue of IL-8 (Devalaraja et ai. 2000). IL-8 and Gro-a have 
also been detected in studies on wound healing in the first few days after wounding, their 
expression correlating with increasing vascularisation (Engelhardt et ai. 1998).
The effects of the cytokine TGF-p on endothelial cells still seem to be controversial. It appears that 
it is important in angiogenesis, however in vitro it has been found to inhibit proliferation and 
migration of endothelial cells (Heimark et ai. 1986). It is thought that TGF-p is not as important in 
the early stages of angiogenesis, as it is later on in the remodelling and tubule formation. The 
inhibition of endothelial proliferation is associated with increases in ECM and proteoglycan 
synthesis. It could be the ‘off’ signal for proliferation and migration before formation of the new 
capillary.
MCP-1 was originally thought to have an indirect effect on angiogenesis via its attraction of 
monocytes to wound sites (Goede et ai. 1999), and the subsequent production of IL-8 and classical 
angiogenic factors by these cell types, however this has been challenged in several recent studies, 
which suggest that MCP-1 is directly Implicated via CCR2 on EC (Weber et ai. 1999a; Salcedo et
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al. 2000a). In our studies, we have not been able to detect CCR2 on endothelium and we have not 
detected any proliferation in response to MCP-1. This result from this present study agrees with 
that observed by Weber et ai. who suggest that although MCP-1 is not proliferative for 
endothelium, it is still acting through its CCR2 receptor (which they have detected on HUVEC) and 
is important in angiogenesis during the migratory stage. Salcedo et ai. also found that in vivo, the 
angiogenic effects were most potent at 5 -  100 ng/ml and It was also shown that this was not due 
to any inflammatory infiltrate, but due to the direct effects of MCP-1 acting via CCR2. They also 
showed chemotaxis in vitro of HUVEC and DMVEC towards MCP-1, with maximal migration 
occurring at 0.5 -  5 ng/ml.
Eotaxin is a potent chemoattractant for eosinophils and has also been shown to be angiogenic and 
to act via its specific CCR3 receptor on endothelial cells (Salcedo et ai. 2001), which we have 
detected at high levels on endothelial cells (chapter 5). Eosinophil products include TGF-p, which 
did raise the question as to whether eotaxin acted indirectly, however, using a rat aortic ring assay, 
which has no eosinophils, Salcedo et ai. were able to show that the effect is directly induced using 
Eotaxin.
Eotaxin was also shown to chemoattract DMVEC, however it was less potent than SDF-1, MCP-1 
or IL-8 and required a higher concentration ( 1 - 1 0  nM, 0.4 -  4 ng/ml showed maximal migration). 
Salcedo et ai. showed no proliferative effects of eotaxin on DMVEC, which is in agreement with our 
study, as SVEC is the only EC type in which we have shown that eotaxin can cause proliferation.
7.3.2 Angiostatic chemokines
CXC chemokines lacking the ELR motif are inhibitors of angiogenesis. These chemokines include 
IP-10, Mig and l-TAC which all bind CXCR3 (Loetscher et ai. 1996; Cole et ai. 1998) and PF-4 for 
which the receptor is unknown (Gentilini et ai. 1999). They have been shown not only to not induce 
vascularisation in vivo or proliferation in vitro, but to actually act as angiostatic agents in the 
presence of ELR+ chemokines or proliferative cytokines such as bFGF or VEGF (Angiolillo et al. 
1995; Gengrinovitch et ai. 1995; Luster et al. 1995; Strieter et al. 1995a). We have shown the 
presence of CXCR3 on endothelium as have other studies (Chapter 5 and Salcedo et ai. 2000b; 
Garcia Lopez et ai. 2001). In this study, we have shown no significant effect of IP-10 on SVEC, 
LMVEC or HUVEC, but we have shown a reduction in proliferation after the addition of 50 ng/ml IP- 
10 to DMVEC. This particular experiment does not cleariy demonstrate whether IP-10 is anti -
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angiogenic. This would be better shown with a higher level of initial proliferation -  perhaps by using 
a higher level of serum or by adding VEGF or bFGF followed by IP-10 and noting the differences 
between cell types In their response to IP-10. Unfortunately we didn't have time to fully work out the 
conditions for the initial experiments, as this would have been an interesting experiment to perform.
7.3.3 Disease implications
Anti-angiogenic therapy has important implications in many disease states -  most obviously 
cancers, but also rheumatoid arthritis and certain ocular diseases. Possible candidates for this 
therapy include chemokines themselves or chemokine antagonists, however because of their 
varied activities on different cell types, it is important to localise them to the site where they are 
required. Although it appears that chemokines exert different effects at different concentrations 
(e.g. Gro-p). The addition of a chemokine at a high dose would not be advisable in vivo as it could 
have many other effects which are often also dose dependent -  In particular at higher 
concentrations, leukocytes tend to be activated which could cause more problems than they solve!
Chemokines are particularly of interest in cancer as inhibiting the formation of blood vessels to 
supply the tumour has many potential therapeutic benefits. It has been shown that IL-8 and its 
receptors OXCR 1 and 2 are present in carcinomas (Richards et al. 1997) and it is thought that 
they may be acting to promote angiogenesis and hence tumour survival. IL-8 has been found to be 
significantly elevated in non-small cell lung cancer. It was also determined to be a major angiogenic 
factor contributing to tumour survival. However, in a mouse model of human non-small cell lung 
cancer the addition of neutralising antibodies to IL-8 has been shown to reduce tumorigenesis via 
reduced angiogenesis (Arenberg et al. 1996a). Patient survival and metastatic potential could be 
related to the type of chemokine produced by different types of carcinoma. For example, squamous 
cell carcinoma produces high levels of IP-10 and has fewer blood vessels present compared to 
adenocarcinoma, which has poorer survival rates and higher metastatic potential (Arenberg et al. 
1996b; Arenberg et al. 1997).
Gro-p has been reported to inhibit angiogenesis (Gao et al. 1995), but the concentrations used in 
this study were approx. one thousand times higher than found for angiogenic activity ( 1 - 1 0  nM) 
suggesting that perhaps high doses significantly reduce the sensitivity of the receptors to specific 
chemokines. The gro chemokines are normally angiogenic at physiological concentrations and their 
expression is also associated with tumours and tumorigenesis in much the same way as IL-8.
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Using a neutralising antibody against Gro has been shown to reduce tumorigenesis associated with 
reduced angiogenesis (Luan ef a/. 1997).
7.3.4 Summary and future work
These assays were the pilot for a potentially very interesting study, which was put into a grant for 
further funding. Unfortunately we have been unable to show much in the way of significant findings, 
mostly due to the preliminary nature of these experiments. To continue this work, these assays 
need to be optimised more carefully for chemokine concentrations, serum concentrations, length of 
assay and cell density. Then the effects of Gro-a, IL-8 and IP-10 on different endothelial cell types 
could be investigated in more detail; In particular the effects of IP-10 on growth factor stimulated 
endothelial cells and the effects of neutralising antibodies.
Other assays that would give clearer indications of the importance of these chemokines in 
angiogenesis in different tissues include chemoattraction assays to identify chemokines that 
endothelial cells will migrate towards as well as in vitro angiogenesis assays.
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8. Discussion
8.1 General Discussion
The aim of this study was to investigate differences between endothelia isolated from different 
vascular beds in particular in relation to leukocyte migration and inflammation. We have focussed 
on the chemokines, as we were interested in their role in controlling selective migration of 
leukocytes across endothelium to different sites of damage or infection. We have compared 
chemokine production and receptor expression across several different vascular beds and then 
investigated the role of the p
roteoglycan layer in the binding of chemokines to these different endothelia. The final exploratory 
study investigated the effects of different chemokines on proliferation of endothelial cells derived 
from different vascular beds. A summary of all these results can be found in table 8.1.
We have shown that there are differences between different endothelial cells in the chemokines 
produced, chemokine receptors expressed and in the carbohydrates of the proteoglycan layer and 
chemokines that bind to them. We have also shown preliminary data showing differences between 
endothelial cells in their proliferative responses to chemokines. Other studies in our group have 
shown differences in adhesion molecule expression under similar stimulation protocols (personal 
communication E. Mordelet). Confluent monolayers were assayed by the cell based ELISA method 
as described earlier, both without stimulation and after stimulation for 24 hours with TNF-a or IFN- 
y. It was found that LMVEC and DMVEC expressed higher levels of adhesion molecules overall, 
and that after TNF-a stimulation ICAM-1 and VCAM were increased in all cell types, as was ICAM- 
1 after IFN-y stimulation. One interesting point was that selectins (E and P) were increased at 24 
hours in DMVEC, LMVEC and HUVEC only. Since selectins are maximally expressed at 4 to 8 
hours after stimulation, this is not the ideal time at which to measure their responses to cytokines, 
but it is certain that at 24 hours BMEC and SVEC do not show increased levels of selectins in 
response to either TNF-a or I FN-y. This is likely because they have been induced and by 24 hours 
have decreased back to baseline, not that they have not been induced at all. Another notable 
difference is that HUVEC express very low levels of both ICAM-2 and PECAM in comparison to 
other cell types. BMEC overall express the lowest levels of adhesion molecules, however as is
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discussed elsewhere, the microenvironment of the bone marrow contains many constitutively 
expressed cytokines, which causes continually increased levels of adhesion molecules on bone 
marrow EC. Hence cytokine stimulated BMEC would represent more closely the in vivo phenotype. 
Although there were several differences observed in adhesion molecule expression between 
different endothelial cell types, these were found to be much less than differences in chemokines 
produced.
There are several different factors that contribute to the positioning of leukocytes in different 
tissues. The first is the difference found,at the rolling stage of recruitment, in adhesion molecules 
present on the endothelial cell surface which dictate whether a particular leukocyte can interact 
with the endothelium to slow down and roll along the vessel wall. Once it is rolling along the vessel 
wall, the leukocyte needs to be activated if it is to migrate into the tissues. This requires that the 
chemokines are presented on the proteoglycan layer of the endothelial cell and that there is a 
specific receptor that they can interact with on the leukocyte surface. If this does not occur, it 
appears that the leukocyte continues rolling and may detach from the vessel wall and return to the 
circulation. If this does occur, then the activated leukocyte can firmly adhere to the vessel wall via 
binding of integrins on the leukocyte to cellular adhesion molecules of the Ig family on the vessel 
wall. Again, this will only occur if pairs of molecules that can bind each other are present on the 
leukocyte and endothelial cell. Finally, the leukocyte can undergo migration through the vessel wall 
along a chemokine gradient, in vivo, these reactions are complex and there would probably be 
more than one chemokine present at different concentrations held on the ECM. it is by a 
combination of different chemokine gradients, that the leukocyte will get to its final position and 
exert its effects (Foxman et ai. 1997).
Chemokines present on the endothelial cell surface in vivo are likely to have been produced by a 
combination of endothelium, tissue cells and infiltrating leukocytes. The proportions of chemokines 
produced by each cell type will vary according to the tissue. For example endothelum from the 
dermis has a more prominent role under resting conditions than that found in the lung due to the 
proportionally larger number of alveolar macrophages and higher production of chemokines by this 
cell type than by endothelium. The proportions will also vary according to the state of the tissue -  
whether it is responding to injury or infection or is in the process of an allergic response to an 
allergen. Under resting conditions, I would expect the chemokines produced by tissue cells and 
endothelium to dominate, but during an inflammatory response, the leukocytes would probably play
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a more prominent role. Tissue cells and endothelia become stimulated on production of cytokines 
by antigen presenting cells such as langerhans cells in the skin and higher chemokine levels are 
induced, recruiting leukocytes, which in turn produce more cytokines and chemokines aiding further 
recruitment.
Chemokine production upon cytokine stimulation is dose dependent -  at low doses, the cells are 
not activated, but at high concentrations, the cells become desensitised to the cytokine and also 
are not activated. There is an optimum cytokine concentration range for stimulation of chemokine 
production, which can vary according to cell type. IFN-y and TGF-p are immunomodulatory 
cytokines, sometimes enhancing and sometimes reducing chemokine production. In this way, 
optimal chemokine concentrations to recruit leukocytes can be maintained, as if concentrations 
become too high, leukocytes could be activated in the 'wrong' place (before they have reached the 
site of infection) and cause more damage.
In all of the studies reported here, we have used in vitro culture systems. In culture, there are 
necessarily differences from the in vivo state. There are several measures that can be taken to try 
to increase the similarities in vitro to those in vivo, but there are still several points that need 
considering.
We use gelatin to provide a substrate in all of our assays to simulate the basement membrane and 
ECM in vivo. During normal culture, growth factors are present in the different media. As they 
would in vivo, the cells respond by proliferating, and as they do so, they lay down their own 
basement membrane, they are also contact inhibited and express many other characteristics of the 
primary endothelium. The distinctive phenotype of endothelium is gradually lost over many 
passages in culture, so that the sooner the cells are used after being placed into culture, the closer 
they will be to the in vivo situation. As we were investigating differences between endothelia, we 
need to use the cells before they lose their distinctive phenotype, and also before there is any 
potential loss of heterogeneity. For this reason, we have used our own primary cells at passages 2 
-  5 while those isolated by Clonetics which we receive at passage 4 are used between passage 5 
and 7. However, several components of the microenvironment in culture are missing from our in 
vitro systems; one is the element of shear force, which has been discussed in relation to 
chemokine expression already, another is the contribution of other cells, plasma, ECM and other 
molecules that would normally be found surrounding the endothelium in vivo. The endothelium can 
also be activated in culture, particularly in the presence of growth factors, so to try to overcome
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this, we have rested the cells for 24 hours at the start of each of our assays in medium lacking 
growth factors. Although in vitro systems are not ideal, they are useful tools to investigate 
endothelial cells and have indeed provided great insights into their functions.
Primary bone marrow endothelium is unstable in culture due to the differences between culture 
conditions and those found in vivo. Cytokines play an important role in the bone marrow 
microenvironment and this is difficult to simulate in vivo, but it appears that the cytokine stimulated 
endothelium is likely to be closer to that found in vivo than the resting BMEC. This issue is made 
slightly easier by the production of the bone marrow cell line that we have used as this stabilises 
the phenotype, and although as yet the transformation process has not been found to have 
affected the phenotype significantly, this is still a possibility.
The liver endothelium were also found to de-differentiate at higher passages (personal 
communication A. Linke), but at the passage used here, they maintain much of the phenotype of 
sinusoidal endothelium.
In this final section, we will explore how our results relate to the in vivo situation in each of the 
different vascular beds that our endothelial cells are taken from.
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8.2 HUVEC
Umbilical vein endothelium is often used as a standard endothelial cell type, however, in this study 
we have found that it produces high constitutive levels of IL-8 and MCP-1 in comparison to the 
other endothelial cell types tested. It responds highly to TNF-a by producing IL-8 at approx. 10 
times the constitutive level and MCP-1 at approx. twice the constitutive level. It does not produce 
IP-10 in response to TNF-a and in this respect is also different to other endothelial cell types tested 
here. IFN-y stimulation reduces constitutive levels of IL-8 and induces IP-10 production. TGF-p 
does not reduce constitutive IL-8 production, but does reduce MCP-1 production. The addition of 
TNF-a and IFN-y in combination reduce the high levels of IL-8 observed with TNF-a stimulation 
alone, but act in synergy to produce high leveis of RANTES, MCP-1 and IP-10. TGF-p and TNF-a 
acting together show similar effects on RANTES, IL-8 and MCP-1 production as those observed 
with TNF-a and IFN-y, but to a lesser extent. Two interesting results are the production levels of 
MCP-1 and IP-10 observed after TGF-p and IFN-y stimulation together. It appears that TGF-p and 
IFN-y act in synergy to produce levels higher than those observed for each cytokine individually.
HUVEC have been found to express CXCR1, 3, 4, CCR3, 4 and low levels of CXCR5. This 
suggests that they couid respond to severai of the chemokines that we have been examining 
including IL-8, RANTES and IP-10. We showed that MIP-1a bound well to the endothelial cell 
surface, while RANTES bound to a lesser extent. We have not shown significant levels of the MIP- 
1a receptors CCR1 or CCR5 present on HUVECs, although different groups have found low levels 
of mRNA for CCR1 and 5 present (Fell and Augustin 1998; Gupta et al. 1998; Weber et al. 1999a). 
It is possible that MIP-1a was binding via either of these specific receptors which were present at a 
low level as digestion of the proteoglycan layer had little effect and MIP-1a was not internalised 
during the time course of the experiment.
The umbiiical vein EC have proven extremeiy useful as a tool to investigate endotheiial function, 
however they are derived from a transport vessel for waste from the placenta and foetus. It does 
have to be remembered that It Is a large vessel and would not normally be the site of leukocyte 
recruitment. The microvascular endothelium is where leukocyte migration normally occurs and 
since it is becoming easier to isolate, will be a better model. However, the constitutive expression 
of IL-8 and MCP-1 does suggest that there could be recirculation of neutrophils and monocytes
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occurring and the weil-documented responses of HUVEC to cytokines show that recruitment couid 
occur in vivo if necessary.
8.3 Bone marrow endothelium
Bone marrow endothelium is situated at the interface between the stroma and the blood and 
regulates the transport of naïve and mature blood cells Into the circulation. This is not normally an 
inflammatory site, but is concerned with the normal recirculation of leukocytes. We have shown that 
bone marrow endothelium does not constitutively produce any chemokines, however, a high level 
of MCP-1 is produced after TNF-a stimulation. IL-8, RANTES and IP-10 are also produced and 
unusually, bone marrow endothelium appears to produce IP-10 more in response to TNF-a than in 
response to IFN-y. The endothelial cell line that we are using constitutively expresses low levels of 
adhesion molecules, but it is unknown as yet whether it expresses cytokines as primary bone 
marrow EC do. Primary BMEC constitutively express over 10 different cytokines including G-CSF, 
GM-CSF, TGF-p, IL-1, IL-6 and IL-11 (Candal et ai. 1996; Li et ai. 2000), this causes increased 
levels of adhesion molecules to be expressed. When IFN-y is added in combination with TNF-a, a 
reduction in IL-8 and MCP-1 levels are seen, but a massive increase in the IP-10 level is observed. 
TGF-p reduces the production of IL-8, MCP-1 and IP-10 from the high levels observed after TNF-a 
stimulation, but has little effect on RANTES expression. Like all the other endothelia tested, 
synergy between TNF-a and IFN-y causes both RANTES and IP-10 to be expressed very highly. 
BMEC have been shown to bind MIP-1a and RANTES to the cell surface and we have shown that 
RANTES binds via HSPG, and possibly by a second mechanism, whereas we have not been able 
to show how MIP-1a binds. Study of receptors detected on the endothelial cell surface show no 
expression of either of the MIP-1a specific receptors, CCR1 or CCR5. The receptors for RANTES 
are CCR1, CCR3 and CCR5. We have shown high levels of expression of CCR3 on the ceil 
surface, this receptor has lower affinity for RANTES than for eotaxin, but this is a second possible 
mechanism by which RANTES might bind.
8.3.1 Implications in vivo
There is only a little known about the effects of chemokines on bone marrow endothelial cells, 
because as yet, only a few chemokines have been investigated. SDF-1 is known to be 
constitutively expressed in the bone marrow stroma; it is thought to be produced by endothelial
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cells, but as yet this has not been demonstrated. CXCR4 is known to be required for survival as 
CXCR4 knockout mice have been found to die in utero due to the lack of development of B cells, 
but T cell development is not affected (Ma et ai. 1998; Zou et ai. 1998). We have shown a very low 
level of CXCR4 expression by BMEC. CXCR4 and its interaction with SDF-1 is important in the 
homing of haematopoietic progenitor ceils to the bone marrow (Mohle et ai. 2001 ; Lapidot and Petit 
2002). SDF-1 has been shown to be associated with endothelium within the bone marrow and was 
recentiy shown to bind to heparan suiphate and dermatan sulphate on the proteoglycan layer 
(Netelenbos et ai. 2001). CXCR4 was shown to be expressed on CD34+ progenitor cells and 
through binding to proteoglycans can induce their migration (Netelenbos et ai. 2002). There is a lot 
of information available on the adhesion molecules expressed by bone marrow endothelium and 
transmigration appears to utilise the constitutiveiy expressed E-seiectin and VCAM-1 (Voermans ef 
ai. 2000). SDF-1 has been shown to activate integrins after immobilisation on HSPG and induce 
firm adhesion to ICAM-1 and VCAM-1. This process of SDF-1 mediated adhesion has been shown 
to be increased after the application of IL-1 to the medium. Despite the high levels of binding 
exhibited by MIP-1a to BMEC in our studies, it has been found to be irreievant to the homing of 
progenitor cells, but is more important in other organs during inflammatory reactions (Cook 1996). 
There have been some differences in the findings, which address the expression of cytokines by 
BMEC. So far there is little information on this particular cell line, however other groups have 
shown that both TGF-p and IFN-y can be constitutively expressed by bone marrow endothelial cell 
lines (Li et ai. 2000).
IP-10 appears to play a role in the regulation of growth of haematopoietic progenitor cells in bone 
marrow. It inhibits colony formation in the presence of certain growth factors such as SCF and GM- 
CSF. Some studies suggest that IFN-y is consistentiy produced by BMEC, this could continuously 
stimulate IP-10 production and act as a negative regulator of colony formation (Sarris et ai. 1993).
in vitro assays performed using mouse cell lines have indicated that the MCP-1 and CCR2 
interaction is important in recruitment of multiple myeloma cells to the bone marrow. In this 
disease, the bone marrow is heavily infiltrated with these monoclonal plasma cells, which gradually 
replace the normal haematopoietic cells present, inducing anaemia and reducing the numbers of 
circulating biood cells, bone absorption also occurs and the patient cannot react properly to 
infection (Vanderkerken et ai. 2002).
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8.4 Saphenous vein endothelium
Saphenous vein endothelium is isolated from the large vessels of the leg, in this study we have 
shown that very low levels of MCP-1 are constitutively produced by these ECs in vitro. IL-8 is the 
major chemokine produced upon TNF-a stimulation, this is in common with all other endothelia 
tested except bone marrow. After TNF-a stimulation, MCP-1 and RANTES are also upregulated, 
but only to a low level. When IFN-y is added in combination with TNF-a, a large increase in IP-10, 
RANTES and MCP-1 production is observed, but IL-8 production is reduced from the levels shown 
by TNF-a alone. TGF-p increases all the IL-8 and MCP-1 from constitutive leveis and increases IL- 
8 from the high levels observed after TNF-a stimulation. TGF-p also increases IFN-y stimulated 
production of IP-10.
SVEC is different from all the other endothelial cell types in its chemokine binding to the cell 
surface. We have shown that RANTES binds highly to SVEC, while MIP-1a binds to a lesser 
extent. RANTES is important in the attraction of eosinophiis, memory T cells and monocytes to 
sites of inflammation via its binding of CCR1, CCR5 and to a lesser extent CCR3.
Many chemokine receptors are expressed on the surface of SVECs, (see summary in table 8.1) 
suggesting that many different inputs could be integrated. We have shown that two of these 
receptors couid be involved in the process of angiogenesis as both Gro-a (CXCR2) and eotaxin 
(CCR3) have significant proliferative effects. It is possible that if conditions were optimised, we 
might demonstrate similar or opposite effects from other chemokines.
8.4.1 Implications in vivo
There is very little in the way of specific data on SVEC, they have been used as a model for large 
vessel endothelium, and have sometimes been used interchangeabiy with HUVECs. From the data 
in this comparative study, however, it can be seen that there are severai differences. One important 
difference is the lack of IP-10 production by HUVEC after TNF-a stimulation as well as the high 
constitutive secretion of MCP-1 and IL-8 by HUVECs. The effects of TGF-p are also different, TGF- 
p appears to be pro-inflammatory in SVEC as well as HUVEC. The chemokine receptor expression 
patterns of the two EC types are simiiar, with the exception of CCR6 which was found on SVEC 
(see table 8.1). CCR6 was not previously shown to be expressed on endothelial cells, but is known 
to bind LARC (also known as MIP-3P or exodus-1), which is mainly expressed in the liver and is an
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attractant for immature dendritic ceils, Th2 cells and NK cells (Baba et al. 1997; Greaves et al. 
1997).
8.5 Dermal endothelium
DMVEC, LMVEC and HUVEC show many similarities in this study, but the differences between 
them are particularly interesting. All three constitutively express both MCP-1 and IL-8, with IL-8 at a 
higher level at the time points investigated. All three express IL-8 as their major chemokine after 
TNF-a stimulation. The microvascular cells produce IP-10 highly after IFN-y stimulation, which 
HUVECs do not, TGF-p also reduces constitutive expression of MCP-1 across all three endothelial 
cell types, but it is only in the microvascular endothelia that IL-8 is decreased by TGF-p stimulation. 
One of the most interesting differences about DMVEC is the high production of RANTES in 
comparison to the other endotheiial cell types after TNF-a stimulation. In common with all other 
endothelial cell types tested, both IP-10 and RANTES are produced in a synergistic manner after 
TNF-a and IFN-y stimulation. TGF-p has anti-inflammatory effects -  reducing the production of all 
chemokines tested. Aiso interesting is the fact that MIP-1a was shown to bind more to the 
endothelial cell surface than RANTES, despite the high levels of RANTES detected in the 
supernatants of endothelial cells. This suggests that perhaps it is produced within the tissues from 
tissue ceils and / or infiltrating cells and is used to recruit more celis from the circulation. RANTES 
was shown to bind as well to collagen as it did to HSPG and shows low binding to laminin and 
fibronectin, the ECM is a particularly Important component of the dermal layer of the skin. DMVEC 
show CXCR1 and 3 and CCR4 on their cell surface in common with all other endothelial types 
tested. They also express CCR3, which is shown by all the endothelial cell types except LMVEC 
and CCR6 at a low level in common with LMVEC and SVEC. As wouid be predicted from studies 
on HUVEC (Luster et al. 1995; Fujisawa et al. 1999), DMVEC are proliferative in the presence of 
Gro-a and proliferation is reduced in the presence of IP-10. Since Gro-a only binds via CXCR2 and 
there is virtually no expression of CXCR2 on the DMVEC cell surface, it appears that only a few 
CXCR2 receptors could be enough to stimulate proliferation, however, there is a slight possibility 
that it couid be due to differences between individuais. This is a somewhat intriguing result that 
deserves further study as cultures for proliferation assays actually had less serum in than those for 
chemokine receptor expression, which could have been an activating factor.
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8.5.1 Implications in vivo
In vivo, the endothelium in the skin is fundamental to the processes of wound healing and also in 
allergic reactions and inflammatory skin conditions such as psoriasis.
The process of wound healing is complicated, in particuiar in reiation to chemokine expression and 
actions. There is still much to be investigated, but some chemokines have been shown to be 
important in this process (reviewed in Gillitzer and Goebeler 2001). Dermal endothelium has been 
shown to be a source of several of these chemokines (Goebeler et al. 1997). Neutrophils are the 
first cell type recruited and it appears that several different CXC chemokines are involved such as 
ENA-78, Gro-a and NAP-2. This acute stage of inflammation in skin appears to use GXCR2 to 
chemoattract neutrophils to the wound site foilowed by CXCR1 interactions with IL-8 to activate the 
respiratory burst. MCP-1 is expressed during the first week of wounding in humans, but in animal 
models, RANTES and MIP-1a are also important at this stage. These chemokines attract 
macrophages and lymphocytes to the wound site. In humans, IP-10 and Mig production stimulated 
by IFN-y after day 4 after wounding are aiso important in the accumulation of lymphocytes. From 
days 1-4, the endothelial cells react to growth factors such as VEGF and angiogenic chemokines 
such as Gro-a and IL-8 to promote the revascularisation of the tissue. It is not yet known whether 
CXCR3 interactions with IP-10, l-TAC or Mig have any effects in wound healing, although their 
addition to wounds has been shown to disrupt neo-vascularisation (Luster et al. 1998). TGF-p 
appears to play an important role in the later stages of angiogenic processes as it seems to be 
involved in tubule formation, but it is anti-proiiferative (Heimark et al. 1986; Pepper et al. 1993; 
Chen and Manning 1996). In our studies, we have also shown that it reduces chemokine 
production by the dermal endothelial cells, also mice lacking TGF-p show massiveiy increased 
inflammatory infiltrates leading to organ failure (Shull et al. 1992). Hence it would appear that the 
modulation of chemokine production by TGF-p could an important regulator of leukocyte 
recruitment leading to healing of the wound and returning to ‘normal’.
We have shown CCR6 expression on DMVEC, this receptor is usualiy expressed on Langerhans 
cells and its interaction with LARC directs their constitutive homing to the epidermis (Charbonnier 
et al. 1999). These cells are antigen presenting cells and are some of the first cells that antigens 
come into contact with.
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Psoriasis is a chronic inflammatory skin condition associated with too much growth of epidermal 
cells causing scaling and redness. Large quantities of IL-8, activated neutrophils and T cells are 
present in this condition. CXCR1 and CXCR2 have both been found to be upregulated in the 
epidermis and drugs, which treat this condition, tend to reduce expression levels of IL-8 receptors.
Hypersensitivity reactions in the skin rely on T helper cells. Th1 cells express CXCR3 and CCR5 
while Th2 cells express CCR3 and CCR4. In a normal delayed type hypersensitivity (DTH) reaction 
in the skin, Th1 are the predominant cell type, but in atopic individuals Th2 is the predominant cell 
type causing chronic inflammation (Wierenga et al. 1990; Romagnani 2002).
In DTH reactions such as contact dermatitis, TNF-a and IFN-y released by Langerhans cells 
increase chemokine production as we have shown in DMVEC. This then attracts macrophages, 
and T cells. In normal individuals, Thi cells dominate, but in an allergic individual, this is polarised 
towards Th2 and encourages the recruitment of eosinophils, basophils and the release of histamine 
and other vasoactive and inflammatory mediators and chemotactic factors. Mast ceils are also 
thought to be important in this type of reaction and RANTES seems to cause their accumulation 
(Conti et al. 1997). The type of cellular infiltrate and disease progression are dependent on the 
relative levels of stimulation and inhibition of chemokine production by various cytokines produced 
by eosinophils, basophils, mast cells, macrophages, T cells and endothelium.
RANTES is important in both Thi and Th2 dominated reactions as it is the only chemokine that can 
recruit both cell types -  Thi via CCR5, and Th2 via CCR3. We have shown high levels of RANTES 
produced by DMVEC, and it appears that these celis also could respond to RANTES via CCR3.
8.6 Lung endothelium
IL-8 and MCP-1 are constitutively expressed by LMVEC in the same way as DMVEC and HUVEC. 
IL-8 is also the major chemokine expressed after TNF-a stimulation. There are however some 
interesting differences between lung endothelium and the other endothelia tested in this study. 
MCP-1 is highly expressed in LMVEC in comparison with DMVEC. It is aiso the highest expressor 
of IP-10 after IFN-y stimulation, however the synergistic effect of TNF-a and IFN-y in this cell type 
appears to be maximal at 24 hours, and has not increased in the second 24 hours. TGF-p showed 
reduction of chemokine production after both TNF-a and IFN-y stimulations; this is in common with 
SVEC, but not any other endothelial cell type. Two other interesting findings were that LMVEC
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bound IP-10 to the cell surface as well as RANTES and MIP-1a and that there was virtually no 
expression of CCR3 by this cell type. There was expression of CXCR1, 3 and CCR4 as in all the 
other EC types tested, and low levels of CCR6 were also demonstrated. This endothelial cell type 
will respond to a range of different chemokines, including IL-8, IP-10, ITAC, Mig, TARC, MDC and 
LARC, but there are only low levels of receptors on its surface to respond to RANTES, MCP-1, 
MIP-1a, Gro-a or eotaxin. Despite this, it does appear to respond to Gro-a and to MCP-1, 
suggesting that maybe these receptors are present at leveis below the detection limit of our 
antibodies. Proliferation was found to occur in response to Gro-a and an anti-proliferative effect 
was observed in response to MCP-1.
8.6.1 Implications in vivo
During acute lung injury, neutrophils are recruited followed by macrophages and lymphocytes in a 
simiiar way to wound healing in skin. IL-8 is the major neutrophil chemoattractant found in the lung 
and its levels are increased after damage. In the lung, the endothelium is not the major producer of 
chemokines and cytokines, there are many alveolar macrophages, which produce many different 
mediators and the smooth muscle cells, epithelial cells and infiltrating T cells also show some 
involvement (Gutierrez-Ramos et al. 2000).
Many of the cell types and chemokines found in allergic disease in the skin are also found in the 
lung. Asthma is a chronic inflammatory disease of the bronchioles, characterised by mononuclear 
cell, eosinophil and mast cell infiltration of the submucosa and sub epithelial fibrosis. It can be 
allergic or viral in origin and chemokines are involved in tightly controlled patterns. From the many 
different animal models of asthma and what can be discovered in vitro, much is now known about 
this disorder, however, there is still a lot which is unknown.
The first cells involved are mast cells and basophils, these are recruited by the MCPs, RANTES, 
MIP-1a and eotaxin and can be activated to produce other mediators including histamine. Th2 cells 
are the major helper cell type and are recruited by eotaxin and MDC via CCR3 and 4 on their ceil 
surface. We have not investigated the expression of these chemokine by endothelia, so we cannot 
determine whether there is any involvement of the endothelium in this recruitment. Th2 cells 
produce IL-4 and IL-5. IL-4 activates cells or potentiates effects of other cytokines on various 
leukocytes, while IL-5 is thought to be involved in the mobilisation of eosinophiis from the bone 
marrow. MIP-laand eotaxin cause chemotaxis of eosinophils into the lung, these then accumulate
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and cause inflammation and damage by release of toxic proteins and lipid mediators. This leads to 
smooth muscle cell contraction, hyper-reactivity of the airway, increased vascular permeability and 
increased mucous secretion -  the classical manifestations of asthma leading to shortness of 
breath. They also lead to further accumulation of leukocytes.
Throughout the disease progression, RANTES MIP-1a and the MCPs are present and appear to 
increase inflammation in a non-specific manner, while the other chemokines mentioned above 
appear to have defined roles (Ying et al. 1997; Gonzalo et al. 1998; Taha et al. 1999; Ying et al. 
1999; Lloyd 2002). Macrophages act to amplify the response and also release further mediators.
8.7 Liver endothelium
The liver endothelium produces only low constitutive levels of IL-8, but is a high producer once 
stimulated with TNF-a. IFN-y reduces the high levels of IL-8 seen after TNF-a stimulation alone as 
does TGF-p. RANTES and IP-10 are only produced to any physiologically significant extent after 
stimuiation with both TNF-a and IFN-y together. In comparison to IL-8, the levels of MCP-1 
expressed by this cell type are low (approx. one sixth). The addition of TGF-p to cytokine 
stimuiated iiver endothelium reduced the production of chemokines.
8.7.1 Implications in vivo
In vivo, large numbers of lymphocytes and macrophages are positioned in the liver to protect it 
from foreign antigens that may arrive in the portal blood from the gastro-intestinal system. This 
resident population can be rapidly expanded during inflammation, hence the chemokines invoived 
in trafficking of iymphocytes and macrophages are most important for this endothelium. The 
lymphocytes found in this tissue indude NK and NKT celis as well as CD4+ and CD8+ T cells. The 
hepatic vasculature is complex, but the type we are concerned with here is from the sinusoids. 
These endothelial cells are discontinuous and express ICAM-1 and PECAM on their surface at 
rest.
An inflammatory response in the liver can be activated to recruit lymphocytes in several different 
conditions, including hepatitis viruses and alcohol damage, but where the lymphocytes localise 
depends on the type of infection. Hepatitis virus inflammation occurs in the parenchyma, whiie 
other infections can locaiise to the biliary ducts.
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Little chemokine has been detected on sinusoidal endothelium in comparison to other endothelial 
types within the liver, low levels of IP-10, Mig and ITAC can be found, which increase after 
stimulation. These chemokines selectively recruit activated T ceiis. Thi ceiis express high levels of 
CXCR3 and are associated with inflammation in the liver (Shields et al. 1999; Lalor et al. 2002).
IL-8, MCP-1, MIP-1a and RANTES are usually associated with portal tract inflammation, but not 
sinusoidal inflammation. The cells we have been given show many of the features of sinusoidal 
endothelium, but it is possible that there are contaminating cells or that there has been de­
differentiation in culture, a phenomenon that was common with BMEC. Hence the production of cell 
lines and our use of a BMEC cell line in this study.
8.8 Possible therapeutic targets
Leukocyte accumuiation in inflammation is an essential part of host defence. In non-infectious 
disorders leukocyte accumulation could be an unwanted effect, leading to impaired organ function. 
Chemokines are bénéficiai in wound healing and in the resolution of infections, however, 
continuous expression causes leukocyte accumulation and activation including the release of 
potentially harmful levels of enzymes and oxygen radicals. In many disorders of allergic and 
chronic inflammation, such as arthritis, asthma, atherosclerosis and dermatitis, chemokines are 
expressed at increased levels. These chemokines are the focus of much research as blocking 
some or all of their actions can have beneficial effects by reducing the leukocyte infiltration and 
hence the damage caused. There are two potential sites at which interference could be targeted, 
one is in the interaction between the chemokine and its specific receptor, this uses the N-terminal 
domain of the chemokine for signaliing and in CXC chemokines the ELR motif too. Blocking this 
interaction can block the signalling pathways and hence chemotaxis and mediator release. The 
other site where there is potential for therapeutic agents to act is in the interaction between the 
proteoglycan layer and the heparin binding site of the chemokine at the C-terminus (Witt and 
Lander 1994; McFadden and Kelvin 1997).
8.8.1 Blocking receptor binding
There have been several encouraging studies showing that neutralising antibodies to chemokines 
and chemokine receptors can be used to decrease or block recruitment and activation of 
leukocytes. For example; a monoclonal antibody to IL-8 was shown to prevent neutrophii
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accumulation and tissue damage in lung reperfusion injury in rabbits (Sekido et al. 1993). Similar 
effects have also been observed in models of acute glomerulonephritis, dermatitis and arthritis 
(Harada et al. 1993; Wada et al. 1994). Antibodies to MCP-1 reduced recruited monocytes in 
glomerulonephritis too (Wada et al. 1996).
Another method of blocking the receptors is to use mutated chemokines that no longer signal. By 
truncating the N-terminus, chemokines can stiil bind to the proteoglycan layer, but cannot signal via 
the specific chemokine receptor. For example; the deletion of five amino acids from the N-terminus 
of IL-8, if used at a sufficiently high concentration can block enzyme release by neutrophils (Moser 
et al. 1993), similarly truncation of MCP-1 reduces monocyte chemotaxis and other MCP-1 
mediated functions (Zhang et a i 1994; Gong and Clark-Lewis 1995).
Perhaps the chemokine that has attracted the most attention is RANTES since it was discovered 
that one of its receptors, CCR5, is a co-receptor for HIV-1 (Alkhatib et al. 1996; Deng et al. 1996; 
Dragic et al. 1996). An N-terminal truncated form of RANTES has been found to prevent HIV-1 
infection by blocking viral entry via CCR5, and CCR5 knockout mice show reduced infection by 
HIV. In response to these findings, several different companies are now using high throughput 
screening to find smaii moiecuie antagonists for both CCR5 and CXCR4 (another HIV co-receptor) 
that could help in the treatment of HIV.
So far, there have been several different small molecule antagonists identified that have 
specificities against chemokine receptors. One, called SB225002 is specifically inhibitory towards 
CXCR2, but not CXCR1, hence it affects Gro-a and angiogenesis, but doesn’t have much effect on 
IL-8 as this chemokine can still bind via CXCR1 (White et al. 1998).
Small molecule antagonists to CCR1 could prove useful in the therapy of patients with rheumatoid 
arthritis and multiple sclerosis as these disorders are characterised by increased levels of MIP-1a 
and RANTES, followed by macrophage infiltration. A combination of neutralising antibodies to MIP- 
1a, RANTES and IL-8 was found to significantly reduce leukocyte infiltration into the synovium in 
animal models of rheumatoid arthritis (al-Mughales et a i 1996). Met-RANTES, a mutated form of 
RANTES was found to deiay the onset and severity of a collagen Induced arthritis model (Plater- 
Zyberk et a i 1997). Anti MIP-1a was found to have beneficial effects in the EAE model of multiple 
sclerosis, as this treatment reduced the number and severity of relapses (Karpus et a i 1995).
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Increased levels of MCP-1 and monocyte infiltration have been found in several disorders including 
rheumatoid arthritis, glomerulonephritis, asthma, stroke and atherosclerotic lesions. The use of anti 
MCP-1 antibody showed reduction in an animal model of inflammation and fibrosis that 
characterises glomerulonephritis (Lloyd et al. 1997). It is hypothesised that a smali moiecuie 
antagonist of CCR2, might be useful in the resolution of this disease.
In asthma, mast cells are triggered to degranulate and release constrictor agents followed a few 
hours later by an increase in levels of eosinophils recruited to the peribronchial region of the 
airway. Their activation is implicated in much of the pathogenesis of this disorder as described 
eariier. CCR3 is found solely on eosinophils, Th2 cells and basophils, this receptor binds eotaxin 
strongly, but also binds at a lower level to RANTES and MCP-3. CCR1 is also present on the 
surface of eosinophils, and via this receptor, MIP-1 a, RANTES and MCP-3 also bind. In vivo, 
depletion of MIP-1a by neutralising antibodies decreases the amount of eosinophils recruited by 
50%, while anti RANTES antibody reduces it by 60% (Lukacs et al. 1996). Blocking these 2 
chemokines, eotaxin or ali together, could considerably reduce the pathogenic effects of asthma.
In rheumatoid arthritis, many chemokines are found in the synovium inciuding IL-8, ENA-78, Gro-a, 
MCP-1, MIP-1a and RANTES. MIP-2 (which is similar to human IL-8) and MIP-1 a levels in mouse 
models were found to parallel the incidence and magnitude of arthritis (Thornton et al. 1999). 
Depletion by neutralising antibodies significantiy reduced the incidence of arthritis.
8.8.2 Blocking the heparin binding site
In a similar way to those described above, molecules can be introduced that can interfere with 
chemokine binding to the proteogiycan layer. This can be done by the prevention of GAG synthesis 
(specific for one type of GAG or blanket across all GAGs) or by the prevention of sulphation. Using 
enzymes (as we have used in chapter 4) the proteoglycan layer can be digested, or the final 
possibility is that soluble synthetic mimetics of GAGs can be produced that can bind the 
chemokines in solution and so competitively inhibit their binding to the proteoglycan layer.
Viruses have been found to encode secreted binding proteins that can interact with chemokines, 
these are non-specific, binding many different chemokines (reviewed in Lalani et al. 2000). One 
recent observation is that in vivo eotaxin can be blocked by the presence of vCkBP-ll (from
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vaccinia virus), a binding protein with specificity for CC chemokines and IL-8 across many species 
(Alcami etal. 1998).
Soluble heparin has in many studies been shown to compete with cell surface GAGs for 
chemokines, but as yet its potential is limited due to its large size. A smaller molecule, with 
specificity only for the heparin binding site of the chemokine may have more potential as an in vivo 
therapeutic agent.
Also in a similar way to the blocking of the chemokine receptor binding site, other molecules could 
act at the heparin binding site on chemokines including anti chemokine antibodies specific for this 
region of the molecule, small molecule antagonists, and non-signalling chemokine peptides.
8.8.3 Possibilities for the future
Each method has its own distinct advantages and disadvantages, but for penetration deeper into 
the appropriate tissues, smali molecule antagonists need to be developed. The blocking of specific 
receptors could inhibit specific sub sets of leukocytes from being recruited, but as there is much 
redundancy within the chemokine / chemokine receptor system, it is possible that more than one 
receptor/chemokine interaction wiil need to be considered in each disease type. An inhibitor of 
binding to HSPG, could have less specific effects and generaliy block most recruitment into a 
specific tissue. From our studies, it has been difficult to determine the specificities of chemokines 
for distinct carbohydrate groups, but with the technology for determining glycoprotein sequences 
advancing all the time, it wiil soon be possible to have a better idea of which chemokines bind best 
to which residues or combinations of residues.
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8.9 Overall conclusions
Our hypotheses stated that;
1. endothelial chemokine production
2. inflammatory chemokine binding to endothelia
3. endotheliai chemokine receptor expression
4. proteoglycan layer carbohydrate composition
5. effects of chemokines on endothelia
will all depend on the tissue of origin of the endothelial cells.
We showed significant differences in the production of the inflammatory chemokines IL-8, 
RANTES, MCP-1 and IP-10 between endothelia under both resting and cytokine stimulated 
conditions, but MIP-1 a was not produced by any endothelia tested.
We also showed that MIP-1 a, RANTES and IP-10 have the ability to bind cultured endothelia, but 
that the binding of these chemokines depends on the tissue of origin of the endotheiium. The 
binding of RANTES could be attributed to binding to HSPG, but MIP-1 a appeared to bind via a 
different mechanism, perhaps to the specific chemokine receptors.
We showed variability in the expression of chemokine receptors CCR1 -  6 and CXCR1 -  5 
between endotheiia derived from different tissues although as yet it has not been estabiished what 
the purpose of many of these receptors may be. There were aiso differences found in the 
composition of the proteoglycan layer, though not such significant differences as seen in the 
production of chemokines or in the binding of chemokines. The final study began to investigate the 
purpose of the chemokine receptors on the endotheliai surface, by examining proiiferation of EC in 
response to different chemokines and cytokines. This study needs to be optimised further before 
any firm conclusions can be drawn.
Our studies have shown that although HUVEC have been a good model endothelium, there are 
subtle differences between endothelia from different vascular beds in their interactions with 
chemokines, which have important consequences in the control of leukocyte migration to different 
tissues. In other studies, our group has also shown differences in adhesion molecules produced by
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these same endothelia. The most significant contribution to differences in recruitment between 
vascular beds appears to come from the differences in chemokine production, which when 
combined with chemokines produced by each of the tissues involved will enable recruitment of very 
distinct sets of leukocytes under inflammatory or allergic conditions. A significant contribution to the 
diversity of leukocyte recruitment aiso comes from the variation in binding of chemokines to the 
endothelial surface with a potential contribution from the smalier differences in adhesion molecules 
present.
8.10 Future studies
One of the most important points that remain to be elucidated is the responses of endothelial cells 
to chemokines. The study that was begun in chapter 7 needs optimising for serum levels, 
chemokine concentrations, assay length and cell density before investigating the effects of 
chemokines in further detail. This could then lead to further investigations into the process of 
angiogenesis by investigating whether endotheiiai celis show differences in their migratory 
properties. Eariy results in our lab indicate that there are differences for example; SVEC are more 
migratory towards both IP-10 and IL-8 than DMVEC (personal communication D. Maie). A final 
assay, to investigate the overali angiogenic potential of different chemokines would be an in vitro 
angiogenesis assay in which capillary tubule formation is assessed. This would confirm that it is not 
simply a growth effect of the endothelial cells. Interesting questions have also arisen about the 
apparent differential effects of TGF-p on endothelia. In most endothelial cell types, it reduces 
chemokine production by endothelial cells, but in some cases, it appears to increase the 
chemokine production. It would be interesting to find if this is related in any way to its proliferative / 
anti-proliferative properties on different endotheiia. It would also be useful to investigate which 
chemokines can activate which endothelial cells and via which receptors. This could be done using 
a calcium mobilisation assay with blocking antibodies to different receptors. An assessment of the 
effects of cytokines and chemokines on the ievels of chemokine receptors present on different 
endothelia would also prove useful in further determining the effects of chemokines produced 
under inflammatory conditions.
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